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ALTERNATIVE MANAGEMENT OF 
A REPLACED COMMON HEPATIC 
ARTERY PSEUDOANNEURYSM
F. Abdelsayed1, W. Curtiss2, M. Jacobs2 and B. Puzsar1
1Providence Hospital & Medical Centers – Department of 
Radiology, Southfi eld, Michigan; 2Providence Hospital & 
Medical Centers – Department of Surgery, Southfi eld, 
Michigan
A 35-year-old male with a past medical history signifi cant for 
chronic alcoholic pancreatitis with pseudocyst presented with 
epigastric pain radiating to the back accompanied by nausea 
and vomiting. Physical examination and laboratory fi ndings 
were consistent with acute pancreatitis. Contrast-enhanced 
computed tomography (CT) of the abdomen demonstrated 
multiple pseudocyts of the pancreas. CT also revealed a 
1.0 cm pseudoaneurysm (PSA) of the replaced common 
hepatic artery adjacent to a pseudocyst in the pancreatic head. 
The patient was not a candidate for embolization therapy due 
to risk of hepatic ischemic injury. Alternatively, the PSA was 
excluded with a covered wall-stent (Figure 1). Completion 
replaced common hepatic artery arising from the superior mes-
enteric artery occurs in 2 to 5% of the population. Rupture of 
visceral aneurysms and pseudoaneurysms are associated with 
poor outcomes and symptomatic visceral aneurysms or aneu-
rysms >2.0 cm should be repaired upon discovery. Suffi cient 
evidence supports the management of visceral aneurysms by 
both open and endovascular techniques. Endovascular tech-
niques can be used to manage visceral aneursymal disease in 
the hostile abdomen. This case showcases a novel combination 
of both endovascular and image-guided management of a vis-
ceral pseudoaneurysm.
SIZE OF TUMOUR PREDICTS OUTCOME 
IN REDO RESECTION FOR 
COLORECTAL LIVER METASTASES
R. A. Adair, A. L. Young, K. R. Prasad, J. P. Lodge 
and G. J. Toogood
St James’s University Hospital, Leeds, West Yorkshire
Background: Seventy-fi ve to 80% of patients undergoing 
liver resection for colorectal liver metastases develop recur-
rence. A signifi cant number of these can be considered for 
re-do liver surgery. We examined the outcomes of re-do liver 
resection for the treatment of recurrent colorectal metastases 
confi ned to the liver.
Methods: Patients who underwent repeat liver resection in 
a single, tertiary referral, Hepatobiliary centre were identi-
fi ed from a prospective database. Clinico-pathological vari-
ables were analysed to assess factors predictive of survival 
using univariate/multivariate analysis. (PASW® version 
17.0)
Results: A total of 173 patients underwent repeat resection 
between 1992 and 2009. Median age was 63 years and the 
median interval between 1st resection to repeat was 13.6 
months. Disease-specifi c 1, 3 and 5 year survival was 89%, 
44% and 25%. Thirty day mortality was 2.3% and morbidity 
13.8%. Twenty-eight patients underwent completion hemi-
hepatectomy with the remainder undergoing non-anatomical 
or segmental resection. Tumour size greater than 5 cm was 
the only independent predictor of overall survival (p = 0.001, 
RR 2.32, 95% CI 1.44–3.77). Neoadjuvant chemotherapy, 
blood transfusion, bilobar disease and multiple metastases 
were among factors which did not signifi cantly infl uence 
survival.
Conclusion: With the advent of future liver remnant deter-
mination and advances in cytotoxic therapy re-defi ning 
resectability, re-do surgery should be considered for patients 
presenting with recurrent metastatic disease confi ned to the 
liver.
angiogram showed persistent slow fi lling. Subsequent 
CT-guided percutaneous thrombin injection obliterated the 
PSA cavity and post-injection Doppler sonography confi rmed 
exclusion. The patient tolerated the procedure well and was 
discharged within 48 hours. Subsequent CT surveillance at 
three months revealed resolution of the pseudoaneurysm. 
Hepatic arterial anatomy is highly variable, with “standard” 
anatomy reported in approximately 50 to 75% of patients. A 
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TREATMENT OUTCOMES AND MSKCC 
SCORING IN 1281 PATIENTS 
UNDERGOING RESECTION FOR 
COLORECTAL LIVER METASTASE
R. A. Adair, A. L. Young, A. J. Cockbain, K. R. Prasad, 
G. J. Toogood and J. P. Lodge
St James’s University Hospital, Leeds, West Yorkshire
Background: Hepatic resection remains the only curative 
option for patients with colorectal liver metastases (CRLM). 
Here, we report treatment outcomes for our large, single 
centre series of resections and assess the predictive value of 
the Memorial Sloan-Kettering Cancer Centre (MSKCC) 
scoring system in an independent cohort.
Methods: Patients who underwent liver resection for CRLM 
in a single, tertiary referral, Hepatobiliary centre were identi-
fi ed from a prospectively kept database. Clinico-pathological 
variables based on the MSKCC scoring system were anal-
ysed to assess factors predictive of survival using univariate/
multivariate analysis. (PASW® version 17.0)
Results: A total of 1281 patients underwent hepatic resec-
tion between 1992 and 2009. Median age was 63 years. 1108 
underwent primary hepatectomy with 173 undergoing repeat 
resection. Overall, disease-specifi c survival at 1, 3, 5 and 10 
year survival was 87%, 52%, 36% and 21% respectively and 
median follow-up was 26.9 months. Thirty day mortality was 
2.6% and morbidity 16.4%. Of the fi ve MSKCC prognostic 
criteria, only node positive primary disease (p ≤ 0.001 95% 
CI 1.26–2.04) and tumour size greater >5 cm (p ≤ 0.05 95% 
CI 1.01–1.61) predicted poorer outcome in our group on 
multivariate analysis. The actuarial 5-year survival was 49% 
for those scoring 0 points and 21% for those scoring 5.
Conclusion: In our patient cohort the MSKCC prognostic 
score did not accurately predict survival and this highlights 
the importance of independent validation of scoring systems. 
Moreover, the contemporary focus on liver rather than 
tumour related factors in defi ning resectability means that 
prognostic scores may prove more useful in predicting 
response to adjuvant, cytotoxic therapy.
A COMPARISON OF MONOPOLAR TO 
BIPOLAR RADIOFREQUENCY 
ABLATION OF LIVER TUMORS
F. Alemi1, E. Kwon1, L. Stewart1,2 and C. U. Corvera1,2
1University of California, San Francisco, San Francisco, 
CA; 2San Francisco VA Medical Center, San Francisco, CA
Introduction: Recently, many hepatobiliary centers have 
abandoned monopolar radiofrequency ablation (M-RFA) and 
switched to other thermal energy devices such as bipolar radio-
frequency ablation (B-RFA). Compared to monopolar devices, 
B-RFA does not require grounding pads, thereby avoiding skin 
burn injuries, and does not position probes directly into tumor 
but rather on the perimeter. Additionally, the broad surface 
area covered by the bipolar probes can be used to precoagulate 
parenchyma to assist in hepatic resection. Herein, we report 
our early experience using bipolar thermal ablation.
Methods: A retrospective review identifi ed 68 patients who 
underwent M-RFA or B-RFA between June 2004 and 
September 2010 in an academic center. Perioperative metrics 
and recurrence rates were analyzed.
Results: M-RFA was used to treat 30 patients, while B-RFA 
was used for 17 patients. Seventeen other patients underwent 
B-RFA precoagulation prior to resection. Four patients with 
multiple tumors were treated by a combination of B-RFA and 
precoagulation. When compared to M-RFA, B-RFA showed 
no differences in perioperative metrics (see Table). B-RFA 
Bipolar RFA Monopolar RFA p-value
# Patients  17  30
DEMOGRAPHICS
Age  63.2  56.6 <0.01
Sex (M:F)  15.2  30.0
Disease Malignant (HCC)- 88.2%
Benign (Adenoma)-11.8%
Malignant (HCC)- 100%
MELD  8.47  7.53 0.2
Tumor Size (cm)  3.2  3.2 0.9
PERIOPERATIVE OUTCOMES
Laparoscopic (%)  94.1%  83.3% 0.29
Cholecystectomy (%)  47.1%  16.6% 0.029
Time (min) 296.6 203.8 <0.01
Blood Loss (mL) 148.8  92.7 0.091
Hospitalization (days)  8.2  4.9 <0.01
Complications** Grade 2 = 1 (PNA) Grade 2 = 2 (arrhythmia)
Grade 3 = 2 (PTX) Grade 3 = 2 (RFA burns)
Grade 4 = 1 (Hepatic insuffi ciency) Grade 4 = 1 (GI bleed)
Complication Rate (overall/major)  23.5%/17.6%  16.7%/13.3% 0.62
FOLLOW-UP
Local Recurrence  11.8%  23.3% 0.34
Overall Recurrence  23.5%  46.7% 0.12
Time to Recurrence (mo.)  15.7  12.4 0.62
Follow-up (mo.)  16.6  35.9 <0.01
*All data reported as mean unless otherwise indicated
**Based on Clavien-Dindo Classifi cation system
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patients had lower local recurrence (11.8% vs. 23.3%) and 
overall recurrence rates (23.5% vs 46.7%). Precoagulation 
was used prior to isolated segmental resections in 11 patients 
and prior to multi-segmental resection or hemihepatectomies 
in 6 patients.
Conclusions: Compared to M-RFA, the early experience 
utilizing B-RFA demonstrates lower local and overall tumor 
recurrence rates, albeit over a shorter mean follow-up period. 
B-RFA is also equivalent to monopolar devices with regards 
to complication rates and perioperative outcomes. Moreover, 
it can be utilized to precoagulate tissue prior to a planned 
resection.
STANDARD LIVER VOLUME FORMULA 
FOR THE MIDDLE EASTERN ARABIC 
ADULTS
H. M. Alghamdi1,2
1King Fahad Specialist Hospital - Dammam, Dammam, 
Eastern Province; 2University of Dammam, AlKhobar, 
Eastern Province
Aim: To determine a formula estimating the standard liver 
volume (SLV) based on body indices for the Middle Eastern 
Arabic adults and to compare with the 12 formulae reported 
in the east and west populations.
Methods: The actual liver volumes (CTLV) were measured 
by computerized tomography in 351 Arabic adults without 
liver or body build abnormality, and were correlated with the 
body indices (age, gender, body height, weight, mass index 
and surface area). The new formula found by stepwise mul-
tiple linear regression analysis was compared with the 12 
reported formulae.
Results: Body weight (BW) was the sole signifi cant factor 
that correlated with the actual liver volume (CTLV) by 
12.255 × BW (kg) + 555.646 (R2 = 0.372, p = 0.000). Only 
Vauthey formula (1267.28 × BSA (m2) − 794.41) could esti-
mate SLV which did not differ signifi cantly from the CTLV 
(p = 0.263,) and had the least mean error (underestimation 
of 15.7 mL) and the closest agreement (62.4% had lesser 
than 16% error). Yoshizumi’s simple formula was the second 
closest though the difference was statistically signifi cant. 
Formulae of Chandramohan, Yuan and Chan also gave 
acceptable estimation. The Japanese formulae of Urata and 
Hashimoto and especially the Chinese Chengdu formulae 
underestimated while all autopsy studies (DeLand, 
Heinemann, Yu and especially Chouker) overestimated 
signifi cantly.
Conclusions: The formulae of the present study and Vauthey 
could be used to estimate SLV of Middle Eastern Arabic 
adults. However, the moderate coeffi cient of determination 
(R2 = 0.372) suggested wide individual variation. One should 
exercise caution when applying these formulae in pre-
operative planning.
PRESENCE OF EXTRA-HEPATIC 
DISEASE SHOULD NOT PRECLUDE 
TRANSARTERIAL 
CHEMOEMBOLIZATION FOR 
METASTATIC CARCINOID
D. Arrese, E. Feria-Arias, R. J. Chokshi, G. Guy, 
H. Khabiri, C. Schmidt, M. Shah and M. Bloomston
The Ohio State University Medical Center, Columbus, OH
Background: Transarterial chemoembolization (TACE) is 
the locoregional therapy of choice for the management of 
patients with inoperable carcinoid liver metastases. Often, 
metastatic disease is not limited to the liver. The impact of 
extra-hepatic metastases on response and outcomes follow-
ing TACE has not been described.
Objective: We hypothesized that patients who have extra-
hepatic disease would have similar tumor response and 
symptom control following TACE.
Methods: We reviewed 198 patients that underwent TACE 
for inoperable carcinoid liver metastases. Two groups were 
identifi ed, those with (N = 129) and without (N = 69) 
evidence of extra-hepatic disease at the time of TACE. 
Demographics, clinicopathologic characteristics, response to 
TACE, complications, and survival were compared.
Results: The two groups were similar in demographics and 
histopathologic characteristics. Complications following 
TACE were similar. There was no difference between the 
groups with and without evidence of extrahepatic disease in 
symptomatic (76% vs 71%), biochemical (78% vs 90%) or 
radiographic response (35.0% vs 46%) to TACE. The group 
without extra-hepatic disease had a median survival of 88 vs 
35 months with fi ve-year survival of 65% vs 30% compared 
to patients with extra-hepatic disease at the time of TACE.
Conclusions: Patients with extrahepatic metastatic disease 
from carcinoid tumor experienced shorter overall survival 
following TACE compared to those without extrahepatic 
disease. However, patients with extra-hepatic disease had 
similar symptomatic, biochemical and radiographic response 
to TACE compared to those with disease confi ned to the 
liver. Although the long-term prognosis for patients with 
extrahepatic disease is worse than those with liver-only 
metastasis, meaningful response to TACE is possible and 
should be considered.
Table 1. Response to TACE
Variables No EHD N = 69 EHD N = 129
P 
value
Mean Age (Range) 56 (16–83) 55 (27–87) 0.87
Gender M:F 27:42 67:62 0.1
Carcinoid Syndrome 
Pre-TACE
62% 65% 0.75
Primary Resected 58% 45% 0.1
Complications 16% 20% 0.56
Symptom Response 71% 76% 0.46
Serologic Response 90% 78% 0.25
Radiographic Response 46% 35% 0.17
Median survival 88 months 35 months 0.001
2 years 76% 69% 0.001
5 years 65% 30% 0.001
10 years 39% 11% 0.001
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POSTOPERATIVE MORTALITY 
FOLLOWING HEPATECTOMY 
FOR METASTATIC DISEASE IN 
THE ELDERLY
A. Artinyan, D. Albo, D. H. Berger and D. A. Anaya
Baylor College of Medicine, Houston, TX
Introduction: Postoperative mortality after hepatectomy 
for metastasis has not been well characterized in the elderly. 
Our aim was to examine the risk and predictors of mortality 
following liver resection in elderly patients with metastatic 
disease. We hypothesized that mortality in well-selected 
patients is comparable to that seen in younger patients.
Methods: Patients undergoing hepatectomy for liver metas-
tasis were identifi ed from the National Inpatient Sample 
Database (2005–2008) using a validated algorithm. Patients 
were categorized into young (<65 y), old (65–74 y), and 
oldest (≥75 y) age groups. Clinical and outcome data were 
recorded. Univariate and multivariate analyses were 
performed.
Results: 4,026 hepatectomy cases were identifi ed. Elderly 
patients (old + oldest) comprised 37% (n = 1,475) of the 
population. Increasing age was associated with a higher 
comorbidity index (CI); 41.8% in the oldest group had a CI 
≥3 compared to 39.5% and 36.5% in the old and young 
groups, respectively (p < 0.001). Overall mortality rate was 
1.8%; mortality was higher but still low in the oldest com-
pared to the old and younger groups (3.3% vs. 2.2% vs. 
1.2%, p = 0.005). On multivariate analysis, age ≥75 y (OR 
2.5 [1.4–4.6]), CI ≥3 (OR 1.8 [1–3.1]), and major resection 
(lobectomy) (OR 1.7 [1.1–2.8]) were identifi ed as indepen-
dent predictors of postoperative mortality.
Conclusions: Well-selected elderly patients experience 
higher – yet acceptable – rates of mortality following hepa-
tectomy for liver metastasis. Advanced age alone should not 
be considered a contraindication to liver resection; other 
predictors including comorbidities and extent of surgery 
should be examined to help select elderly patients most likely 
to benefi t from hepatectomy.
ANTITUMOR ACTIVITIES OF SUNITINIB 
IN COMBINATION WITH GEMCITABINE 
IN EXPERIMENTAL PANCREATIC 
CANCER
N. Awasthi, M. A. Schwarz and R. E. Schwarz
University of Texas Southwestern Medical Center, 
Dallas, TX
Background: Gemcitabine (Gem) has limited clinical ben-
efi ts in pancreatic ductal adenocarcinoma (PDAC). Sunitinib 
(Su) is a novel, multitargeted receptor tyrosine kinase inhibi-
tor that has antitumor activities against colon, lung, breast 
and pancreatic islet cell malignancies. We tested combination 
benefi ts of Gem with the antiangiogenic agent Su in PDAC.
Methods: In vitro cell proliferation was evaluated by 
WST-1 assay in human PDAC cells (AsPC-1), endothelial 
cells (HUVECs) and fi broblasts (WI-38). Animal survival 
and tumor growth studies were performed in murine 
xenografts.
Results: In AsPC-1 cells Gem and Su caused 28 and 22 
percent inhibition in proliferation at 100 nM; combination of 
Su with Gem had additive effects and 48% inhibition was 
observed. In HUVECs, Gem and Su caused 49 and 32 
percent inhibition in proliferation and 72% inhibition in com-
bination. In WI-38 cells, Gem and Su caused 65 and 14 
percent inhibition in proliferation and 79% inhibition in com-
bination. In vivo, the relative net tumor growth compared to 
controls in Gem, Su and Su + Gem groups was 57, 6 and 0.8 
percent. The median survival in controls, Gem, Su + Gem 
was 19, 26 and 37 days (p = 0.001 for Su + Gem over Gem 
alone).
Conclusions: In vitro, Sunitinib, either alone or in combina-
tion with Gem, had a strong antiproliferative effect. In vivo, 
sunitinib enhanced the Gem-related antitumor effects signifi -
cantly. These fi ndings support combinations of multitargeted 
antiangiogenic agents with standard Gem therapy for PDAC 
treatment.
LAPAROSCOPIC SPLEEN-PRESERVING 
DISTAL PANCREATECTOMY IN THE 
ELDERLY: INITIAL EXPERIENCE AND 
LESSONS LEARNED
K. M. Baldwin, P. Somasundar, S. C. Katz and N. Espat
Roger Williams Medical Center, Providence, RI
The laparoscopic approach for distal pancreatic lesions has 
gained popularity in recent years and there has been a trend 
towards preservation of the spleen, with or without splenic 
vessel preservation (SVP). The response of elderly patients 
>70 years old to these approaches is not well defi ned.
Methods: Nine patients >70 years old underwent attempted 
spleen preserving laparoscopic distal or subtotal pancreatec-
tomy over an 18 month period. Age, ASA score, imaging 
fi ndings, estimated blood loss, operative time, details on 
technique of splenic preservation, length of stay, morbidity 
and mortality were examined. Chi-Squared analysis evalu-
ated the association between the operative technique (SVP 
or no SVP) and splenic infarct.
Results: Median age was 81. The median OR time was 
150 min, and EBL was 100 cc. One spleen was not preserved 
due to carcinoma with hilar invasion. The other 8 patients 
had spleen preserving pancreatectomies. Of these 8, SVP 
was performed in 5 and the vessels were stapled in 3, relying 
on short gastric collateral fl ow. All 3 patients undergoing 
vessel division developed splenic infarcts, and two required 
splenectomy (p = 0.012). These patients were 74, 84 and 92 
years old. There were no mortalities and one pancreatic leak.
Conclusions: Spleen preserving laparoscopic distal and 
subtotal pancreatectomy can be performed safely in the 
elderly. The present data suggest that patients undergoing 
laparoscopic spleen preserving distal pancreatectomy without 
SVP are at a higher risk for splenic infarction requiring 
splenectomy than otherwise reported for the younger aged 
population.
MINIMALLY INVASIVE 
PANCREATICODUODENECTOMY
P. Bao and K. Watkins
Stony Brook University Medical Center, Stony Brook, NY
Purpose: Surgical units continue to explore and improve 
minimally invasive pancreatic surgery. This video details our 
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current technique for combined laparoscopic and robotic 
pancreaticoduodenectomy.
Results: The video presents a 72-year-old woman who 
underwent MIPD for a 4.5 cm duodenal adenoma. Fifteen 
lymph nodes were harvested with the specimen and she was 
discharged home post-operative day 6 without complica-
tions. We review port placement, port choice and instrumen-
tation, and key maneuvers for successful resection and 
reconstruction. Special attention is given to dissection along 
the pancreatic uncinate margin, transection, and duct identi-
fi cation. Optimal utilization of the surgical robot is discussed 
and demonstrated. The approach to minimally invasive pan-
creaticoduodenectomy (MIPD) has evolved over a learning 
curve of approximately 10–15 cases. Operative times have 
diminished signifi cantly to a current median of 395 (range 
340–454) minutes.
Conclusions: Laparoscopic and robotic MIPD is feasible 
and safe with operative time, completeness of resection, and 
short-term perioperative outcomes comparable to the open 
procedure. Further long-term study will determine if this 
becomes a preferred approach to pancreaticoduodenectomy.
HIGH GRADE DYSPLASIA AT CYSTIC 
DUCT MARGIN AFTER 
CHOLECYSTECTOMY
K. A. Bickenbach, R. P. DeMatteo, Y. Fong, P. J. Allen, 
W. R. Jarnagin and M. I. D’Angelica
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: 750,000 cholecystectomies are performed 
each yearly in the United States. No data exist on patients 
with microscopic high grade dysplasia at the cystic duct 
margin and the associated incidence of cholangiocarcinoma.
Methods: A free text search of all pathology reports at our 
institution was performed for the following terms: “chole-
cystectomy”, “cystic margin”, and “dysplasia”. Pathology 
reports were reviewed for patients that had high grade dys-
plasia of the cystic duct margin but did not have invasive 
gallbladder cancer. Clinical data was obtained from chart 
review.
Results: The initial search identifi ed 193 patients from 1992 
to 2010 with the correct terms in pathology report. From this 
data set we identifi ed 8 patients with high grade dysplasia at 
the cystic duct margin. One patient had a non-invasive papil-
lary cancer and the remaining 7 patients had high grade 
dysplasia in the gallbladder and at the cystic duct margin. 
Three patients had their slides submitted for pathologic 
second opinion and were not treated at out institution. Of the 
5 patients treated at our institution, radiologic imaging was 
abnormal in 2 of 5 (40%) patients. The cystic duct stump was 
abnormal in both patients. Four of the 5 patients have under-
gone exploration and bile duct excision. Of those, 3 (75%) 
had no evidence of malignancy. One patient was found to 
have a node positive cholangiocarcinoma.
Conclusion: High grade dysplasia at the cystic duct margin 
without evidence of invasive gallbladder cancer is a rare 
occurrence. Consideration should be given to the diagnosis 
of an underlying cholangiocarcinoma and re-exploration.
A SINGLE CENTER COMPARISON OF 
OUTCOMES IN HEPATIC RESECTIONS 
USING TWO DIFFERENT DEVICES FOR 
PARENCHYMAL DIVISION
A. S. Bodzin1, A. M. Frank1, C. G. Ramirez1, B. E. Leiby2, 
W. M. Maley1 and C. Doria1
1Thomas Jefferson University Hospital, Division of 
Transplantation, Philadelphia, PA; 2Thomas Jefferson 
University Hospital, Division of Biostatistics, 
Philadelphia, PA
Objective: The goal of this study was to evaluate safety and 
effi cacy of two devices used in parenchymal division during 
hepatic resections.
Methods: We retrospectively compared 47 patients who 
underwent liver resection at our Institution from 2004 to 
2010 using the TissueLink Monopolar Floating Ball (TL) 
with either the ultrasonic dissector (CUSA) or harmonic 
scalpel (HS). CUSA plus TL was used in 27 patients while 
HS plus TL was used in 20 patients. Demographics, intraop-
erative data, and postoperative outcomes were analyzed 
(Table 1). Wilcoxon rank sum and Fisher’s exact tests were 
used in statistical analysis.
Table 1. Patient Group Demographics and Outcomes
CUSA/TL
Harmonic 
Scalpel/TL P-value
No. Patients 27 20
Age 51 (23–76) 55 (28–85) 0.29
Female (%) 16 (59.3) 13 (65.0) 0.77
Patients with Major Resection 
(%)
17 (63.0) 11 (55.0) 0.76
Median Number of lesions 
resected (Range)
1 (1–3) 1 (1–3) 0.47
Median Operative Time in 
Minutes (Range)
290 (117–533) 185 (63–681) 0.08
Median Estimated Blood 
Loss in ml (Range)
700 (0–5850) 250 (0–1500) 0.01
Patients transfused with 
banked blood (%)
8 (29.6) 2 (10.0) 0.15
Median LOS in days (Range) 7 (6–27) 6 (2–49) 0.02
Patients with Complications 
(%)
9 (33.3) 4 (20) 0.35
Bile Leak (%) 3 (11.1) 1 (5.0) 0.63
Perioperative Mortality (%) 1 (3.7) 1 (5.0)
Results: The median estimated blood loss (EBL) of the HS 
and CUSA groups were respectively 250 and 1035 ml (p < 
0.05). Two patients (10%) were transfused intraoperatively 
in the HS group and 8 (66.7%) in the CUSA group (p = 0.15) 
with banked blood while the remaining transfused patients 
received autologous blood. The median operative time of the 
HS and CUSA groups were respectively 185 and 290 minutes 
(p = 0.08). Length of stay (LOS) was shorter in the HS group 
at 6 days compared to 7 days in the CUSA group (p < 0.05). 
There were 4 morbidities (20%) including 1 bile leak (5%) 
and one perioperative death in the HS group, and 9 morbidi-
ties (33.3%) with 3 bile leaks (11.1%) and 1 intraoperative 
death in the CUSA group with no signifi cant differences in 
these outcomes.
Conclusions: Our results show that HS with TL is a safe 
and effective method of parenchymal division with signifi -
cantly less EBL and LOS.
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A COMPARATIVE STUDY OF 
OPERATIVE RESECTION VERSUS 
RADIOFREQUENCY ABLATION FOR 
THE TREATMENT OF METASTATIC 
COLORECTAL METASTASES TO THE 
LIVER FOR INITIALLY RESECTABLE 
DISEASE
S. Y. Boostrom1, M. Callstrom2, D. Nagorney1, F. Que1, 
J. Donohue1, M. Kendrick1, M. Farnell1, S. Harmsen3 and 
K. M. Reid Lombardo1
1Division of Gastroenterologic and General Surgery, 
Rochester, MN; 2Department of Radiology, Rochester, MN; 
3Division of Biomedical Statistics and Informatics, 
Rochester, MN
Introduction: Radiofrequency ablation (RFA) is a valuable 
treatment adjunct for selected patients with colorectal liver 
metastases (CRLM). The objective of this study was to 
compare local recurrence, DFS and OS between RFA and 
operative resection (OR) in patients with new onset and 
resectable CRLM.
Methods: Patients treated for CRLM between 1/2000 and 
1/2007 at Mayo Clinic in Rochester, MN were reviewed 
(n = 581). Kaplan-Meier Survival and Cox proportional 
hazards models were used to examine the association 
between treatment group and OS and DSF.
Results: Of the 99 eligible patients 64% were male with a 
median age of 61 (28–81) years. Six of the 79 (7.6%) lesions 
treated with OR (n = 48) developed a local recurrence versus 
19/51 (37%) treated with RFA alone (n = 12). Twelve of the 
31(38.7%) patients treated OR and RFA developed a recur-
rence, all at the ablation site. The 1-, 3-, and 5-year DFS in 
OR versus RFA treated lesions is 96%, 88%, 88%, and 74%, 
36%, 36%, respectively. The 1-, 3-, and 5-year OS in patients 
treated with OR, combined OR/RFA and RFA alone was 
85%, 71%, 66%; 96%, 71%, 53% and 83%, 69%, 46%, 
respectively. The mean size of the lesions treated with RFA 
with and without recurrence was 1.9 cm and 1.2 cm respec-
tively. A 1 cm increase in size of an RFA treated lesion has 
a 2.3 increased recurrence risk, p < 0.001.
Conclusions: Surgical resection is superior to RFA in terms 
of local disease recurrence; however, there is no difference 
in OS when comparing the two modalities.
PANCREATIC NEOPLASMS IN 
PREGNANCY: A CASE REPORT AND 
REVIEW OF THE LITERATURE
C. A. Boyd, J. Benarroch-Gampel, L. A. Mata, 
I. D. Okpara and T. S. Riall
University of Texas-Medical Branch, Galveston, TX
Mucinous cystic neoplasms of the pancreas are a rare entity, 
and occur almost exclusively in women. These tumors tend 
to be responsive to both estrogen and progesterone. We 
report a case of a 21-year-old female at 20 weeks gestation 
who presented with a 9-month history of abdominal disten-
tion. After further imaging, the patient was found to have a 
20 cm multiloculated cystic mass in the lesser sac, in addi-
tion to a second cystic mass in the pelvis. Liver function 
tests, amylase, and lipase were within normal limits. Given 
the size of the mass and massive abdominal distention early 
in the fi rst trimester, the obstetrical team was concerned that 
she would not be able to carry the pregnancy to term without 
surgical intervention. In addition, there was signifi cant 
concern for malignancy. Laparotomy was performed at 20 
weeks gestation. The mass originated from the body of the 
pancreas and measured 17 cm in diameter. A distal pancre-
atectomy with splenic preservation and resection of the mass 
was performed. An oophorectomy was performed for a 
14 cm ovarian mass. The fi nal histologic diagnoses were 
a mucinous cystic neoplasm with moderate dysplasia and a 
mature cystic ovarian teratoma. The patient had an unevent-
ful postoperative course. There are a small number of pub-
lished cases of mucinous cystic neoplasms associated with 
pregnancy. This is the fi rst reported case of simultaneous 
cystic neoplasms discovered during pregnancy. We present 
the case and a brief review of the literature regarding the 
diagnosis and management of pancreatic neoplasms during 
pregnancy.
RESECTION OF A SYMPTOMATIC 
PORTAL VEIN ANEURYSM IN A PATIENT 
WITH PRIOR GASTRIC BYPASS
L. P. Brewster1, E. L. Chaikof2 and J. M. Sarmiento1
1Emory University Hospital, Atlanta, GA; 2Beth Israel 
Deaconess Medical Center, Boston, MA
A 43-year-old women with a 5.4 × 4.4 cm extrahepatic portal 
vein aneurysm was referred for evaluation related to debili-
tating severe abdominal pain. She had prior laparoscopic 
gastric bypass in 2003 with subsequent pouch dilatations, 
C-sections, cholecystectomy, hysterectomy, and laparoscopic 
adhesiolysis ×3; the last lysis of adhesions was negative for 
adhesions. Due to her debilitating pain and no other identifi -
able source, she underwent exploratory laparotomy. The 
proximal portal vein was encircled, and the aneurysm was 
saccular with a normal posterior wall but densely adhered to 
a paper thin neck of the pancreas anteriorly. Thus transection 
of the pancreas (and duodenum) to the left of the aneurysm 
established excellent visualization. After heparinization, the 
SMV, splenic and portal veins were clamped. The aneurysm 
was opened, persistent feeding veins oversewn, the aneurys-
mal vein was resected, and the portal vein was repaired with 
a bovine pericardial patch. A pancreaticogastrostomy was 
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used for draining the body and tail of the pancreas, the duo-
denum was primarily anastomosed, and omentum was placed 
between the portal vein repair and the pancreaticogastros-
tomy. Postoperative complications include anemia requiring 
transfusion and superfi cial wound infection. At 4 month 
follow up, her wound has healed, and she is pain free. 
Postoperative surveillance shows a patent portal vein with 
normal fl ow. Portal vein aneurysms are rare and their symp-
tomatology is often diffi cult to relate to the aneurysm itself, 
but after resection long term pain relief and portal vein 
patency are expected.
increased risk of further recurrence (p = 0.01). Among 29 
patients with further recurrence after repeat hepatectomy, 
one-third (10/29) were retreated with curative intent, includ-
ing third hepatectomy (5), radiofrequency ablation (3) or 
resection of lung metastases (2).
Conclusion: Repeat hepatectomy for recurrent CLM is 
associated with long-term survival in patients with negative 
margins. However, defi nitive cure of metastatic colorectal 
cancer remains a challenge in patients with hepatic 
recurrence.
REPEAT HEPATECTOMY FOR 
RECURRENT COLORECTAL LIVER 
METASTASES IS ASSOCIATED WITH 
HIGH SURVIVAL RATE
A. Brouquet, J. Vauthey, A. Andreou, S. A. Curley and 
E. K. Abdalla
MD Anderson Cancer Center, Houston, TX
Background: Outcome after repeat hepatectomy for recur-
rent colorectal liver metastases (CLM) is not well defi ned.
Methods: Prospectively collected data on 115 consecutive 
patients operated for recurrent CLM at our Center were 
studied. Patients treated by radiofrequency ablation at any 
time were excluded. Outcomes were analyzed.
Results: Forty-three patients underwent repeat hepatectomy 
for CLM. At fi rst resection of CLM, patients had a mean of 
2.2 ± 2.2 lesions and mean tumor size was 3.1 ± 2.7 cm. At 
recurrence, patients had a mean of 1.2 ± 0.5 lesions and mean 
tumor size was 2.5 ± 1.1. The mean interval between fi rst 
resection of CLM and recurrence was 16 ± 22 months. 
Postoperative morbidity and mortality rates were 12% and 
0% respectively. After median follow-up of 34 months, 3- 
and 5-year overall survival rates were 82% and 73% respec-
tively. Three- and 5-year disease-free survival rates were 
22% and 22% respectively. Factors associated with worse 
overall survival included tumor size >5 cm (p = 0.004) and 
positive surgical margins (p = 0.04) at initial liver resection. 
Positive margins at repeat hepatectomy were associated with 
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HEALTH-RELATED QUALITY OF LIFE 
CHANGES FOLLOWING MAJOR LIVER 
RESECTION
R. E. Brown, C. R. St. Hill, B. A. Roach, S. F. Ellis, 
C. R. Scoggins, K. M. McMasters and R. C. Martin
University of Louisville, Louisville, KY
Purpose: To evaluate the health-related quality of life 
(QOL) changes experienced by patients following major 
liver resection (LR).
Methods: Following major (≥3 segments) LR, postoperative 
(90-day) complications were graded prospectively using a 
validated 5-grade scale. QOL parameters were recorded pro-
spectively at baseline (pre-operative), and through 6-months 
follow-up using the EORTC QLQ-C30 instrument.
Results: QOL parameters were obtained after major LR for 
malignancy in 41 patients. Major (grade ≥ 3) complications 
occurred in 10 (24.4%) patients. Postoperative chemotherapy 
was administered in 17 (41%) patients. Early (<6 month) 
recurrence was noted in 7 (17.1%) patients. At the initial 
outpatient visit, patients reported decreased global QOL, 
physical functioning, role functioning, and social function-
ing, along with increased fatigue compared with baseline (all 
p < 0.05). These measures normalized at 6-weeks follow-up 
and remained stable at 6-months. When comparing patients 
with and without major complications, those with major 
complications reported increased severity of pain over base-
line at initial follow-up (p = 0.031) and at 6 months (p = 
0.047). No signifi cant difference was noted in other QOL 
metrics between patients with or without major complica-
tions (p > 0.11). Using a repeated-measures model, neither 
age, complication occurrence, adjuvant therapy, nor early 
recurrence were predictive of decreased QOL at 6-months.
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Table 1. Meta Analysis of PSVT Incidence and Associated 
Morbidity
Proportion
95% confi dence 
interval Proportion
PSVT Incidence 0.108 0.067 0.150
PSVT Incidence for Ap 0.157 0.046 0.267
PSVT Incidence for Cp 0.082 0.044 0.120
Incidence of Varices 0.530 0.264 0.796
Incidence of Gastric Varices 0.410 0.116 0.703
Incidence of Esophageal Varices 0.033 0 0.068
Incidence of Gastroesophageal Varices 0.200 0.026 0.374
Bleed Rate 0.190 0.105 0.274
Bleed Rate for Ap 0.067 0 0.186
Bleed Rate for Cp 0.069 0 0.149
Splenomegaly 0.519 0.262 0.776
Conclusion: Overall, QOL metrics tend to normalize to pre-
operative levels within 6-weeks after LR. However, major 
complications are associated with increased reporting of pain 
that persists at 6 months. Better attention to pain control, 
especially among patients with major complications, may 
improve QOL after major LR.
PANCREATITIS-INDUCED SPLENIC VEIN 
THROMBOSIS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS OF ITS RATE OF 
OCCURRENCE AND FREQUENCY OF 
ASSOCIATED GASTROINTESTINAL 
BLEEDING
J. R. Butler1, G. J. Eckert2, N. J. Zyromski1, 
M. J. Leonardi1, K. D. Lillemoe1 and T. J. Howard1
1Indiana University Department of Surgery, Indianapolis, 
Indiana; 2Indiana University Division of Biostatistics, 
Indianapolis, Indiana
Introduction: Pancreatitis-induced splenic vein thrombosis 
(PSVT) is an important anatomic abnormality impacting deci-
sion-making in pancreatic surgery. The frequency of PSVT and 
rate of associated gastrointestinal (GI) bleeding is unknown.
Methods: The Medline, EMBASE, Cochrane CRCT and 
Cochrane DSR databases were searched from their inception 
to June, 2010 for abstracts documenting PSVT in acute (AP) 
or chronic pancreatitis (CP). Two authors independently 
graded abstracts for inclusion in this study. Heterogeneity in 
combining data was assumed prior to pooling. Random-
effects meta-analyses were performed to estimate percent-
ages and 95% confi dence intervals.
Results: After review of 241 abstracts, 47 studies and 52 
case reports were graded as relevant. To date, 805 cases of 
PSVT have been reported in the literature. Across all case 
reports and studies. A meta-analysis of studies meeting inclu-
sion criteria show a mean reported PSVT incidence of 10.8%, 
varying between AP (15.7%) and CP (8.2%). The incidence 
of associated splenomegaly was only 51.9%. Varices were 
identifi ed in 53% of patients, 77.3% of which were gastric. 
The overall rate of GI bleeding was 19%.
Conclusions: While the incidence of PSVT varies widely 
between individual studies, an overall incidence of 10.8% in 
pancreatitis is reported. Splenomegaly is an unreliable sign 
of PSVT. Although the true natural history of PSVT remains 
unknown, the reported incidence of associated GI bleeding 
is 19%.
THE ROLE OF LAPAROSCOPIC 
RESTAGING IN PATIENTS WITH 
INCIDENTAL GALLBLADDER CANCER
J. M. Butte, M. Gönen, P. J. Allen, M. I. D’Angelica, 
Y. Fong, R. P. DeMatteo, L. H. Blumgart and 
W. R. Jarnagin
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: The role of laparoscopy as a staging method 
during re-exploration of patients with incidental gallbladder 
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cancer is ill-defi ned. This study evaluates the yield and accu-
racy of staging laparoscopy, and to identify variables associ-
ated with disseminated disease during re-exploration.
Methods: Data from consecutive patients with incidental 
gallbladder cancer undergoing re-exploration between 1998 
and 2009 were identifi ed from a prospective database. The 
yield and accuracy of restaging laparoscopy were calculated. 
Demographics, tumor and treatment related variables were 
correlated with disseminated disease.
Results: One hundred-forty three patients with incidental 
gallbladder cancer underwent re-exploration for possible 
defi nitive resection, and staging laparoscopy was performed 
in 46. Twenty-nine (63%) were female and the median age 
was 66 years (41–90). Ten (21.8%) patients were diagnosed 
with disseminated disease during re-exploration (carcinoma-
tosis = 6, liver metastases = 3, and retroperitoneal disease = 
1); laparoscopy identifi ed 2 of these patients (yield = 4.2%), 
while 8 were diagnosed after conversion to open surgery 
(accuracy = 20%). Thickening of gallbladder wall in pre-
cholecystectomy ultrasound (p = 0.03), poorly differentiated 
tumors (p = 0.02), and perineural invasion (p = 0.02) were 
factors associated with disseminated disease on univariate 
analysis. Risk of disseminated disease during reexploration 
increased from 39% with 1 factor to 100% with 3 factors 
present.
Conclusions: Staging laparoscopy has a very low yield for 
identifying disseminated disease during re-exploration of 
patients with incidental gallbladder cancer. Gallbladder wall 
thickening, poorly differentiated histology, and perineural 
invasion may help select the small subset of patients who 
may benefi t from this added procedure.
EVALUATION OF PROGNOSTIC INDICES 
AND OVERALL SURVIVAL OF 
RESECTABLE AMPULLARY 
ADENOCARCINOMA
C. Y. Chai1, M. E. Mabis2, J. Weber1, E. Henderson1, 
B. A. Centeno1 and P. J. Hodul1
1Moffi tt Cancer Center, Tampa, FL; 2University of South 
Florida , Tampa, FL
Introduction: Ampullary adenocarcinoma offers a better 
prognosis compared to other periampullary malignancies 
such as pancreatic or distal bile duct cancers. Different prog-
nostic indices have been evaluated for periampullary tumors 
to aid in determination of adjuvant treatments. Here, we 
reviewed our experience with ampullary adenocarcinomas 
for prognostic indices and overall survival (OS). In our 
ampullary database, we found 72 patients who underwent a 
resection of ampullary adenocarcinoma from 1996 to 2010. 
Pathological data including tumor size, histological grade, 
nodal status, lymphovascular or perineural invasion were 
evaluated, and OS analysis was performed.
Results: Of 72 patients, 52% was male, and 48% was 
female. The median age at diagnosis was 70 yrs (38–86). The 
median follow up was 14.5 mo (1–106). 71 patients under-
went a pancreaticoduodenectomy, and 1 patient had an 
ampullectomy. There were 32% stage I disease, 53% stage 
II, and 14% stage III. 19% of our patients had a recurrence 
with a median time to recurrence at 8 mo (2–25). Patients 
with N1 disease were more likely to develop a recurrence 
(p = 0.023). Lymphovascular or perineural invasion did not 
infl uence recurrence of disease. The 5 year OS was 39% for 
resectable ampullary adenocarcinoma. When comparing OS 
by tumor size, histological grade, nodal status, lymphovas-
cular invasion and perineural invasion, N1 (p = 0.01) disease 
and poorly differentiated histological grade (p < 0.01) indi-
cated worse OS on multivariate analysis.
Conclusions: Although patients with ampullary adenocarci-
noma have improved OS, prognostic indices are similar to 
other periampullary malignancies. N1 disease and poorly 
differentiated histological grade indicate a worse OS.
ALTERED EFFICACY OF AT1R-
TARGETED TREATMENTS FOR 
COLORECTAL CANCER LIVER 
METASTASIS RESULTING FROM AT1R 
UPREGULATION
J. Chan, J. Neo, C. Christophi and E. I. Ager
The Department of Surgery, Austin Health, 
Heidelberg, VIC
Background: Blockade of the angiotensin (ANG) II type 1 
receptor (AT1R) or angiotensin converting enzyme (ACE) 
inhibition reduces tumour growth in a mouse model of 
colorectal cancer liver metastases (CRLM). ANG-(1–7), an 
antagonistically acting peptide, has also been identifi ed as a 
potential anti-cancer agent.
Objective: To establish if combined RAS-targeting could 
result in greater inhibition of CRLM than either treatment 
alone.
Methods: Irbesartan at 50 mg/kg/day s.c., captopril at 
250 mg/kg/day i.p., and ANG-(1–7) at 24 μg/kg/hr i.p mini-
pump were administered for 21 days in a mouse model of 
CRLM either alone or in combinations of ANG-(1–7) with 
irbesartan/captopril. Tumour burden was assessed by stereol-
ogy. Immunohistochemistry was used to assess tumour 
AT1R, iNOS, and VEGF levels.
Results: While irbesartan previously inhibited tumour 
growth in this model, in the current experiments irbesartan 
failed to affect tumour burden. Analysis of AT1R expression 
showed increased expression in tumour cells from irbesar-
tan-insensitive compared to irbesartan-sensitive tumours. 
In contrast to irbesartan, captopril retained its anti-tumour 
activity against the high AT1R-expressing tumours. Neither 
combined strategy improved treatment outcomes.
Conclusions: Although the results do not support increased 
effi cacy with combined treatment, they provide intriguing 
evidence of the importance of RAS expression in determin-
ing patient response and suggest that components of the RAS 
could be used as biomarkers to determine optimal treatment 
strategies.
ROLE OF PANCREATIC DUCT STENT 
PLACEMENT PRIOR TO DISTAL 
PANCREATECTOMIES IN PREVENTION 
OF PANCREATIC LEAK
N. Chandolias, S. Lopez, P. Y. Parikh and A. Nigam
Albany Medical Center, Albany, NY
Background: Pancreatic leak represents a signifi cant cause 
of morbidity and mortality after distal pancreatectomies. In 
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the literature, the role of preoperative pancreatic duct stent 
placement remains undefi ned. The objective of our study was 
to assess whether stenting of the ventral pancreatic duct prior 
to distal pancreatectomy reduces the rate of pancreatic leak.
Methods: Between February 2005 and June 2008 a total of 
19 patients underwent distal pancreatectomy following 
ERCP and pancreatic duct stent placement. Clinical, periop-
erative and outcome data were retrospectively analyzed and 
compared with data of 42 patients after distal pancreactec-
tomy without preoperative stent placement.
Results: No statistically signifi cant difference was present 
in the pancreatic leak rate between the stented (S) and non-
stented (NS) group. The S group had a pancreatic leak rate 
of 36% compared with 45% for the NS group (P > 0.05). The 
most common complications in both groups were manifesta-
tions of pancreatic leak (fi stula, abscess, pseudocyst) with 
abscess rate being similar in the S group (26.3%) vs the NS 
group (26.2%). The wound infection rate was also similar in 
the two groups (S group 11% vs NS group 10%). Morbidity 
and mortality rates were equivalent in both groups. The S 
group had a median length of stay of 6 days compared to 7 
days for the NS group.
Conclusions: Pancreatic duct stent placement offers no 
therapeutic benefi t compared to no intervention in prevention 
of pancreatic leaks prior to distal pancreatectomies. It also 
does not affect the severity of complications, LOS, overall 
morbidity and mortality.
MICROWAVE ABLATION FOR 
HEPATOCELLULAR CARCINOMA IN 
PATIENTS WITH CIRRHOSIS AND 
PORTAL HYPERTENSION
J. Chapochnick Friedmann1,2, M. Olaywi1, 
M. Kinkhabwala1,2, A. Lu1,2, S. Bellemare1,2, P. Gaglio1,2, 
J. Reinus1,2, H. Massoumi1,2 and H. Kalia1,2
1Montefi ore Medical Center, Bronx, NY; 2Albert Einstein 
College of Medicine, Bronx, NY
Background: The purpose of this study is to analyze effec-
tiveness and morbidity of microwave ablation (MW) of HCC 
in patients with cirrhosis and portal hypertension and to 
compare different modalities of liver directed therapy (LDT) 
in association with it.
Methods: From July 2009 to September 2010, 24 patients 
with cirrhosis and portal hypertension underwent 25 surgical 
MW for HCC. A total of 30 tumors were treated. Twenty-one 
patients had postoperative follow and were included in the 
analysis. The results were compared among patients previ-
ously treated with different modalities of LDT; transarterial 
chemoembolization (TACE), TACE + percutaneous radiofre-
quency ablation (RFA) or multiple combinations of 
these.
Results: The results are summarized in the table attached. 
The median follow up was 174 ± 130 days. Most of the 
surgeries were done laparoscopically (86%). There were no 
differences between the groups in terms of age, gender, 
tumor size, severity of liver disease (Child-Pugh score and 
MELD score) and etiology of liver disease. There were no 
differences in morbidity either and all complications were 
mild (Clavien I and II). The residual tumor at one month post 
MW, tumor recurrence and incidence of new tumors on 
Variable Total MWA TACE+MW TACE+RFA+MW Multiple+MW P-value
Patients, n 21 9 6 7 10
Surgeries, n 22 9 6 7 10
Tumors, n 30 12 9 9 13
Age (mean ± SD), years 62 ± 8 63 ± 7 60 ± 9 63 ± 9 62 ± 8 0.89
Gender, n(%) 0.41
 Male 15 (71) 7 (78) 4 (67) 5 (71) 7 (70)
 Female 6 (29) 2 (22) 2 (33) 2 (29) 3 (30)
Etiology, n(%) >0.99
 HCV 19 (86) 8 (89) 5 (83) 6 (86) 9 (90)
 HVB 2 (9) 1 (17) 1 (14) 1 (9)
 Others 1 (5) 1 (11)
Tumor size (mean ± SD), cm 2.7 ± 1.8 2.0 ± 1.4 3.6 ± 2.4 2.8 ± 1.3 3.5 ± 2.1 0.16
Child-Pugh score, n(%) 0.91
 A 18 (82) 8 (89) 4 (67) 6 (86) 7 (70)
 B 4 (18) 1 (11) 2 (33) 1 (14) 3 (30)
MELD (mean ± SD)
 Preop 11 ± 5 12 ± 6 9 ± 4 10 ± 5 11 ± 5 0.71
 Postop 13 ± 5 14 ± 6 10 ± 4 12 ± 5 13 ± 4 0.46
 DMELD 2 2 1 2 2
Morbidity, n(%) 5 (23) 1 (11) 4 (67) None 1 (10) 0.75
 Clavien I 3 3
 Clavien II 2 1 1 1
Residual tumor, n(%) 3 (10.7) 1 (10) 1 (11) 1 (11) 2 (15) 0.41
Recurrent tumor, n(%) 2 (9.5%) None 1 (17) 1 (11) 1 (7.7) 0.41
New Tumors, n(%) 3 (14) None 3 (50) None 1 (10) 0.75
Number of treatments (mean ± SD) 2.2 ± 1 1 ± 0 2.5 ± 0.5 3.1 ± 0.4 3.1 ± 0.3 <0.0001
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follow up were 10.7%, 9.5% and 14% respectively for the 
entire group and they were similar among all subgroups. The 
patients in the MWA group required signifi cantly less treat-
ments than the patients in any other group.
Conclusions: In our series, patients treated with MW alone 
achieve the same results that patients previously treated with 
combinations of LDT.
AGGRESSIVE SURGERY FOR 
UNRESECTABLE PANCREATIC 
NEUROENDOCRINE TUMORS 
FOLLOWING CAPECITABINE-
OXALIPLATIN-BEVACIZUMAB 
CHEMOTHERAPY
Y. Chen1, P. L. Kunz2, G. A. Fisher2, G. A. Poultsides1, 
J. A. Norton1 and B. C. Visser1
1Department of Surgery, Stanford University Medical 
Center, Stanford, CA; 2Division of Medical Oncology, 
Department of Medicine, Stanford University Medical 
Center, Stanford, CA
Background: While neoadjuvent chemotherapy is used 
routinely for some gastrointestinal cancers with the intent of 
“downstaging”, there has been no effective chemotherapeu-
tic regimen for pancreatic neuroendocrine tumors (PNET) 
that would allow this strategy. A single-institution phase II 
study using capecitabine-oxaliplatin-bevacizumab at our 
institution for advanced PNET has shown promising prelimi-
nary results. We evaluated the possibility of aggressive 
surgery following chemotherapy.
Methods: Nineteen patients with locally advanced and/or 
metastatic PNET not considered surgical candidates at 
presentation were enrolled in the study. All patients were 
reassessed on an ongoing basis by the multidisciplinary team 
for the possibility of surgical resection.
Results: Among the 19 patients, 7 were felt to be surgical 
candidates after an average of 11 cycles of chemotherapy 
(range 4–28) because of the response to chemotherapy or 
stable disease after prolonged therapy suggesting favorable 
biology. In two cases, portal vein tumor thrombus withdrew 
suffi ciently to allow resection and vascular reconstruction. 
Six underwent subtotal pancreatectomy and 1 pancreatico-
duodenectomy. Four had concurrent or staged hepatectomy 
and 3 had SMV/portal vein resection. There was no operative 
mortality. Postoperatively, 3 underwent liver radioemboliza-
tion and 1 radiolabeled somatostatin therapy. With a median 
follow up of 13.5 months after surgery, 6 of 7 are alive. One 
died of brain metastases; 3 had slow progression of liver 
metastases, and 3 had stable disease. Two with progression 
of hepatic metastases have re-started chemotherapy.
Conclusions: This capecitabine-oxaliplatin-bevacizumab 
chemotherapy regimen has demonstrated very promising 
results. Selective patients with advanced PNET at presenta-
tion may be candidates for resection after “neoadjuvant” 
chemotherapy.
THE ELEVATION OF ZINC-FINGER 
TRANSCRIPTION FACTOR ZBP-89 IN 
HEPATOCELLULAR CARCINOMA AND 
ITS CLINICAL VALUE
G. G. Chen1, C. Z. Zhang1, Y. Cao2, J. P. Yun2 and 
P. B. Lai1
1The Chinese University of Hong Kong, Hong Kong; 2Sun 
Yat-Sen University, Guangzhou
ZBP-89, a Krüppel-type zinc-fi nger transcription factor, is 
universally expressed and participates in the regulation of 
cell growth and cell death. It has been shown to be elevated 
in some cancers, including gastric cancer, colorectal cancer 
and breast cancer. However, ZBP-89 expression in hepato-
cellular carcinoma (HCC) is not well documented. In this 
study, we examined ZBP-89 expressions in 6 types of HCC 
cell lines and in 14 pairs of HCC tissues and the adjacent 
hepatic tissues by RT–PCR, western blot and immunofl uo-
rescent staining. Another 182 paired tissues consisting of 
tumorous ones and their corresponding non-tumorous ones 
were used to measure expression of ZBP-89. Our results 
showed that ZBP-89 was expressed higher in HCC cancer 
cells than normal liver cells at both mRNA and protein 
levels. Furthermore, ZBP-89 expression was signifi cantly 
higher in tumorous tissues than that in the nontumorou hepa-
tocytes. ZBP-89 was localized in nucleus in most of the cases 
but presented in cytoplasm in 11.5% (21 of 182) of the HCC 
tissues. Altered ZBP-89 expression in HCC was signifi cantly 
correlated with two clinicopathological parameters the his-
tological grade and the status of HBV. Moreover, the high 
expression of ZBP-89 in HCC tissues was associated with 
better survival in patients. Over-expression of ZBP-89 in 
HCC cells dramatically decreased the colonies formation, 
likely via regulating p53 and p21. In conclusion, our data 
suggest that ZBP-89 has anti-tumor property and is a poten-
tial biomarker for prognosis of HCC.
LYMPHADENECTOMY IN THE STAGING 
AND TREATMENT OF INTRAHEPATIC 
CHOLANGIOCARCINOMA – A 
POPULATION-BASED STUDY USING THE 
SEER DATABASE
C. J. Clark, M. L. Kendrick and F. G. Que
Mayo Clinic, Rochester, MN
Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 
second most common primary hepatic malignancy with a 
steady increase in incidence over the last two decades. 
Although lymphatic spread is common with ICC, lymphad-
enectomy is not a widely accepted component of surgical 
resection for ICC. The aim of this study was to characterize 
trends in lymph node assessment and the impact of lymph-
adenectomy on survival in patients with ICC.
Methods: We conducted a population-based study using 
patients with ICC identifi ed in the Surveillance, Epidemiology, 
and End Results (SEER) registry from 1988 to 2007. Survival 
was assessed with Kaplan-Meier and Cox Regression 
analyses.
Results: 4946 patients with ICC were identifi ed with 5.3% 
5-year overall survival. Lymph node evaluation (N0 and N1) 
was available in 49% (n = 2432) of patients and nodal status 
(number removed and number positive) was available for 
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only 14% (n = 680) of patients. A median of two (1 to 33) 
nodes were removed during major hepatic resection. Positive 
lymph node status strongly predicted worse survival in 
resected patients (5-year overall survival 27% vs 5%, p < 
0.001). Increasing number of positive nodes (hazard ratio, 
1.13; 95% CI, 0.94 to 1.32; p = 0.17) or number of nodes 
removed (hazard ratio, 1.03; 95% CI, 0.99 to 1.07; p = 0.11) 
did not predict worse survival.
Conclusion: Nodal status remains an important prognostic 
factor in the survival of patients diagnosed with ICC and 
should be performed in the staging of ICC. However, the 
extent of lymph node evaluation does not signifi cantly 
impact survival.
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SMOKING HISTORY AFFECTS 
SURVIVAL IN HEPATOCELLULAR 
CARCINOMA PATIENTS UNDERGOING 
LIVER RESECTION BUT NOT OTHER 
TREATMENTS
J. J. Clark3 and L. L. Wong1,2
1Cancer Research Center of Hawaii, Honolulu, HI; 
2Hawaii Medical Center-East, Honolulu, Hawaii; 
3Department of Surgery, Honolulu, Hawaii
Purpose: Smoking is a risk factor in development of hepa-
tocellular carcinoma (HCC), but little is known if smoking 
affects survival. Our objective was to examine the effect of 
smoking on survival of patients with HCC.
Methods: A retrospective review of an HCC database 
(1993–2009) identifi ed 629 cases. Data collected included: 
demographics, hepatitis B (HBV), hepatitis C (HCV), diabe-
tes, alcohol use, smoking history, amount of smoking in 
pack-years, tumor characteristics, treatment, recurrence and 
survival. Patients were divided into smokers (n = 354) and 
nonsmokers (n = 275).
Results: Smokers were more likely to be male (60.6% vs. 
45.1%, p = 0.001), have HCV (63.8% vs. 36.2%, p = 0.005), 
drink alcohol (74.4% vs. 25.6%, p = 0.001) and have higher 
BMI (26.9 vs. 25.6, p = 0.009). There was no difference in 
Figure 1. Survival based on rymph node status in patients 
with intrahepatic cholangiocavcionma after major hepatic 
resection
TREATMENT
n = 610
Median survival 
smokers (days)
n = 343
Median survival 
nonsmokers (days)
n = 267
p 
value
No theatment (180) 138 (n = 105) 115 (n = 75) NS
Ablation (n = 232) 780 (n = 139) 824 (n = 93) NS
Chemotherapy (n = 17) 113 (n = 8) 292 (n = 9) NS
Resection (n = 126) 969 (n = 61) 1659 (n = 65) 0.028
Transplant* (n = 55) >1614 (n = 30) >1614 (n = 25) NS
*Median survival not yet reached
age, ethnicity, HCC screening, diabetes, cirrhosis, tumor 
size, stage, MELD or treatment. Among smokers there was 
no difference in pack-years smoked by gender, race, diabe-
tes, HBV or HCV, cirrhosis, or stage. Smoking was not 
associated with survival using Cox regression. Overall sur-
vival between smokers and nonsmokers did not differ using 
Kaplan Meier but when stratifi ed by treatment, survival was 
better in nonsmokers. This effect was independent of the 
pack-years smoked and recurrence.
Conclusions: Smoking does not affect overall survival in 
HCC although smokers who undergo liver resection have 
worse survival compared to nonsmokers. This is independent 
of the amount of smoking, etiology of HCC, and recurrence. 
This effect may be due to the overall health of the surgical 
patient who smokes rather than HCC tumor biology.
ROLE OF ENDOSCOPIC ULTRASOUND 
AND CYST FLUID ANALYSIS IN INITIAL 
EVALUATION AND FOLLOW UP OF 
INCIDENTAL PANCREATIC CYSTIC 
LESIONS
A. Cocieru, S. Brandwein and P. Saldinger
Danbury Hospital, Danbury, CT
Introduction: To assess the role of endoscopic ultrasound 
(EUS) and cystic fl uid analysis in the initial evaluation and 
follow up of incidental pancreatic cystic lesions (PCL).
Methods: Retrospective analysis of patients with incidental 
PCL and had minimal follow-up of 1 year.
Results: There were 62 patients. Mean patient age was 67.7 
years (range, 30–89). Mean follow-up was 23 months (range, 
12–72 months). Mean PCL size was 21.6 mm (6–51). 
Patients with fi ndings suspicious of a malignant PCL were 
referred to surgery. Thirteen patients underwent surgery 
(20.9%). Diagnosis of neoplasm was confi rmed in 11 patients 
and included mucinous cystic tumor (7), adenocarcinoma 
(2), intraductal papillary mucinous neoplasm (1) and cystic 
neuroendocrine tumor (1). Overall malignancy rate among 
patients who underwent surgery was 15.3% (2 patients). In 
10 patients (16.1%) PCL increased in size. Repeated EUS 
was performed in all of them to rule out neoplasm. Mean 
PCL size was larger in the surgical group (27.8 mm) vs. 
stable group (18.8 mm) vs. enlarging PCL group (17.8 mm). 
Mean CEA level from PCL fl uid analysis was also signifi -
cantly higher in surgically treated group (7760) vs. stable 
group (184.7) vs. enlarging PCL group (361.1).
Conclusion(s): EUS can be successfully used to rule out 
pancreatic neoplasms and to follow-up incidentally discov-
ered PCL. High CEA levels >192 ng/ml can be used to 
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reliably distinguish between mucinous and non-mucinous 
cystic neoplasms. The presence of a solid component, pan-
creatic duct dilatation and enlargement during follow up 
require surgical evaluation for possible resection.
CONTINUOUS INFUSION WITH TIMP-3 
PRESERVES LIVER HISTOLOGY BY 
PROMOTING A FAVORABLE CYTOKINE 
PROFILE DURING SUB-LETHAL TOTAL 
HEPATIC ISCHEMIA IN RATS
A. J. Cohen, C. Zetzmann, O. R. Swamy, H. Bohorquez 
and G. E. Loss
Ochsner Clinic Foundation, New Orleans, LA
Background: TNF-α Converting Enzyme (TACE) plays a 
critical role in the infl ammatory cascade after ischemia/reperfu-
sion (I/R) injury. TIMP-3 injected after injury inhibits hepatic 
TACE expression. In this report, we administered TIMP-3 as a 
continuous infusion 1 hour after the ischemic injury.
Methods: Male Wistar rats (n = 4/group) underwent our 
standard total warm ischemia model for 30 minutes. One 
hour after ischemia, all animals were cannulated for 1 hour 
with TIMP-3, a TACE-specifi c inhibitor at a dosage of either 
0 (control group) or 1000 ng/Kg body weight (treatment 
group). After 6, 24, 48 hours or 7 days of reperfusion, blood 
and liver tissue samples were collected. Quantitative ALT 
levels and serum TNF-a, IL-6, and IL-19 levels were mea-
sured. Liver histology was undertaken.
Results: All animals survived sub-lethal hepatic ischemia. 
In control livers at 6 hours, there are notable early ischemic 
changes. TIMP-3 treated livers have intact cytoarchitecture 
for the fi rst 6 hours post I/R. With a continuous TIMP-3 
infusion, there was notable inhibition of TNF-α, IL-6, and 
IL-19 cytokine levels, as well as ALT enzyme activity.
Conclusion: A continuous infusion of TIMP-3 results in a 
cytokine profi le that appears to promote favorable histology 
following sub-lethal total hepatic ischemia in rats. This study 
suggests that TIMP-3 administered as an infusion after I/R 
injury may have a clinical application in saving injured livers.
SALVAGE THERAPY WITH TIMP-3 
PRESERVES LIVER HISTOLOGY BY 
PREVENTING APOPTOSIS DURING 
SUB-LETHAL TOTAL HEPATIC 
ISCHEMIA IN RATS
A. J. Cohen, O. R. Swamy, C. Zetzmann, H. Bohorquez 
and G. E. Loss
Ochsner Clinic Foundation, New Orleans, LA
Background: Prior research has proven the inhibition of 
Tumor Necrosis Factor-α Converting Enzyme (TACE) by 
TIMP-3 and the treatment’s protective role on liver biochem-
istry. We administered TIMP-3 as a bolus injection 1 hour 
after the ischemic injury to examine the drug’s effect on 
infl ammatory cytokines and apoptosis.
Methods: Male Wistar rats (n = 4/group) underwent our 
standard total warm ischemia model for 30 minutes. One 
hour after ischemia, all animals were injected with TIMP-3, 
at a dosage of either 0 (control group) or 1000 ng/Kg body 
weight (treatment group). After 6, 24, 48 hours or 7 days of 
reperfusion, blood and liver tissue samples were assessed for 
ALT levels, hepatic Caspases-3/7, and serum TNF-a, IL-6, 
and IL-19 levels. Liver histology was undertaken.
Results: All animals survived sub-lethal hepatic ischemia. 
After 7 days, the control animals showed typical ischemic 
changes. The treated group showed near normal liver paren-
chyma. With TIMP-3 salvage therapy, there was signifi cant 
inhibition of ALT and Caspases-3/7 enzyme activities. Also, 
levels of infl ammatory cytokines TNF-a, IL-6 and IL-19 
were signifi cantly inhibited in TIMP-3-treated animals.
Conclusion: Salvage therapy with TIMP-3 results in an 
inhibited infl ammatory cascade with decreased Caspase 
activity, which appears to promote favorable histology fol-
lowing sub-lethal total hepatic ischemia in rats. TIMP-3 
administered after I/R injury may have a clinical application 
in rescuing injured livers.
Table 1. Signifi cant inhibition of infl ammatory biomarkers 
by TIMP-3
6 hours 24 hours 48 hours
TNF-α (pg/ml) 137.2 C 59.5 C 35.1 C
49.8 T** 31.4 T* 19.5 T*
IL-6 (pg/ml) 237.1 C 163.2 C 73.3 C
161.5 T* 142.5 T 45.8 T
IL-19 (pg/ml) 360.8 C 177.9 C 24.5 C
165.1 T** 65.5 T** 21.1 T
ALT (u/l) 720.2 C 565.2 C 343.4 C
460.0 T* 396.7 T* 214.8 T
c = saline control; T = TIMP-3-treated
*p < 0.05
**p < 0.01
Table 1. Signifi cant inhibition of infl ammatory biomarkers 
by TIMP-3
6 hours 24 hours 48 hours
ALT (u/l) 258.4 C 192.2 C 76.4 C
198.7 T* 118.1 T* 59.3 T
Caspases-3/7 (rlu) 1123.2 C 753.9 C 491.3 C
317.6 T** 437.5 T* 403.8 T
TNF-α (pg/ml) 59.0 C 33.1 C 17.2 C
40.7 T** 23.5 T** 11.3 T**
IL-6 (pg/ml) 135.6 C 68.4 C 49.9 C
89.5 T** 39.5 T** 38.9 T*
IL-19 (pg/ml) 367.0 C 141.8 C 18.3 C
129.5 T** 68.7 T** 16.1 T
c = saline control; L = TIMP-3-treated
*p < 0.05
**p < 0.01
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REGIONALIZATION OF PANCREATIC 
RESECTION FOR MALIGNANCY IN NY 
STATE
D. D. Cox1,2, A. Miller1 and B. Kuvshinoff1,2
1Roswell Park Cancer Institute, Buffalo, NY; 
2SUNY-University of Buffalo Department of Surgery, 
Buffalo, NY
Introduction: Regionalization of pancreatic resections for 
malignancy in New York State (NY) has shifted procedures 
to higher volume centers with a reduction in perioperative 
mortality. We examined the patterns of patient access and 
distances traveled for NY residents having pancreatic resec-
tions relative to the availability of a high volume facility 
(HVF) in their local Health Service Area (HSA).
Methods: Hospital discharge abstracts were obtained from 
NY Statewide Planning and Research Cooperative System 
for patients undergoing pancreaticoduodenectomy or total 
pancreatectomy for malignancy from 2002 to 2007. Hospitals 
were assigned to similarly distribute average annual volume 
tertiles. Travel distance to the hospital performing surgery 
was estimated by zip codes. Logistical regression analysis 
was used to model the probability of perioperative mortality 
and hospital access.
Results: NY residents underwent 2568 pancreatic cancer 
resections. Perioperative mortality was 2.2% in HVF, 4.7% 
in medium volume facilities (MVF), and 7.4% in low volume 
facilities (LVF), (p < 0.01). Patient travel distances were 
greater to HVF (24.7 mi) and MVF (21.5 mi) facilities com-
pared to LVF (9.6 mi., p < 0.01). Patients without commer-
cial insurance or Medicare were twice as likely to have 
surgery at a low volume hospital (p < 0.01).
Conclusion: Patients living near a high volume hospital are 
no more likely to have surgery at the high volume facility 
than a low volume one. Patients living close to a medium or 
low volume facility are most likely to have surgery at that 
facility. Local health care service practices and patient insur-
ance status may limit access to high volume pancreatic 
cancer facilities.
Probability of having pancreatic surgery done in a hospital volume group based on 
highest volume facility in patients Health Service Area (HSA), * (p < 0.01) within 
Volume Tier
Highest Volume Facility Hospital Annual Volume Tier
In Patients HSA
HIGH ( > 32)
N = 731
MEDIUM (10–32)
N = 879
LOW(1–9)
N = 958
HIGH 34% 26% 40%
MEDIUM 18% 57% 25%
LOW 30% 27% 43%
NONE 30% 43% 27%
LAPAROSCOPIC DISTAL 
PANCREATECTOMY, A SINGLE 
CENTRE EXPERIENCE
M. D’Hondt1,3, A. Roy1,2,3, M. Dagenais1,2,3, 
R. Letourneau1,2,3, M. Plasse1,2,3, R. Lapointe1,2,3 and 
F. Vandenbroucke-Menu1,2,3
1Hopital Saint Luc - CHUM, Montreal, QC; 
2Centre de Recherche Du CHUM , Montreal, QC; 
3Universite de Montreal, Montreal, QC
Introduction: Laparoscopic surgery for pancreatic diseases 
has gained in popularity during the last decade. We have been 
performing laparoscopic distal pancreatectomy (LDP) since 
2005; therefore we report our current experience.
Materials and methods: This is a single centre retrospec-
tive study including 40 patients who underwent LDP between 
2005 and 2010. Perioperative factors were analyzed as such 
operative time, blood loss, hospital stay, postoperative 
recovery and complications.
Results: There were 12 men and 28 women (mean age 52.6 
years). Indications consisted of mucinous cystadenoma, 
(n = 16), endocrine tumors (n = 8), serous cystadenoma (n = 
4) and chronic pancreatitis (n = 2), IPMN (n = 3), adenocar-
cinoma (n = 4), pseudopapillary tumor (n = 1), insulinoma 
(n = 1) and renal metastasis (n = 1). Ten patients (25%) had 
LDP with splenic preservation using Warshaw technique 
without any postoperative splenic ischemia or infarction. 
Mean blood loss was 125 ml (range 0–500 ml) and mean 
operating time was 283 min (range 135–460 min). Mean 
tumor size was 3.2 cm (range 0.8–7.0 cm). Conversion rate 
was 17.5% (7 cases). There was no postoperative mortality. 
Postoperative complications occurred in 10 patients (25.0%): 
pancreatic fi stula (Grade A) in 9 patients (22.5%), hepatic 
abscess in 1 patient (2.5%) and gastroparesis in 3 patients. 
No patient needed surgical reexploration. The median hospi-
tal stay was 7 days.
Conclusions: Results of our study showed that LDP is a safe 
and effective procedure and a reasonable alternative to open 
distal pancreatectomy in selected patients. From our own 
experience, Warshaw technique is a good option for splenic 
preservation.
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WHAT IS THE ROLE OF INTRA-
OPERATIVE ULTRASOUND IN THE 
DETECTION OF HEPATIC LESIONS IN 
THE ERA OF MODERN PREOPERATIVE 
IMAGING?
M. D’Hondt1,3, F. Vandenbroucke-Menu1,2,3, M. Plasse1,2,3, 
R. Letourneau1,2,3, A. Roy1,2,3, M. Dagenais1,2,3 and 
R. Lapointe1,2,3
1Hopital Saint Luc - CHUM, Montreal, QC; 2Centre de 
Recherche Du CHUM - CRCHUM, Montreal, QC; 
3Universite de Montreal, Montreal, QC
Introduction: The role of intraoperative ultrasound (IOUS) 
is questioned because of recent progress in medical imaging. 
The aim of the study was to determine the accuracy of IOUS 
in detection of hepatic tumor (HT) compared to preoperative 
CT and MRI.
Material and methods: This is a retrospective study includ-
ing 320 patients. One hundred seventy seven patients were 
evaluated using an 8-slice CT-scan (SCAN8), 85 using a 
64-slice CT-scan (SCAN64) and 167 using an MRI with or 
without a CT-scan. Pathological result was used as gold 
standard.
Results: The number of HT found on pathology per patient 
was 0, 1, 2, 3 and more for 8, 190, 60, 22 and 40 patients 
respectively. Fifty-nine patients had a primary HT and 261 
hepatic metastasis. The correlation rates for number of 
detected lesions compared to pathology results were 0.664 
for the SCAN8, 0.761 for the SCAN64, 0.647 for MRI, and 
0.895 for IOUS. All correlations were signifi cant different 
from 0 (p < 0.001). IOUS concordance rate was signifi cantly 
higher than with SCAN8 (p = 0.014), SCAN64 (p = 0.049) 
and MRI (p = 0.003). The planned hepatic resection was 
extended due to IOUS in 27 patients (15%) with a SCAN8, 
in 11 patients (13%) with a SCAN 64 and in 21 patients 
(12%) with an MRI (intergroup difference not signifi cant).
Conclusions: Compared to more recent preoperative 
imaging, IOUS still remains superior for detection of HT. 
Planned hepatic resection was extended in 12 to 15% of 
patients. Then, IOUS remains mandatory as a routine proce-
dure in patients having hepatic resections.
OUTCOMES OF MINIMALLY-INVASIVE 
DISTAL PANCREATECTOMY: SINGLE 
INSTITUTION COMPARISON OF 
ROBOTIC AND LAPAROSCOPIC 
METHODS
M. Daouadi, J. L. Steel, M. H. Choudry, D. R. Magge, 
A. H. Zureikat, D. L. Bartlett, K. K. Lee, J. A. Moser AJ 
and H. J. Zeh
University of Pittsburgh Medical Center, Division of 
Surgical Oncology, Pittsburgh, PA
Background: Multicenter data indicate that laparoscopic 
distal pancreatectomy (LDP) has safety equivalent to open 
distal pancreatectomy (ODP). We hypothesized that improved 
dexterity and visualization during Robotic Assisted Distal 
Pancreatectomy (RADP) would create improved outcomes 
compared to LDP.
Methods: Outcomes of RADP for 12 benign lesions and 8 
pancreatic ductal adenocarcinomas (PDA) were matched to a 
contemporaneous lap DP group with 28 PDA and 28 benign 
lesions, between January 2004 and September 2010. 
Perioperative outcomes and 30 days mortality were compared.
Results: The age, gender, and racial demographics of the 
cases/lap controls were statistically equivalent, and the 
groups were matched in terms of American Society of 
Anesthesiologists Score and tumor size (Table 1). RADP and 
Table1. Outcomes of laparoscopic versus robotic-assisted distal pancreatectomy
Parameters Lap Distal(LDP) Robotic Assisted (RADP) p Value
Age (Mean, SD) 61 (15) 56 (14) 0.16
Race (Caucasian) 48 (90%) 18 (95%) 0.57
Gender (Female) 37 (66%) 12 (60%) 0.63
ASA Score (I & II) 44% (I & II) 55% 0.45
(III & IV) 56% (III & IV) 45%
Size of primary tumor (Median, IQR) 3.5 (2.5) 2.5 (2) 0.16
OR time (Median, IQR) 300 (176) 312 (162) NS
Conversion to open 12 (21%) 0 (0%) P Ch sq 0.024 0.02
Blood loss (Median, IQR) 200 (287, 20–1500) 150 (200, 30–700) 0.7
Transfusion 9 (17%) 0 (0%) P ch sq 0.51 0.05
ICU Admission 20 (36%) 6 (30%) 0.46
30 days morbidity 25 (45%) 8 (44%) 0.99
Complications (Claviean Score) Minor (1&2) 19% Minor (1&2) 10% 0.22
Major (3&4) 3% Major (3&4) 0% 
Pancreatic Fistula (all grades) 18 (44%) 7 (35%) 0.51
ISGP grade A (23%) A (25%) 0.78
B (5.3%) B (10%) 
Readmission Rate 13 (24%) 7 (35%) 0.37
LOS (Median, IQR) 6.5 (4) 6 (3) 0.35
30 days Mortality 0% 0%
Margin from the tumor > = 2(81%) > = 2 (95%) 0.26
Lymph nodes harvested (median, IQR) 9 (11.0) 17 (17.3) 0.09
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LDP demonstrated similar operative times, estimated blood 
loss, rates and severity of pancreatic fi stula, and lengths of 
hospital stay. However, RADP demonstrated a signifi cantly 
reduced rate of conversion to open as well as a reduced 
frequency of blood transfusion with a trend toward improved 
lymph node harvest (p = 0.09).
Conclusions: RADP is equivalent to LDP in all important 
measures of outcome and safety without an increased OR 
time. However, RADP signifi cantly reduced the risk of con-
version to open as well as a trend toward a reduced risk of 
blood transfusion. These benefi ts were independent of the 
learning curve for RADP. We speculate that improved dex-
terity and stereoscopic visualization enable superior control 
of bleeding and completion of intended minimally-invasive 
resections. These benefi ts of robotic DP should be investi-
gated in a prospective multicenter trial.
RECURRENT COLORECTAL LIVER 
METASTASES FOLLOWING 
RADIOFREQUENCY ABLATION, 
TREATMENT FAILURE OR DISEASE 
PROGRESSION?
K. M. Davis1, C. W. Hammill2, M. A. Cassera2 and 
P. D. Hansen2
1Department of Surgery, Maricopa Integrated Health 
System, Phoenix, AZ; 2Hepatobiliary and Pancreatic 
Surgery Program, Providence Portland Medical Center, 
Portland, OR
Background: A detailed analysis of treatment failures may 
lead to a better understanding of the appropriate and rational 
application of radiofrequency ablation (RFA) in the manage-
ment of colorectal liver metastases (CRLM).
Methods: A review of patients with CRLM treated by lapa-
roscopic RFA was performed. An outside HBP trained 
surgeon retrospectively analyzed preoperative imaging to 
determine ‘technical’ resectability of the CRLM. ‘Medical’ 
resectability was determined by the primary HBP surgeon. 
Disease recurrence was analyzed to determine the role a 
resection may have played in patient outcome.
Results: 130 patients underwent laparoscopic RFA for 
CRLM. Mean tumor number was 2.0 and size was 2.9 cm. 
83/130 (64%) patients were unresectable, 31 technically and 
52 medically. 47/130 (36%) were electively ablated. With a 
mean follow-up of 28.6 months, 67/130 patients developed 
recurrence. Twenty-two (33%) of the 67 patients with recur-
rence were liver only, 8 of these had been ablated electively. 
Five of 8 would have been prevented by initial resection. 
Two of these had repeat RFA and remain disease free, one 
had chemotherapy, one refused further medical intervention, 
and one was lost to follow up.
Conclusions: Two-thirds of the recurrences were extrahe-
patic at the time of presentation. These patients were unlikely 
to have benefi ted from initial resection. Eight of 22 patients 
with liver only recurrence underwent RFA electively. Five of 
these 8 recurrences may have been prevented by an initial 
resection, although 2 had salvage RFA. Up to 3 of the 47 
(6.4%) patients who had an elective RFA missed an oppor-
tunity for cure.
SEVERE ACUTE PANCREATITIS AND 
ABDOMINAL COMPARTMENT 
SYNDROME – INCIDENCE AND 
OUTCOMES OF DECOMPRESSIVE 
LAPOROTOMY
P. J. Davis, M. Molinari, T. Topp and M. Walsh
Department of Surgery, Division of General Surgery, 
Dalhousie University, Halifax, NS
Objective: To determine the incidence and outcomes of 
decompressive laparotomy in patients with severe acute 
pancreatitis (SAP) and abdominal compartment syndrome 
(ACS).
Methods: Using our ICU database we identifi ed patients 
presenting to our ICU with a diagnosis of pancreatitis (ICD 
9 code 577.x) between July 1, 2005 and June 30, 2009. 
Charts were reviewed, and patients who did not meet the 
Atlanta criteria for SAP were excluded. A database was then 
compiled using our electronic medical record system 
(Horizon Patient Folder), to obtain demographic data (age, 
gender, obesity, Charlson comorbidity score), details of the 
admission (type of pancreatitis, Ranson and APACHE 
scores), whether ACS developed (intrabdominal pressure 
>20 mmHg with signs of organ failure), whether decompres-
sive laparotomy was preformed, and the sequelae of this 
intervention. Descriptive and parametric statistics were then 
performed.
Results: In all, 72 patients were identifi ed, of which, 27 
were excluded. Of the remaining 45, 13 patients (28%) 
developed ACS, and 16 (36%) decompressive laparotomies 
were preformed. Overall mortality was 24% and was not 
altered by decompressive laparotomy. Decompressive lapa-
rotomy was associated with signifi cant morbidity (dehis-
cence (19%), ventral hernia (50%), wound infection (63%), 
pancreaticocutaneous fi stula (19%), enterocutanous fi stula 
(44%)). Multivariable analysis showed that mortality in 
patients with SAP was associated with obesity (p = 0.019) 
and Charlson comorbidity score (p < 0.001), while 
decompressive laparotomy was associated with male gender 
(p = 0.012).
Conclusion: Decompressive laparotomy does not alter mor-
tality in patients with SAP and ACS, but is associated with 
signifi cant morbidity.
UNDERSTANDING BARRIERS TO 
ACCESS IN THE MANAGEMENT OF 
COLORECTAL CANCER LIVER 
METASTASES: A QUALITATIVE 
APPROACH
K. S. Devitt1, M. E. Wiebe1, L. Sandhu1, E. D. Kennedy1,2, 
N. N. Baxter1,3, A. R. Gagliardi1, D. R. Urbach1 and 
A. C. Wei1
1University Health Network, Toronto, Ontario; 2Mount 
Sinai Hospital, Toronto, Ontario; 3St Michael’s Hospital, 
Toronto, Ontario
Background: Colorectal cancer (CRC) is the 3rd most 
common malignancy in North America. Liver resection is the 
standard treatment for CRC liver metastases but hepatec-
tomy is often underutilized in Canada. Results from a physi-
cian self-reported survey demonstrated a knowledge gap 
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exists between current practice patterns and best available 
evidence. However, contributing factors are not well 
understood.
Objective: To explore the factors responsible for the 
underutilization of surgical management in CRC liver 
metastases.
Methods: Two focus groups were conducted using a moder-
ated, semi-structured format with general surgeons and 
medical oncologists in Ontario. Three domains of interest 
were explored regarding the management of CRC liver 
metastases: processes of care, barriers and enablers of care. 
Responses were recorded and analyzed using standard quali-
tative methods. Themes were extracted by three coders using 
open and axial coding using a modifi ed grounded theory 
approach.
Results: Themes emerged included: variability of the pro-
cesses of care, barriers to accessing health care resources, 
and issues related to medical expertise and continuing 
medical education. Barriers identifi ed included: economic 
and resource constraints, lack of physician engagement, and 
diffi culty ensuring quality of local medical expertise. Multi-
disciplinary Cancer Conferences were identifi ed as a key 
enabler of clinical care and were a focal point for interdisci-
plinary communication and continuing medical education.
Conclusions: The quality of care for patients with CRC 
liver metastases can be optimized by reducing the knowledge 
gap between current practice patterns and evidence based 
treatment. These study results identify opportunities for 
quality improvement interventions that will overcome these 
barriers to care.
EXTERNAL VALIDATION OF A PRE-
OPERATIVE NOMOGRAM TO PREDICT 
RISK OF PERI-OPERATIVE MORTALITY 
FOLLOWING LIVER RESECTIONS FOR 
MALIGNANCY
M. Dhir1, S. K. Reddy2, L. M. Smith1, F. Ullrich1, 
J. W. Marsh2, A. Tsung2, D. A. Geller2 and C. Are1
1University of Nebraska Medical Center, Omaha, NE; 
2University of Pittsburgh Medical Center, Pittsburgh, PA
Introduction: We have recently developed a pre-operative 
nomogram by using a population based database (National 
Inpatient Sample–NIS) to predict the risk of peri-operative 
mortality following liver resections for malignancy. The aim 
of the current study is to undertake an external validation of 
this population dataset-based nomogram by using data 
derived from a single institute.
Methods: The NIS database (2000–2004) was used initially 
to develop the nomogram which included age, race, sex, liver 
primary, coagulopathy, renal failure, heart failure and other 
major co-morbidites. The dataset for external validation was 
obtained from a high volume single institute specializing in 
hepatobiliary surgery, and validation of nomogram was 
undertaken by using calibration plots and concordance 
index.
Results: A total of 794 patients who underwent liver resec-
tion from 2000 to 2010 at the single institute were included 
in the validation set with an observed mortality rate of 1.6%. 
The mean total points for this sample of patients was 124.9 
(SE = 1.8, range = 0 to 383) which translates to a nomogram 
predicted mortality rate of 1.5%, which is similar to the 
actual observed overall mortality rate. The nomogram con-
cordance index was 0.65 (95% confi dence interval of 0.46 to 
0.82) and calibration plots stratifi ed by quartiles revealed 
good agreement between the predicted and observed mortal-
ity rates (Figure).
Conclusions: The current study provides external validation 
of the pre-operative nomogram to predict the risk of peri-
operative mortality following liver resection for malignancy. 
The nomogram provides good prediction of peri-operative 
mortality for both population-based datasets as well as data 
derived from single institutes.
EARLY LIVER RECURRENCE AFTER 
ADJUVANT CHEMOTHERAPY FOR 
COLORECTAL CANCER IS ASSOCIATED 
WITH WORSE DISEASE-FREE SURVIVAL 
FOLLOWING HEPATIC RESECTION
A. L. Diniz, H. S. Ribeiro, W. L. Costa, M. D. Begnami, 
P. Herman, M. J. Silva, C. A. Mello and F. J. Coimbra
Hospital A. C. Camargo, Sao Paulo, Sao Paulo
Aim: The aims of this study are to determine prognostic 
factors of survival and to analyze the impact of che motherapy 
prior to liver surgery for colorectal metastases in outcome.
Methods: This is a retrospective study that included 170 
patients with liver metastases from colorectal tumors who 
were treated with curative intent between 1998 and 2009. 
They were divided in four groups: patients who had no che-
motherapy prior to liver surgery; patients who had preopera-
tive chemotherapy for liver lesions; patients who developed 
liver metastasis after adjuvant chemotherapy for the primary 
tumor up to and after six months.
Results: Preoperative chemotherapy for liver metastasis 
was performed in 81 patients, 28 had no chemotherapy and 
61 received adjuvant therapy after resection of the primary 
tumor, 17 up to 6 months and 44 more than six months after 
surgery. Disease-free survival numbers of these groups were 
25.2%, 67.9%, 29.4% and 48.6% (P = 0.002). Bilobar 
disease, extra-hepatic lesions and the primary tumor N stage 
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were also prognostic factors of disease-free survival. In 
multivariate analysis, these three factors remained as inde-
pendent prognostic factors of disease-free survival. 
Chemotherapy as a factor was not an independent one. 
However, patients who had liver metastasis up to 6 months 
after adjuvant chemotherapy for the primary tumor had a HR 
for recurrence of 3.2 (P = 0.034).
Conclusion: Along with bilobar disease, extra-hepatic 
lesions and primary tumor N stage, patients who had liver 
metastasis up to six months after adjuvant chemotherapy for 
the primary tumor had worse prognosis, which suggests 
unfavorable tumor biology.
PANCREATIC RESECTION FOR 
METASTATIC TUMORS TO THE 
PANCREAS: ANALYSIS OF 5 CASES AND 
REVIEW OF LITERATURE
A. L. Diniz, R. M. Spencer, W. L. Costa, H. S. Ribeiro, 
M. D. Begnami, M. J. Silva and F. J. Coimbra
Hospital A. C. Camargo, Sao Paulo, Sao Paulo
Aims: The aim of this study was to evaluate the outcome of 
patients who underwent pancreatic resection for metastatic 
tumors and review the literature concerning this topic.
Methods: Five patients underwent pancreatic resection for 
metastatic tumors from February 1999 to August 2003. 
Patients who had surgery for local tumor invasion to the 
pancreas were excluded.
Results: Primary tumors were: ovarian carcinoma (n = 2), 
melanoma (n = 1) and renal cell carcinoma (n = 2). Two 
patients underwent pancreatoduodenectomy; two a distal pan-
createctomy and one had total pancreatectomy. Four patients 
had distant relapses and none had local recurrence. One patient 
is alive with 8 years of follow-up. She had a diagnosis of 
ovarian coriocarcinoma. Among the ones who recurred, a 
patient who also had the diagnosis of ovarian cancer had 
peritoneal relapse and died 15 months after surgery. The indi-
vidual with the diagnosis of melanoma had brain metastasis 
and died 3 months after surgery. One patient with renal cell 
carcinoma (RCC) died of complications after a colonic resec-
tion for diverticulitis 26 months after pancreatic surgery. He 
had no signs of disease. The other one with RCC was alive 
but with pulmonary relapse after 50 months, but was lost to 
follow-up. Review of the literature identifi ed a 5-year survival 
up to 72.6% in patients with renal cell carcinoma.
Conclusions: Pancreatic resection for metastatic disease 
should be reserved for extremely selected cases. It seems to 
be associated with good survival rates in patients with renal 
cell carcinoma and ovarian cancer who present with 
pancreatic-only disease relapse.
A RISK ASSESSMENT OF BILIARY 
COMPLICATIONS AFTER DECEASED 
DONOR LIVER TRANSPLANTATION
C. Enestvedt, M. Yin, B. K. Enestvedt, B. S. Diggs, 
D. L. Scott and S. L. Orloff
Oregon Health & Science University, Portland, OR
Background: Biliary complications cause signifi cant mor-
bidity following deceased donor orthotopic liver transplanta-
tion (OLT). We hypothesized that bile duct ischemia time 
(donor organ off-ice to hepatic artery reperfusion) signifi -
cantly affects biliary complications. This study aimed to 
identify risk factors associated with biliary complications, 
including the bile duct ischemia time.
Methods: A retrospective review was performed on all 
OLTs from 2003 to 2009. Recipient and donor demographics, 
anastomosis type, stent or T-tube placement, bypass, brain 
death v cardiac death donors (DCD) and postoperative 
biliary complications were assessed. The latter were divided 
into biliary stricture, anastomotic stricture, and bile leak 
identifi ed at ERCP or PTC. Univariate and multivariable 
regression analyses were performed.
Results: There were 354 liver transplants during the study 
period. The biliary complication rate was 21%. Overall bile 
duct stricture rate was 16%. There were 16 bile leaks (5%) 
and 36 anastomotic strictures (10%). Anastomotic strictures 
were more frequent with concomitant bile leak (p = 0.045). 
Predictors of biliary stricture included DCD donor and PSC 
and alcohol as causes of liver failure (Table). Bile duct, 
warm, and cold ischemia times, MELD score, T-tube or stent, 
and anastomosis type were not associated with biliary 
complications.
Table. Multivariate predictors of bile duct stricture 
following deceased donor OLT
OR 95% CI P value
Donation after 
cardiac death 
(DCD)
21.49 5.07–116.05 <0.001
Primary Sclerosing 
Cholangitis 
(PSC)
4.93 1.23–19.91 0.023
Laennec’s cirrhosis 2.81 1.25–6.52 0.013
Conclusions: The rate of biliary complications in this series 
was similar to other published reports. Despite a theoretical 
relationship between arterial ischemia and biliary complica-
tions, bile duct ischemia time did not predict the presence of 
bile duct stricture or leak. Further research is required to 
identify the factors which contribute to bile duct morbidity 
after OLT.
FACTORS PREDICTIVE OF OUTCOMES 
FROM CAUDATE LOBE RESECTION
R. W. Farmer, C. R. Scoggins, K. M. McMasters and 
R. C. Martin
Division of Surgical Oncology, Louisville, KY
Background: Despite the increasing frequency of liver 
resection for multiple types of disease, caudate lobe resection 
remains a rare surgical event. The goal of this study is evalu-
ate possible predictors of outcome in patients undergoing 
caudate resection.
Methods: We reviewed a 1712 patient prospective hepato-
pancreatico-biliary database from January 2000 to September 
2010, identifying 31 hepatectomy patients undergoing 
caudate lobe resection. Clinicopathologic characteristics and 
outcomes data were compared using Chi-Square, T-test, 
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ANOVA, Kaplain–Meier, and Cox Regression. Primary end-
points were complication and overall survival (OS).
Results: 31 patients underwent caudate lobe resection for 
cholangiocarcinoma (41.9%), metastatic colorectal cancer 
(38.7%), Hepatocellular cancer (9.7%), or benign disease 
(9.7%); 9 patients (29%) had further liver resection. 
Complications occurred in 54.8% (17/31) of patients with 
median grade of 2 (scale = 1 to 5). Tobacco abuse was associ-
ated with increased risk of operative complication (58.8% 
vs. 14.3%, p = 0.011) as was CEA > 34 for metastatic CRC 
patients (33.3% vs 66.7% p = 0.022), and total number of 
lesions (mean 5.83 vs 1.80, median 2 vs 2, p = 0.001). 
Complication was decreased in patients undergoing concur-
rent 2nd and 3rd segmentectomies (0% vs. 28.6%, p = 0.018). 
Median OS was 19 months. The only factors noted to affect 
OS was infl ammatory pathology on intraoperative liver 
biopsy (20% vs. 71.4%, p = 0.021), and CEA > 34 (16.7% 
vs. 83.3%, p = 0.036).
Conclusions: With appropriate patient selection, caudate 
lobe resection is an effective component of surgery for 
hepatic disease. Further investigation is needed to determine 
factors that will improve outcomes.
MANAGEMENT ALGORITHM FOR 
HEPATIC ANGIOMYOLIPOMA
M. Feinman1, S. Marcus1,2 and S. Joseph1,2
1New York Medical College, Valhalla, NY; 
2St Vincent’s Medical Center, Bridgeport , CT
Introduction: Hepatic Angiomyolipoma (AML) is a rare 
entity with approximately 200 cases reported. Due to the 
limited experience with this disease no standard treatment 
algorithm exists. Since the recent discovery of malignant 
AML the treatment paradigm has changed. We set out to 
develop a simple management algorithm.
Methods: The largest case series contains 49 patients. There 
is a strong female predominance (60%). Most tumors are 
found incidentally. Tumors vary in size between 2 and 20 cm. 
These lesions are often found via abdominal CT, while 
Ultrasound and MRI have also been used. Preoperative diag-
nosis based on imaging was incorrect in greater than 50% of 
patients. The vast majority of patients underwent surgical 
resection. Of the few that were managed conservatively 
(n = 8), no progression of disease was noted. Recurrence 
after resection was reported in three patients; one died of 
their disease.
Conclusions: We have presented a simple algorithm for the 
management of hepatic AML. Due to the increasing inci-
dence of HCC in non-cirrhotic patients, coupled with the 
inaccuracy of preoperative radiographic diagnosis, we advo-
cate for surgical resection of hepatic AML greater then 5 cm. 
Final diagnosis of hepatic AML is only possible after immu-
nohistochemical confi rmation. However, we suggest that 
biopsy should not be performed as this has been shown to 
reduce survival for patients with HCC. Resection of the 
tumor results in minimal morbidity and mortality with 
improvement in quality of life. With the development 
of minimally invasive liver surgery, early referral to an 
advanced liver center for any questionable liver lesions is 
advised.
Factor
No 
Complication Complication P value
Tobacco 
Abuse
14.3% 58.8% .011
CEA > 34 33.3% 66.7% .022
Mean # 
Lesions
 5.83  1.80 .001
Factor Alive Dead P value
Infl ammatory 
pathology
20% 71.4% .021
CEA > 34 16.7% 83.3% .036
ANATOMIC LIVER RESECTIONS FOR 
THE TREATMENT OF HEPATOLITHIASIS
E. O. Figueroa, M. A. Gabrielli, F. Navarrete, F. Pimentel, 
J. Guerra, J. Valbuena, J. Martinez, S. Guzman and N. Jarufe
Pontifi cia Universidad Catolica de Chile, Santiago, Ragion 
Metropolitana
Background: Intrahepatic stones (IHS) can be associated to 
serious complications and its treatment is reason for 
controversy.
Objectives: To evaluate clinical data, peri-operative and 
long-term results of anatomic hepatic resections for IHS.
Patients and methods: Clinical data, immediate and long-
term outcomes of a cohort of 50 consecutive patients who 
underwent anatomic hepatic resections for IHS between 
November 1986 and July 2010 were analyzed. Immediate 
outcomes included stone clearance rate (SCR), operative 
morbidity and mortality. Long-term results were focused on 
stone recurrence rate, with a median follow-up of 73.8 (range 
6–274) months.
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Results: Mean age was 49.1 years, 66% were women. 
Almost all patients (98%) were symptomatic, being abdomi-
nal pain (89.3%), cholangitis (34.7%) and jaundice (32.6%) 
the most frequent symptom. Abdominal ultrasound was diag-
nostic in 76.1%. ERCP was performed in 73.9%, MRI in 
98% after year 2000. Twenty-nine patients (58%) had lithia-
sis in the left biliary tree, 17 (34%) in the right biliary tree 
and 4 patients (8%) had bilateral disease. Left lateral seg-
mentectomy was done in 50%. Ninety four percent with right 
IHS had history of Cholecystectomy vs 59.3% in patients 
with left IHS (p = 0.027). The immediate SCR was 95.6%. 
Morbidity was 32%. Recurrent stones in 5 patients. There 
was no mortality in this series.
Conclusions: Anatomical hepatic resection is a safe and 
effective surgical treatment for IHS with a low rate of resid-
ual disease. There is a relationship between history of biliary 
surgery and development of IHS in the right biliary tree that 
may be explained by unsuspected right artery lesion during 
cholecistectomy.
ROSIGLITAZONE ANTAGONIZES 
GEMCITABINE ACTIVITY IN 
PANCREATIC ADENOCARCINOMA VIA 
CELL-CYCLE ARREST
M. A. Firpo1,2, J. D. Coursen1, B. R. White1, G. L. Livers1 
and S. J. Mulvihill1,2
1Department of Surgery, Salt Lake City, UT; 
2Huntsman Cancer Institute, Salt Lake City, UT
Gemcitabine has remained the standard of care for pancreatic 
cancer even though its clinical effi cacy is limited. Gemcitabine 
is a nucleoside analog that incorporates into DNA during the 
synthesis phase, resulting in S-phase arrest and apoptosis. 
Since combination therapy may augment the activity of gem-
citabine, we examined the potential to improve the gem-
citabine effectiveness through combined treatment with 
rosiglitazone. However, we found that gemcitabine and rosi-
glitazone demonstrate antagonistic effects on pancreatic 
adenocarcinoma (PA) cell lines. PA cell lines BxPC-3 and 
PANC-1 were exposed to graded doses of gemcitabine and 
rosiglitazone, either alone or in combination, and prolifera-
tion was measured. The drug interaction was assessed using 
isobologram analysis (Figure 1) and the multiple drug effect 
equation of Chou-Talalay. At all drug combinations tested, 
combination index values were greater than 1, indicating 
antagonism between gemcitabine and rosiglitazone in both 
BxPC-3 and PANC-1. We further examined this antagonism 
using fl ow cytometry to assess cell cycle progression. As 
expected, gemcitabine alone resulted in S-phase arrest in 
BxPC-3 and PANC-1 cells, consistent with accumulation of 
DNA lesions. Treatment with rosiglitazone alone resulted in 
G1 arrest in both BxPC-3 and PANC-1 cells. In BxPC-3 cells 
co-treated with gemcitabine and rosiglitazone, S-phase arrest 
was reduced by 43%. In PANC-1, the rosiglitazone effect 
was delayed relative to gemcitabine, yet drug combination 
still resulted in 15% reduction of gemcitabine-dependent 
S-phase arrest. The data suggest rosiglitazone antagonizes 
gemcitabine activity via G1 arrest thereby blocking progres-
sion to S-phase. This antagonism should be considered when 
treating diabetic cancer patients with rosiglitazone.
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Figure 1. Rosiglitazone (RGZ) and gemcitabine (GEM) act antagonistically in pancreatic adenocarcinoma cell lines. The 
interaction between rosiglitazone and gemcitabine was analyzed in BxPC-3 (A) and PANC-1 (B) cell lines. Cell viability was 
measured using resazurin reduction after 72 hours of drug exposure. Isobologram analysis shows the lines of additivity for 
ED25 (25% effective dose), ED50, and ED75. The actual drug concentrations required for ED25, ED50, and ED75 are repre-
sented by points on the graph. Antagonism is indicated by points falling above the line of additivity
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SERUM MMP-7 IS AN INDEPENDENT 
PREDICTOR OF SURVIVAL IN PATIENTS 
WITH PANCREATIC ADENOCARCINOMA
M. A. Firpo1,2, J. E. Shea1, K. A. Brown1, L. L. Emerson3, 
K. M. Boucher2,4, C. L. Scaife1,2 and S. J. Mulvihill1,2
1Department of Surgery, Salt Lake City, UT; 2Hunstman 
Cancer Institute, Salt Lake City, UT; 3Department of 
Pathology, Salt Lake City, UT; 4Department of Oncological 
Sciences, Salt Lake City, UT
Although serum MMP-7 has been proposed as a diagnostic 
biomarker for pancreatic adenocarcinoma (PA), its prognos-
tic effi cacy has not been evaluated. We assessed serum 
MMP-7 levels in 80 consecutive subjects with histologically 
or cytologically confi rmed PA by ELISA. Survival analyses 
were performed using univariate and multivariate Cox 
models. MMP-7 levels ranged from 2 to 99 ng/ml with a 
median of 10 ng/ml and mean of 14 ± 14 (mean ± standard 
deviation). MMP-7 levels were a signifi cant predictor of 
survival when MMP-7 was used as a continuous variable 
(P = 0.037). Serum MMP-7 was inversely related to survival, 
with higher levels corresponding to poorer prognosis. PA 
patients with MMP-7 serum levels below the mean had a 
median survival of 330 days, while those above mean 
MMP-7 serum levels had a median survival of 167 days, a 
difference of over 5 months. Diagnostic plots of serum 
MMP-7 showed a marked distribution change at a threshold 
of 20 ng/ml, which also showed prognostic signifi cance 
when used as a discrete cut off in Cox models (P = 0.002). 
Subjects with MMP 7 above this threshold had higher than 
expected risk indicating that 20 ng/ml may be useful clini-
cally. Serum MMP-7 remained a signifi cant predictor of sur-
vival after stratifying for treatment and dissemination status 
in multivariate analysis. Serum MMP-7 levels may be useful 
for patient stratifi cation and to direct treatment options in 
patients with pancreatic cancer. The mechanistic relation-
ships between high MMP-7 levels and poorer outcomes 
require further study.
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Figure 1. Overall survival in PA subjects using serum MMP-7 as a grouping variable. Kaplan-Meier curves are shown using 
MMP-7 as a discrete variable with a threshold cut-off at the mean value of 14 ng/ml (left panel) and as a discret variable with 
a threshold cut-off of 20 ng/ml (right panel). PA patients withlow serum MMP-7 had longer overall survival than PA patients 
with high serum MMP-7
OUTCOMES ARE INFERIOR IN 
PATIENTS REQUIRING VENOUS 
RESECTION FOR LOCALLY ADVANCED 
PERIAMPULLARY TUMORS
C. P. Fischer1, B. Fahy1, T. Aloia1, E. Jo2, C. H. Ahern3 and 
W. E. Fisher2
1The Methodist Hospital and Weill Cornell Medical 
College, Houston, Texas; 2Baylor College of Medicine, 
Houston, Texas; 3Baylor College of Medicine, Houston, 
Texas
Background: Single-institution series suggest that patients 
with periampullary cancer who require portal venous resec-
tion (PVR) at the time of pancreaticoduodenectomy have 
similar outcomes to patients who undergo standard pancre-
aticoduodenectomy. We report the results of a multi-
institutional data registry with contemporary cancer-specifi c 
and perioperative outcomes.
Methods: From 2002 to 2010, 621 consecutive patients 
with periampullary tumors underwent pancreaticoduodenec-
tomy; 527 (85%) without and 94 (15%) with PVR at two 
high-volume academic medical centers. Outcomes for these 
two cohorts were recorded in a prospective institutional data-
base. Categorical variables were examined with Chi Square/
Fisher’s exact test, and continuous variables with the 
Wilcoxon rank sum test. Survival was calculated using the 
Kaplan-Meier method.
Results: No differences were noted between the two cohorts 
regarding demographic variables, or comorbidities. The 
addition of PVR to standard pancreaticoduodenectomy 
resulted in increased operative time, blood loss, and need for 
blood transfusion compared to patients who underwent stan-
dard pancreaticoduodenectomy. Patients who underwent 
PVR were more likely have major complications (Clavien 
Grade ≥3) and had prolonged length of stay. Despite the use 
of neoadjuvant chemoradiation in patients requiring PVR for 
borderline resectable disease, patients requiring PVR were 
more likely to have incomplete (R1) resections and a shorter 
survival.
Conclusion: These data suggest that, contrary to prior reports, 
patients who require venous resection may not have periopera-
tive or cancer-specifi c outcomes that are equivalent to patients 
who undergo standard pancreaticoduodenectomy.
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A RANDOMIZED TRIAL OF GENOMIC 
DATA SHARING OPTIONS IN PANCREAS 
TISSUE DONORS
W. E. Fisher, S. E. Hodges, J. M. Oliver, S. G. Hilsenbeck, 
T. Wang, F. C. Brunicardi, R. A. Gibbs and 
A. L. Mcguire
Baylor College of Medicine, Houston, Texas
Background: Although it has become possible to identify 
an individual from pooled DNA data, investigators are 
encouraged to comply with established data sharing policies. 
We conducted a single blind, randomized controlled trial of 
three different types of consent to assess the impact on 
research enrollment and participants’ data sharing choices. 
The three different consent types tested afforded different 
levels of control over the decision about data sharing
Methods: Subjects were enrolled with an IRB-approved 
waiver of consent and randomized to one of three types of 
consent (traditional, binary, or tiered). After signing, partici-
pants were debriefed, given a detailed review of the data 
sharing options in all three consent forms, and an option to 
change their data sharing choice or opt out of the study 
entirely.
Results: There were no signifi cant differences in demo-
graphic characteristics between the three consent arms. Most 
subjects initially chose public (internet) release of their per-
sonal genomic information but after debriefi ng, almost a 
third of the patients chose more restricted release. No patients 
opted out of the study (refused to donate tissue for genomic 
research).
Conclusion: Our fi ndings suggest that most patients are 
willing to donate pancreatic tissue for DNA sequencing 
studies but, when well-informed, a signifi cant portion prefer 
restricted release of their genomic data. Tissue donors being 
enrolled in DNA sequencing studies should be informed 
about genomic data sharing risk and provided with the option 
to restrict data sharing.
Randomized Consent Type
Total (n = 101) Traditional (n = 35) Binary (n = 32) Tiered (n = 34)
Original Data Release Selection
Public (Internet) 89(88) 35(100) 28(88) 26(77)
Restricted 7(7) - - 7(21)
No Release 5(5) - 4(13) 1(3)
Final Data Release Selection*
Public (Internet) 60(60) 23(66) 21(66) 16(47)
Restricted 35(35) 11(31) 9(28) 15(44)
No Release 6(6) 1(3) 2(6) 3(9)
Changed Selection** 31(31) 12(34) 9(28) 10(30)
Data are #(%) of participants
*No signifi cant difference in fi nal data release selection based on original consent type P = 0.443
**No signifi cant difference in number of patients that changed consent type based on original consent type P = 0.845
PANCREATIC RESECTION WITHOUT 
ROUTINE INTRAPERITONEAL 
DRAINAGE
W. E. Fisher, S. E. Hodges, E. J. Silberfein, A. Artinyan, 
E. Jo, C. H. Ahern and F. C. Brunicardi
Baylor College of Medicine, Houston, TX
Background: Due to the high incidence of pancreatic leak, 
most surgeons routinely place intraperitoneal drains at the 
time of pancreatic resection, however, this practice has 
recently been challenged.
Objective: To evaluate clinical outcomes when pancreatic 
resection is performed without operatively placed intraperi-
toneal drains.
Methods: 227 consecutive patients underwent pancreatic 
resection (153 pancreaticoduodenectomy, 74 distal pancre-
atectomy) and outcomes were recorded in a prospective data-
base. In the fi rst cohort (179 patients) drains were routinely 
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placed at the time of surgery and removed when output 
decreased to <20 mL/day and amylase concentration was 
<360 IU/mL. In the second cohort (48 patients) no intraop-
erative drains were placed. Outcomes were compared with 
Chi-square/Fisher’s exact test for categorical variables, and 
the Wilcoxon test for continuous variables (median, inter-
quartile range).
Results: Demographic, surgical, and pathologic details 
were similar between the two cohorts. The rate of clinically 
signifi cant pancreatic fi stula was also similar between the 
two cohorts. There was an increased need for readmission 
and percutaneous drainage in the cohort without intraopera-
tive drainage. However, elimination of intraoperative drains 
did not change the rate of intra-abdominal abscess, overall 
morbidity, or mortality, and decreased the rate of wound 
infection (Table 1).
Conclusion: This study suggests that abandoning the prac-
tice of routine intraperitoneal drainage after pancreatic resec-
tion may not increase the severity of postoperative 
complications.
Intraoperative Drain 
(n = 179)
No Intraoperative Drain 
(n = 48) P-value
Pancreatic Fistula (ISGPF A, B, or C) 81 (45%) 6 (13%) 0.0001
Clinically Signifi cant Pancreatic Fistula (ISGPF B, C) 19 (11%) 6 (13%) 0.712
Post-Operative
Percutaneous
Drain
2 (1%) 6 (13%) 0.001
Intra-abdominal
Abscess
6 (3%) 2 (4%) 0.677
Wound Infection 19 (11%) 0 (0%) 0.020
Readmission 6 (3%) 8 (17%) 0.003
Reoperation 8 (4%) 0 (0%) 0.208
Morbidity 50 (28%) 16 (33%) 0.119
Mortality (30-Day) 1 (1%) 1 (2%) 0.379
Routine NGT (n = 179) No NGT (n = 48) P-value
Delayed Gastric Emptying (ISGPS)
A 7 (4%) 4 (8%) 1.000
B 6 (3%) 0 (0%)
C 2 (1%) 0 (0%)
NGT Reinsertion 5 (3%) 4 (8%) 0.078
Pneumonia 19 (11%) 6 (13%) 0.712
Morbidity 50 (28%) 16 (33%) 0.119
Mortality (30-Day) 1 (1%) 1 (2%) 0.379
ROUTINE NASOGASTRIC SUCTION IS 
UNNECESSARY AFTER PANCREATIC 
RESECTION
W. E. Fisher, S. E. Hodges, A. Artinyan, E. J. Silberfein, 
E. Jo, C. H. Ahern and F. C. Brunicardi
Baylor College of Medicine, Houston, TX
Background: Most surgeons routinely place a nasogastric 
tube (NGT) at the time of pancreatic resection.
Objective: To evaluate clinical outcome when pancreatic 
resection is performed with and without routine postopera-
tive nasogastric suction.
Methods: 227 consecutive patients underwent pancreatic 
resection (153 pancreaticoduodenectomy [141 (92%) pylo-
rus-sparing], 74 distal pancreatectomy). In the fi rst cohort 
(n = 179), an NGT was placed in all patients at the time of 
surgery and removed in the postoperative period at the sur-
geon’s discretion. In the second cohort (n = 48), the NGT 
was removed in the operating room in all patients and 
replaced only if the patient developed gastric distension or 
emesis. Outcomes for these two cohorts were recorded in a 
prospective database and compared using Chi-Square/
Fisher’s exact test and the Wilcoxon rank sum test.
Results: Demographic, surgical, and pathologic details 
were similar between the two cohorts. In the fi rst cohort, 
the median day for NGT removal was postoperative day 2 
(interquartile range, 1–4). After removal of the original NGT, 
5 patients (3%) required reinsertion of another NGT 
later during their hospital stay. Among the group without 
routine postoperative nasogastric suction, 4 patients (8%) 
required insertion of an NGT postoperatively and this was 
accomplished without any complications. There were no 
statistically signifi cant differences between the two cohorts 
with respect to the incidence of delayed gastric emptying 
(ISGPS A, B,C), pneumonia, overall morbidity or mortality 
(Table 1).
Conclusion: Our data suggest that elimination of routine 
postoperative nasogastric suction after pancreatic resection 
may not be associated with any adverse outcomes.
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IN-VITRO SENSITIVITY PROFILE OF 
LOCALIZED AND METASTATIC 
PANCREATIC CANCER
J. Franko1, M. M. Bilimoria2, S. Chalikonda3, 
D. A. Iannitti4 and C. Tian5
1Mercy Medical Center, Des Moines, IA; 2Northwestern 
Community Hospital, Arlington Heights, IL; 3Cleveland 
Clinic, Cleveland, OH; 4Carolinas Medical Center, 
Charlotte , NC; 5Precision Therpeutics, Pittsburgh, PA
Background: Gemcitabine and 5-fl uorouracil represent 
mainstay of chemotherapy for pancreatic cancer. Effi cacy is 
limited and chemotherapeutic alternatives are poorly defi ned. 
Moreover, differential activity in localized versus metastatic 
cancers has been identifi ed among other gastrointestinal 
cancers. We tested the hypothesis that in vitro sensitivity of 
pancreatic cancer is the same among localized/resectable 
versus metastatic cases.
Methods: 93 pancreatic cancer cases with complete testing 
for 5-FU and gemcitabine using an in vitro chemosensitivity 
assay (ChemoFx, Precision Therapeutics, Pittsburgh, PA) 
were included. Sensitive/resistant status was determined 
based on in vitro dose response curves.
Results: There were 68 resected and 25 metastatic cases 
(total 93). Resistance to both 5-FU and gemcitabine was seen 
in 68 cases (73%), 11 were sensitive to 5-FU or gemcitabine, 
and 14 were sensitive to both agents. Proportion of sensitive 
tumors was similar among localized/resected versus meta-
static cases for 5-FU, gemcitabine and their combination, but 
different for oxaliplatin and docetaxel (Table). A total of 42 
(45%) tumors were resistant to all tested drugs (31/68, 46% 
localized versus 11/25, 44% metastatic; p = 0.891).
SOLID PSEUDOPAPILLARY TUMOR OF 
THE PANCREAS: SURGICAL OUTCOMES 
AT A SINGLE TERTIARY CENTER
J. S. Galovich, F. G. Que, M. B. Farnell, J. H. Donohue, 
K. M. Reid-Lombardo, D. M. Nagorney and 
M. L. Kendrick
Mayo Clinic College of Medicine, Rochester, MN
Background: Solid pseudopapillary tumor of the pancreas 
(SPT) is a poorly defi ned, uncommon neoplasm with known 
malignant potential. Current data is limited to case reports 
and small series. Our aim was to characterize the presenta-
tion, surgical treatment and outcomes of a single, tertiary 
center specializing in pancreatic disease.
Methods: A retrospective review of all patients undergoing 
surgical treatment of SPT from 1990 to 2010 was performed. 
All data is presented as mean ± standard deviation or median 
with range.
Results: We identifi ed 25 patients with a mean age of 27; 
all but two were female. Common presenting signs included 
abdominal pain (60%) and nausea/vomiting (20%). Surgical 
resection included distal pancreatectomy in 16 (64%) and 
pancreaticoduodenectomy in 8 (32%). Mean operative time 
and blood loss were 212 (±87) minutes and 336 (±300) ml 
respectively. Median tumor size and lymph nodes harvested 
were 5.7 (2–11) cm and 6 (0–19) respectively. No patient had 
lymph node involvement and all patients underwent an R0 
resection. Tumor recurrence developed in 2 patients (8%) 13 
and 19 months postoperatively, presenting as liver metastasis 
in one and carcinomatosis in another.
Conclusion: SPT is an uncommon neoplasm affecting pre-
dominantly women. Surgical resection should continue to be 
the mainstay of treatment. Tumor recurrence occurs in 8% 
of patients. Surveillance after resection may be indicated 
although chemotherapeutic or surgical treatment options for 
these patients remains undefi ned.
FACTORS ASSOCIATED WITH 
RECIDIVISM FOLLOWING 
PANCREATICODUODENECTOMY
S. S. Grewal1,2, R. J. McClaine1,2, D. J. Hanseman1,2,3, 
J. J. Sussman1,2, N. Schmulewitz1,2, M. Smith1,2, 
K. A. Choe1,2, O. O. Olowokure1,2, M. Mierzwa1,2 and 
S. A. Ahmad1,2
1The Pancreatic Disease Center , Cincinnati, Ohio; 2The 
University of Cincinnati Medical Center, Cincinnati, Ohio; 
3Center For Sustainment of Trauma and Readiness Skills 
(C-STARS), United States Air Force, Cincinnati, Ohio
Introduction: Few reports have delineated factors associ-
ated with recidivism following pancreaticoduodenectomy. 
Factors related to readmission may include post-operative 
morbidity and/or functional status of the patient. This study 
aims to retrospectively review our institutional experience 
with readmission following the Whipple procedure.
Methods: After IRB approval, the UC pancreatic surgery 
database was retrospectively analyzed. Recidivism was 
defi ned as readmission to the primary or a secondary hospital 
within 1 month and 1–3 months. The associations between 
recidivism, perioperative factors and patient characteristics 
were evaluated by multivariate analysis.
Results: During the past fi ve years, 124 patients underwent 
pancreaticoduodenectomy. The 30-day, 1–3 month and 90 
Individual Chemosensitivity 
All tumors (n = 93)
# sensitive / # tested (%)
Drug Resected Metastatic p
5-FU 13/68 (19%) 5/25 (20%) 0.924
gemcitabine 14/68 (21%) 7/25 (28%) 0.576
5-FU + 
gemcitabine
27/58 (47%) 7/16 (44%) 0.842
irinotecan 20/59 (34%) 6/17 (35%) 0.915
oxaliplatin  3/63 (5%) 5/18 (28%) 0.012*
carboplain 13/55 (24%) 8/22 (36%) 0.257
5-FU + oxaliplatin 25/58 (43%) 5/16 (31%) 0.566
gemcitabine + 
cisplatin
14/56 (25%) 5/17 (29%) 0.757
docetaxel  0/52 (0%) 5/24 (21%) 0.002*
NOTE: Not all tumors were tested for all drugs.
* denotes statistical signifi cance p < 0.05
Conclusions: In vitro resistance rate to traditional chemo-
therapy is high (73%). Chemosensitivity to 5-FU, gem-
citabine, and their combination is similar between localized 
and metastatic cases. Chemosensitivity to oxaliplatin and 
docetaxel is signifi cantly higher among metastatic as com-
pared to localized cases. Clinical outcome correlation is 
planned to determine clinical value of the ChemoFx assay.
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day recidivism rates were 14.5%, 18.5%, and 27.4%. The 
most common reasons for readmission included dehydration 
and/or malnutrition (37% of readmissions), and pain (12%). 
Patients who underwent pancreaticoduodenectomy for 
chronic pancreatitis were more likely to be admitted within 
3 months of surgery when compared to patients that under-
went surgery for malignancy (p < 0.01). Intraoperative trans-
fusion was also associated with 1–3 month and 90-day 
recidivism (p < 0.01). Pre-operative comorbidities, including 
the Charleston Co-morbidity Index, number of pre-discharge 
complications, type of Whipple reconstruction, pre-operative 
biliary stenting, need for vascular reconstruction and patient 
BMI were not associated with recidivism.
Conclusion: Our data confi rms previous reports indicating 
high re-admission rates following pancreaticoduodenectomy. 
To our knowledge, our report is the fi rst to demonstrate 
chronic pancreatitis as an independent risk factor for re-
admission. Patients that are debilitated and need signifi cant 
pain control may require prolonged hospital stays. Further 
studies need to be performed to confi rm these results.
GALLBLADDER CARCINOMA: 
EXPERIENCE AT A NON-URBAN 
REFERRAL CENTER
D. R. Hall1, J. W. Jones1,2 and J. R. Lee1,2
1East Tennessee State University James H. Quillen College 
of Medicine Department of Surgery, Johnson City, TN; 
2Blue Ridge Surgical Associates, Johnson City, TN
Background: Gallbladder carcinoma is a rare but aggres-
sive malignancy. Aggressive operative intervention by hepa-
tobiliary surgeons is the key to patient survival. We present 
ten cases of gallbladder carcinoma referred to our non-urban 
tertiary care center over a three-year period.
Methods: Ten patients with gallbladder carcinoma were 
referred to our center from 2007 to 2010. Patients were 
referred by physicians located in Tennessee and Virginia 
(total population 275,150).
Results: Nine patients underwent radical cholecystectomy 
with segment 4b and 5 hepatectomy. Eight patients under-
went portal lymphadenectomy. Pathologic examination 
revealed two patients with stage 1A, three patients with stage 
1B, one patient with stage 2A, one patient with stage 2B, and 
three patients with stage 4 carcinoma. Follow-up time ranged 
from 6 to 44 months, with a mean of 30 months. Overall 
patient survival is 60%, with 100% disease-free survival 
amongst patients with stage 1A, 1B, and 2A gallbladder 
carcinoma. Aggressive disease progression and early 
mortality were seen in the patients with stage 2B and 4 
carcinoma.
Conclusions: Early diagnosis and aggressive hepatobiliary 
surgical treatment remain the best hope for survival in 
patients with gallbladder carcinoma. Our non-urban tertiary 
care center is managed by two surgeons with hepatobiliary 
fellowship training. Patient survival in our center is compa-
rable to survival at urban tertiary care centers. SEER data 
shows the nationwide incidence of biliary malignancies like 
gallbladder cancer is increasing. More hepatobiliary sur-
geons and hepatobiliary centers in non-urban areas are neces-
sary to meet the growing needs of patients.
HEALTH CARE DELIVERY FOR 
HEPATOCELLULAR CARCINOMA IN 
MISSISSIPPI: DO DISPARITIES EXIST?
T. S. Helling
University of Mississippi Medical Center, Jackson, MS
Health care delivery represents the fi nal pathway converting 
advances in science to better outcomes. Disparities in delivery 
may impact eventual patient outcomes for many public health 
concerns, including cancer. Mississippi (MS) has been char-
acterized as one of the most underprivileged states in the 
union. It is the intent of this study to determine outcomes for 
hepatocellular carcinoma (HCC) across the state compared to 
national (US) data. ACS NCDB, SEER, and Mississippi 
Cancer Registry data was used. From 2000 to 2007 it was 
extrapolated that 1,272 Mississippians developed HCC. The 
age-adjusted rate trended lower than US rates. There was no 
difference in MS rates from rural versus urban or Delta versus 
non-Delta counties. Only 549 patients were treated in ACS 
CoC hospitals in the state (n = 14). There was no difference 
in age distribution, but more MS patients presented with stage 
III or IV disease. Fewer MS patients received surgery for HCC 
(15.85% vs. 25.88%, p < 0.0001) and fewer received addi-
tional treatment (12.02%vs. 18.14%, p < 0.0001). Overall 
survival in MS was lower than US (9.4% vs. 15.0%), including 
stage III (4.9% vs. 18.2%) and IV (5.2% vs. 15.0%) disease. 
Fifty-seven percent of patients were treated outside ACS CoC 
hospitals or not treated at all. When treated, patients more 
often had advanced stage disease and were less likely to 
receive surgical therapy. Outcomes for advanced stage disease 
may refl ect these disparities. In an underprivileged state deliv-
ery of health care may be a signifi cant obstacle to advanced, 
coordinated cancer care.
ROBOTIC-ASSISTED MINIMALLY-
INVASIVE CENTRAL 
PANCREATECTOMY: VIDEO 
AND OUTCOMES
H. T. Huss, D. L. Bartlett, H. J. Zeh and A. J. Moser
University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Central pancreatectomy is debated for low 
grade tumors of the central pancreas to preserve parenchyma 
and the spleen. We present a video and outcomes of the 
largest series of robotic-assisted minimally-invasive central 
pancreatectomies (RACP) to date.
Methods: Eight RACP were performed between August 
2009 and June 2010 at a high-volume center. The da Vinci® 
Surgical System was used for all eight cases (Intuitive 
Surgical, Sunnyvale California).
Results: The indications for surgery were benign cystic neo-
plasm (5) and pancreatic neuroendocrine tumor (3). The 
average age of the study population was 60 (range 32–75 
years), and all but two were women. The average tumor size 
was 3.3 cm (range 1.9–6.0 cm). All patients achieved R0 
status, although the fi rst patient was converted to open to 
control bleeding. The spleen was preserved in all eight. The 
pancreatic remnant was drained via pancreaticogastrostomy in 
six cases and pancreaticojejunostomy in two. Surgical drains 
and pancreatic duct stents were placed routinely. The average 
operative time was 425 minutes (range 305–506 min), with 
mean blood loss of 187 ml (range 50–350 ml). The mean 
hospital length of stay was 10 days (range 7–19). Seven 
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patients developed pancreatic fi stula (88%). There were two 
clinically signifi cant leaks and one required percutaneous 
drainage (ISGPF Grade C). None of the patients required 
insulin at discharge or the 30 day postoperative visit.
Conclusions: RACP is a complex minimally invasive opera-
tion that can be performed safely in experienced hands. In this 
early experience non-clinically signifi cant pancreatic fi stula 
rates were high, but endocrine function was highly preserved.
POST-OPERATIVE BILE LEAKAGE 
IN LIVER RESECTION: EARLY 
EXPERIENCE IN NATIONAL 
GENERAL HOSPITAL H. ADAM 
MALIK MEDAN INDONESIA
B. Irwan and B. Surya
National General Hospital H. Adam Malik Medan 
Indonesia, Medan, Sumatera Utara
Background: Post-operative bile leakage in liver resection 
is still one of the most common complications leading to a 
prolonged hospital stay. The knowledge of risk factors and 
meticulous liver dissection could reduce its incidence.
Methods: This study included any patient with primary or 
metastatic liver tumor. Makuuchi criteria were used to select 
the appropriate patients. Bile leakage test was carried out by 
injecting the normal saline solution via stump of the cystic 
duct. A tube drain was then inserted along the transected area 
and connected to close drainage system. Bile leakage was 
considered as continuous drainage with a bilirubin level 
>5 mg/dL, longer than 7 days.
Results: From April 2009 to 2010, Fourteen patients under-
went liver resection in our hospitals. Five patients (35.7%) 
were enrolled for major liver resection which 3 of them 
should have pre-operative portal vein embolization prior 
operation due to small size for future remnant liver volume. 
Most of the tumor were primary liver origin (64.3%, n = 9), 
where as the rest of them were metastatic liver from colorec-
tal cancer. Bile leakage developed in 3 cases (21.4%), which 
two of them underwent right extended hepatectomy. The 
mean volume bile leak was 62 ± 135 ml/day (range from 0 
to 450 ml/day). All the biliary leak stopped spontaneously at 
day 11 and 23 without any intervention.
Conclusions: Bile leakage in liver surgery managed conser-
vatively gives good results. Transection of liver parenchyma 
was considered to be the most important maneuver to reduce 
the leak.
VARYING CLINICAL AND 
RADIOLOGICAL PRESENTATION OF 
DUODENAL GASTROINTESTINAL 
STROMAL TUMORS
K. L. Jackson1, D. J. Grand2, M. B. Resnick2 and 
K. P. Charpentier2
1University of Utah, Salt Lake City, U; 2Brown University, 
Providence, RI
Objective: Duodenal gastrointestinal stromal tumors 
(GISTs) account for 6% of GISTs. We describe the wide 
variation in clinical and radiological presentation, the 
approach to surgical management and outcomes.
Methods: Retrospective chart review of eight consecutive 
patients with duodenal GIST, from 1/1/2001 to 3/1/2010.
Results: The average age was 56 years (42–73). The most 
common presentation was anemia (75%), followed by gastro-
intestinal bleeding (62.5%), abdominal pain (25%), weight 
loss (25%) and diarrhea (12.5%). Tumors ranged from 
3–11.5 cm and were distributed in the second portion (4), third 
portion (3), and fourth portion (1) of the duodenum. Only 3/8 
tumors were correctly identifi ed pre-operatively. Wide vari-
ability on cross sectional imaging led to tumors being incor-
rectly identifi ed as neuroendocrine tumor (2), mucinous cystic 
neoplasm (1), duodenal sarcoma (1) and not visualized (1). 
(Figure 1) Three patients underwent segmental duodenectomy 
and four patients underwent pancreaticoduodenectomy. All 
patients who had surgical resection are alive and disease free, 
with an average follow-up of 943 days (23–2212 days). One 
patient received no intervention and was lost to follow up.
Conclusions: Our study highlights the wide variability in 
the clinical and radiographic presentation of duodenal GISTs. 
Only 38% of cases are correctly diagnosed pre-operatively. 
An improved understanding of the varying clinical and radio-
graphic appearance of duodenal GIST may lead to improved 
pre-operative diagnosis and treatment planning. Long-term 
results following surgical resection can be excellent, with 
100% disease free survival in our series. An approach to 
surgical management is proposed.
Figure 1a. revals a ducdenal GIST which has intense enhancement in the arterial phase (arrow) similar to a typical pancreatic 
neuroendocrine tumor. b. shows a duodenal GIST also in second portion of the duodenum, that is hypoattenuated (arrow) and 
has an appearance similar to a cystic neoplasm of the pancreas
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THE MCGILL BRISBANE PRE 
OPERATIVE CLINICAL SCORE 
IS A BETTER PREDICTOR 
OF RESECTABILITY 
AT PANCREATICODUODENECTOMY 
THAN IMAGING
M. Jamal1, J. Abou Khalil1, E. Simoneau1, P. Chaudhury1, 
M. Hasanain1, J. Tchervenkov1, S. Doi2 and J. Barkun1
1McGill University Health Center, Montreal, Quebec; 
2University of Queensland , Brisbane, Queensland
Purpose: The goal for surgical resection of pancreatic ade-
nocarcinoma (PA) is to achieve an R0 resection but this is 
not reliably predicted by use of conventional imaging modal-
ities. We have previously described and validated the McGill-
Brisbane scoring system (MBSS), which predicts survival in 
palliative PA patients based on 4 clinical variables recorded 
at the time of fi rst clinical encounter. The aim of the current 
study in patients undergoing pancreaticodudenectomy for PA 
is therefore to determine the value of MBSS in predicting 
postoperative margin status.
Methods: We conducted a retrospective study of 84 con-
secutive patients diagnosed with PA who had a pancreati-
codudenectomy at our institution from January 2001 to 
August 2009. Multivariable analyses were performed to 
determine predictors of margin status on pathology.
Results: Based on radiology 32.5% were inaccurately 
thought to be amenable to an R0 resection (See patient char-
acteristics Table). The preoperative MBSS was superior to 
imaging and signifi cantly discriminative of margin status on 
ROC analysis with optimal cutoff at MBSS > 12: the odds 
of a non-R0 margin was 3.56 (95% CI 1.34–9.46) times those 
of an R0 margin with 77% specifi city and 52% sensitivity 
and positive likelihood ratio of 2.2. Thus if the non-RO status 
is expected to be present in a third of subjects overall, those 
with a MBSS > 12 have a 20% increased chance of this 
outcome.
Conclusion: The MBSS is a preoperative predictor of 
margin status in patients undergoing pancreaticodudenec-
tomy and can be used as an additional tool to stratify patients 
in a clinical or trial setting.
MAJOR HEPATIC RESECTION 
COMBINED WITH PORTAL VEIN OR 
HEPATIC ARTERY RECONSTRUCTION 
FOR ADVANCED BILIARY CARCINOMA 
IN THE HEPATIC HILUM
H. Kamachi, T. Kamiyama, M. Tahara, T. Kakisaka, 
H. Yokoo, K. Nakanishi, M. Taniguchi, K. Yamashita and 
S. Todo
General Surgery, Graduate School of Medicine, Hokkaido 
University, Sapporo, Hokkaido
Purpose: We evaluated whether hepatectomy with vascular 
reconstruction (VR) for biliary carcinoma is justifi ed in terms 
of complications and outcome.
Patients: Patients with hilar cholangiocarcinoma (n = 39) 
and gallbladder carcinoma (n = 6) who underwent over bi-
sectionectomy and biliary reconstruction were enrolled. 
Right hemihepatectomy (n = 29; two with pancreaticoduo-
denectomy), left hemihepatectomy (n = 10), right trisectio-
nectomy (n = 4), left trisectionectomy (n = 1) and right 
anterior and left medial sectionectomy (n = 3) were per-
formed. Preoperative portal vein embolization was per-
formed on 27 of 31 patients underwent right side hepatectomy. 
VR was required on 14 of these 45 (31.1%) patients (portal 
vein reconstruction, n = 9; hepatic artery reconstruction, 
n = 4; portal vein and hepatic artery reconstruction, n = 1).
Result: There were no signifi cance differences between 
non-VR and VR group in operation time (non-VR vs. VR: 
614 ± 127 vs. 720 ± 201 min) and blood loss (non-VR vs. 
VR: 1316 ± 775 vs. 1705 ± 834 ml). Postoperative liver 
failure (serum T.bil >5 mg/dl after 7POD) occurred 8 patients 
(non-VR, n = 7; VR, n = 1) but not resulted in lethal. Early 
and late vascular complications as thrombosis and stenosis 
were not observed. Mortality case include hospital death was 
not recorded. Pathological surgical margins negative/positive 
rates were 58/42% in non-VR group, and 50/50% in VR 
group (N.S.). The 3- and 5-year survival rates were 58 and 
44% in the non-VR group and 41 and 0% in the VR group, 
respectively (p = 0.06, log-rank test).
Conclusion: We conclude hepatectomy with VR for biliary 
carcinoma is acceptable operative procedure and has benefi ts 
considering its 3-year survival rate. Effective adjuvant 
therapies should be established to improve survival.
N (%)
Variable
Median (range)
N = 83
Age
 Median 65 y
 Range 23–88 y
 Missing N = 4
Sex
 Men 44 (53)
 Women 39 (47)
Tumor size
 Median 3.1 cm
 Range 1–11 cm
 Missing N = 4
Presenting symptoms
 Weight loss (any) 56 (67.5)
 Weight loss > 10% 40 (48.2)
 Smoking 21 (25.3)
 Pain 47 (56.6)
 Jaundice 65 (78.3)
Margin status
R0 56 (67.5)
R1 27 (32.5)
1 year Survival
R0 Overall = 85.6%
Recurrence free = 66.5%
R1 Overall = 68.4%
Recurrence free = 42.8%
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ANALYZE OF THE RISK FACTORS OF 
DEATH FROM CANCER PROGRESSION 
WITHIN 1 YEAR AFTER HEPATECTOMY 
FOR THE PATIENTS WITH 
HEPATOCELLULAR CARCINOMA (HCC)
T. Kamiyama1, K. Nakanishi2, H. Yokoo1, H. Kamachi2, 
M. Tahara1, T. Kakisaka1, M. Taniguchi2, M. Matsushita3 
and S. Todo1
1General Surgery, Hokkaido University, Sapporo, 
Hokkaido; 2Department of Organ Transplantation and 
Regenerative Medicine, Hokkaido University, 
Sapporo, Hokkaido; 3Graduate School of Health Sciences, 
Sapporo, Hokkaido
Objective: The long survival must be hoped when hepatec-
tomy was performed for the patients with hepatocellular 
carcinoma (HCC). Unfortunately, some patients are died 
from cancer progression within 1 year after hepatectomy. We 
analyzed the risk factors of early cancer-death.
Methods: Between 1997 and 2009, consecutive 522 patients 
who underwent hepatectomy were classifi ed to Group A 
(dead from cancer progression within 1 year after hepatec-
tomy) and Group B (alive over 1 year after hepatectomy). 
Risk factors were analyzed.
Results: The cause of death were cancer progression (150; 
78.1%), operation related (1; 0.5%), hepatic failure (15; 
7.8%) and other (26; 13.5%). Group A and Group B included 
55 cases and 466 cases. The signifi cant factors related with 
early cancer death by univariate analysis were albumin level, 
Child-Pugh classifi cation, AFP level, AFP-L3 level, 
PIVKA-II level, anatomic resection, tumor number, tumor 
size, differentiation, portal vein invasion, hepatic vein inva-
sion, distant metastasis and curability. Multivariate analysis 
revealed that AFP level >1000 ng/ml, tumor number >4, 
tumor size >5 cm, differentiation; poor, portal vein invasion. 
Of the preoperative risk factors as AFP level, tumor number 
and tumor size, 3 (1.1%) of 280 patients with no risk factors, 
12 (7.8%) of 153 patients with one risk factor, 24 (32.9%) 
of 73 patients with two factors, and 9 (60.0%) of 15 patients 
with three risk factors died within 1 year (p < 0.0001).
Conclusion: Hepatectomy should be carefully selected for 
large and multiple HCC with high AFP level because patients 
with these preoperative risk factors tended to died within 1 
year after hepatectomy.
PARAGANGLINOMA OF THE 
PANCREAS: CASE SERIES AND REVIEW 
OF LITERATURE
E. Kansakar and M. Jacobs
Providence Hospital and Medical Centers, Southfi eld, MI
Paragangliomas are rare tumors that derive from cells coming 
from the neuronal crests in the embryo. They are most fre-
quently found in the para-aortic retroperitoneum, adrenal 
glands, carotid body or along any areas where sympathetic 
chains are present. More rarely they can be seen in the lung, 
larynx, thyroid, bladder and pancreas. Their infrequency as 
pancreatic tumor has not allowed them to be extensively 
studied. We report two cases of confi rmed pancreatic gan-
gliocytic paragangliomas. Both patients had shown on 
CT-scan a hypervascular exophytic mass arising from the 
head of the pancreas. The patients’ main complaints were 
abdominal pain and early satiety. Decision to take to surgery 
was based of the potential malignancy appearance seen on 
CT-scan. Both patients had surgical resections with curative 
intent. Intra-operative fi ndings showed an encapsulated and 
highly vascularized mass with its blood supply pedicle deriv-
ing from the pancreas. One patient had pancreatico-duode-
nectomy and simple excision was performed in another. No 
further adjuvant therapy given. Pathology showed a highly-
vascularized mass with staining positive for chromogranin 
A, synaptophysin and neuron specifi c enolase. One of 
patients had single positive lymph node metastasis and has 
not exhibited recurrence based on surveillance. The intimate 
relationship of the pancreas with other retroperitoneum 
organs makes it possible for aberrant migration of neuroen-
docrine cells to occur and transform into tumors in the pan-
creas. Surgery has so far demonstrated to be the only effective 
treatment. It is still debated which type of resection should 
be performed and close surveillance warranted.
RESECTION AND RFA IN THE 
TREATMENT OF HCC
K. Karabulut1, F. Aucejo2, H. Y. Akyildiz1, A. Siperstein1 
and E. Berber1
1Department of Endocrine Surgery, Endocrinology and 
Metabolism Institute, Cleveland Clinic, Cleveland, Ohio; 
2Department of HPB and Transplant Surgery, Digestive 
Disease Institute, Cleveland Clinic, Cleveland, Ohio
Background: We have been approaching hepatocellular 
cancer (HCC) in a multidisciplinary fashion and triaging 
patients to resection or radiofrequency ablation (RFA) based 
on certain criteria. The aim of this study is to describe patient 
characteristics and outcome from a single institution.
Methods: Medical records of all HCC patients who under-
went resection (N = 91) or laparoscopic RFA (N = 92) 
between April 1997 and May 2010 were reviewed. Univariate 
Kaplan-Meier and multivariate Cox Proportional Hazards 
model were used to analyze overall and disease-free 
survival.
Results: The characteristics and outcomes of two groups are 
summarized in the Table. In general patients with normal 
liver function and larger tumors were resected and those with 
liver dysfunction, multiple tumors and portal hypertension 
ablated. On univariate analysis, the number of tumors (p = 
0.02), alpha feto-protein level (p = 0.05), type of surgery 
(p = 0.02), Barcelona Clinical Liver Cancer (BCLC) staging 
(p < 0.0001), and Child classifi cation (p < 0.0001) were 
predictors of overall survival. On multivariate analysis, 
Child class was the only independent predictor of overall 
survival (p = 0.007). For Child’s A patients, there was no 
difference in overall survival between the Resection and RFA 
groups when subgroup analyses were performed based on 
tumor size <3 cm, 3–5 cm or >5 cm.
Conclusion: To our knowledge, this is the largest North 
American series reporting on RFA and resection for HCC 
from a single institution. Although the groups were not com-
parable, the patterns of recurrence were similar for resection 
and laparoscopic RFA. Survival was determined by the 
underlying liver function and not the type of surgical 
intervention.
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THE INTERACTION OF LOW STANDARD 
LIVER VOLUME, HIGH PACKED CELL 
VOLUME, PORTAL HYPERTENSION AND 
RISK OF PORTAL VEIN THROMBOSIS IN 
CLINICAL ISLET TRANSPLANTATION
T. Kawahara, T. Kin, S. Kashkoush, D. L. Bigam, 
N. M. Kneteman and J. Shapiro
University of Alberta, Edmonton, Alberta
Islet transplantation improves glycemic control in type1 dia-
betes complicated by refractory hypoglycemia. Percutaneous 
transhepatic portal access avoids surgery, but is rarely associ-
ated with bleeding or portal venous thrombosis. Here, we 
evaluate factors affecting portal pressure and thrombosis 
after islet infusion. 116 patients underwent 256 percutaneous 
intraportal islet-alone transplant procedures (mean 2.16 infu-
sions/patient). The mean islet mass was 407,221 IE (5,908 IE/
kg) with mean packed cell volume (PCV) of 4.1 ml (1.5–
7.9). Univariate analysis revealed that standard liver volume 
had a negative correlation with portal pressure elevation (r = 
−0.257, P < 0.01), and those with larger liver volume had 
less perturbation in portal venous pressure. PCV correlated 
positively with elevated portal pressure (r = 0.463, P < 0.01).
10 patients (3.9%) developed partial thrombosis of periph-
eral segmental branches of the intrahepatic portal vein. None 
had complete portal thrombosis. Multivariable logistic 
regression revealed that only elevated portal pressure was 
associated with portal thrombosis (Odds Ratio 1.16, P = 
0.045), but not PCV nor actual number of islets infused. Of 
note, we have not encountered this complication in the past 
5 years, since institution of full heparin anticoagulation pro-
tocols combined with effective avitene-paste plugging of the 
transhepatic tract, and limitation in PCV to less than 5 ml.
We conclude that in patients with low standard liver volume, 
islet PCV should be kept below 5 ml and full anticoagulation 
given, if risk portal vein thrombosis is to be mitigated. Portal 
thrombosis is a completely avoidable complication.
FACTORS INFLUENCING RECURRENCE 
PATTERNS AFTER RESECTION FOR 
HEPATOCELLULAR CARCINOMA
K. J. Kelly1, S. K. Maithel2, D. A. Kooby2, R. C. Martin3, 
C. R. Scoggins3, E. R. Winslow1, C. S. Cho1 and 
S. M. Weber1
1University of Wisconsin, Madison, Wisconsin; 2Emory 
University, Atlanta, Georgia; 3University of Louisville, 
Louisville, Kentucky
Introduction: Hepatocellular carcinoma (HCC) frequently 
recurs after surgical resection. Intrahepatic (IH) and extrahe-
patic (EH) recurrence may occur by different mechanisms. 
RESECTION (n = 91) RFA (n = 92) p
Age 64.9 ± 1.4 63.1 ± 1.1 0.3
Gender 0.3
 Female 32 18
 Male 59 74
Mean dominant tumor size (cm) 6.3 ± 0.4 3.6 ± 0.2 <0.0001
Mean number of tumors 1.2 ± 0.1 1.7 ± 0.1 <0.0008
Extrahepatic disease 0.8
 Absent 65 85
 Present 3 2
 Unknown 23 5
Child stage <0.0001
 Noncirrhotic 38 0
 A 52 50
 B 1 29
 C 0 13
BCLC stage <0.0001
 A 44 51
 B 42 22
 C 5 0
 D 0 13
 Unknown 0 6
PLT count = 100,000 8% 49% <0.0001
Hospital stay (day) 7.6 ± 0.5 1.4 ± 0.1 <0.0001
Morbidity 37% 5% <0.0001
Mortality (30-day) 2.2% 1.2% 0.6
Median follow-up (month) 17 22 0.5
New hepatic tumor 46% 56% 0.1
New extrahepatic tumor 19% 16% 0.9
Local recurrence 9% 14% 0.4
Disease-free survival (month) 19.5 13.5 0.2
Overall survival (month) 44.5 26.5 0.02
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Although many studies have assessed predictors of recur-
rence at any site, none have separately analyzed predictors 
of different patterns of recurrence. We examined patient and 
tumor factors for their associations with recurrence patterns 
following resection for HCC.
Methods: A prospectively-collected multi-institutional 
database of patients who underwent resection for HCC 
was retrospectively analyzed for recurrence patterns. 
Clinicopathologic factors associated with different sites and 
patterns of recurrence were identifi ed by univariate (UV) and 
multivariate (MV) analyses.
Results: Of 230 patients submitted to partial hepatectomy 
for HCC (median FU, 16 months), 116 (50%) experienced 
postoperative recurrence at a median time to recurrence of 7 
months. Of these, 82% experienced IH and 40% EH recur-
rence. Sites of EH recurrence included lungs (50%), perito-
neum (28%), adrenals (17%), and other (bone/lymph nodes, 
5%). There were no variables that predicted IH recurrence. 
After multivariate analysis controlling for multiple factors 
(including microvascular invasion, satellite lesions, and cir-
rhosis), independent predictors of EH recurrence, and of 
specifi c EH recurrence patterns, were identifi ed (Table).
Conclusion: Recurrence is a signifi cant problem after resec-
tion for HCC. Identifi cation of variables that predict specifi c 
patterns of recurrence could allow for optimization of 
treatment of primary lesions, focused surveillance, and 
identifi cation of patients who may benefi t most from 
adjuvant therapies.
EH Recurrence Independent Predictors OR (95% CI) P-value
Any Site EH Positive Lymph Nodes 9.47 (1.47 – 60.93) 0.02
Estimated Blood Loss 0.02
Intrahepatic Recurrence 2.18 (1.05 – 4.50) 0.04
Pulmonary Narrow Margin (<1 cm) 6.58 (1.39 – 31.26) 0.02
Perforation 6.43 (1.32 – 31.45) 0.02
Peritoneal Intrahepatic Recurrence 4.39 (1.15 – 16.71) 0.03
Estimated Blood Loss 0.04
Preoperative Biopsy 0.19 (0.04 – 0.97) 0.05
Adrenal None
Other Site EH Lymph Node Status 65.29 (5.09 – 837.46) <0.01
Hepatitis C 8.25 (1.19 – 57.21) 0.03
MAJOR VENOUS RESECTION DURING 
TOTAL LAPAROSCOPIC 
PANCREATICODUODENECTOMY
M. L. Kendrick and G. M. Sclabas
Mayo Clinic College of Medicine, Rochester, MN
Background: The feasibility of total laparoscopic pancre-
aticoduodenectomy (TLPD) has recently been established. 
Laparoscopic major venous resection during pancreaticoduo-
denectomy has not previously been described. Our aim was 
to describe the technique and outcomes of patients undergo-
ing TLPD with major venous resection.
Methods: Of 120 patients undergoing TLPD, laparoscopic 
major venous resection was performed in 10 patients with 
a mean age of 69 years. Indication for venous resection 
included expected or presence of venous malignant invasion. 
Median operative time and blood loss was 405 (301–653) 
minutes and 475 (75–900) ml respectively. Major venous 
resection included portal vein (n = 4), superior mesenteric 
vein (n = 3), or both (n = 3). Reconstruction included patch 
venorrhaphy (n = 5), primary suture venorrhaphy (n = 3), and 
tangential stapling (n = 2). Median mesoportal clamp time 
was 31 (10–72) minutes. An R0 resection was obtained in all 
patients. Postoperative complications occurred in 5 patients 
including pancreatic leak (n = 3), DGE 1, postoperative 
anemia/hemorrhage (n = 2) and arrhythmia (n = 1). No 
patient required reoperation. Median length of hospital stay 
was 7 (4–35) days. Postoperative imaging was available in 
9 patients. No patient had thrombosis at the site of major 
venous resection.
Conclusions: Laparoscopic major venous resection during 
TLPD is feasible in selected patients and outcomes appear 
similar to those reported for open approaches. Extensive 
experience with complex laparoscopic pancreatic resection 
and reconstruction is advocated prior to attempting this 
complex procedure.
CONDITIONAL SURVIVAL IN 
PANCREATIC CANCER: BETTER 
THAN EXPECTED
T. S. Kent, T. Sachs, N. Sanchez, C. M. Vollmer and 
M. P. Callery
Beth Israel Deaconess Medical Center, Boston, MA
Background: Traditional survival estimates following 
resection for PDAC are based on clinicopathologic variables 
at the time of diagnosis, and are often grim. Thus far, esti-
mates have not refl ected time accrued following resection, 
as has been investigated for other malignancies. We sought 
to understand whether survival estimates following pancre-
atic resection for cancer change based on time already sur-
vived (conditional survival).
Methods: Pancreatic resections performed for pancreatic 
ductal adenocarcinoma (PDAC) between 2001 and 2010 
were reviewed. Clinicopathologic variables were evaluated 
to identify predictors of survival. Expected survival accord-
ing to a validated nomogram for pancreatic cancer as well as 
conditional survival estimates were calculated and compared 
to actual survival.
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Results: 188 patients underwent pancreatic resection for 
PDAC (156 Whipple, 26 Distal, 6 Total). Median survival 
was 22 months (3.4–107.3 m). Predictors of overall survival 
were: absence of nodal disease (OR 8.8), age >67 (OR 8.4), 
and lower stage (OR 4.3). Survival according to the nomo-
gram was 70% (1 y), 39.5% (2 y), and 24% (3 y). As time 
accrued, and overall and predicted survival decreased, con-
ditional survival increased (Table 1).
Discussion: The available prognostic scoring system for 
PDAC underestimated survival compared to actual survival 
in this study. Conditional survival estimates, based on 
accrued lifespan, were better than either predicted or actual 
survival, suggesting that survival is a dynamic, rather than 
static, concept. Conditional survival may therefore be a 
useful tool to allow patients and clinicians to project subse-
quent survival based on time accrued since resection.
Table 1. Predicted, actual, and conditional survival for resected PDAC (%)
survival
Predicted 
survival
Actual 
survival
Survival conditional on initial:
6 mos 12 mos 18 mos 24 mos 36 mos 48 mos
6 m - 93.6 - - - - - -
12 m 70 78.5 83.6 - - - - -
18 m - 60.9 65.1 77.6 - - - -
2y 39.5 42.3 45.2 53.9 69.4 - - -
3y 24 26.2 28 33.4 43.1 62.1 - -
4y - 24.7 26.4 31.4 40.5 58.4 94.1 -
5y - 20 21.4 25.5 32.8 47.3 76.2 81
SURGICAL MANAGEMENT OF RENAL 
CELL CARCINOMA METASTATIC TO 
THE PANCREAS
A. S. Khan1, J. Mitchem2, M. Haseebuddin2, D. Sanford2, 
S. M. Strasberg2, W. G. Hawkins2 and D. C. Linehan2
1Baylor Regional Transplant Institute, Dallas, TX; 
2Washington University School of Medicine, St Louis, MO
The pancreas is an uncommon site of metastasis from Renal 
Cell Carcinoma (RCC). Rarely metastatic disease is local-
ized to the pancreas and resection can be considered This 
study is a retrospective review of our experience and out-
comes with pancreatic resection for metastatic RCC over 
past 15 years (1995–2010) During the study period, 18 
patients underwent 19 pancreatic resections for metastatic 
RCC. Average age was 68 years (range 55–81), Seventeen 
of the eighteen patients were white and 61% were female. 
The mean time since index nephrectomy was 12.2 years 
(range 0–42). Nine patients were asymptomatic, 5 presented 
with upper gastrointestinal bleeding, 2 with abdominal pain, 
1 with obstructive jaundice and presentation in 2 was 
unknown. All imaged lesions had a hyper-vascular appear-
ance. Ten patients had preoperative biopsy performed, which 
was diagnostic in 6 (60%). The choice of operation was 
pancreaticoduodenectomy (Whipple) in 8 (42%), distal-pan-
createctomy in 8 (42%) and 2 required total-pancreatectomy. 
There was no correlation between side of index nephrectomy 
and type of resection. All patients had negative margins. One 
patient had positive lymph nodes in resection specimen and 
died from recurrent disease. Mean follow up was 43.8 
months with 11 (61%) patients remaining alive at last follow 
up. The median survival after resection was 66 months. 
Metastatic RCC to pancreas is rare and becomes apparent 
years after treatment of primary tumor. Long-term surveil-
lance for metastatic disease is essential. Aggressive surgical 
resection of isolated pancreatic metastasis can result in excel-
lent long-term survival and should be performed when 
possible.
PANCREATICODUODENECTOMY (PD) 
COMPLICATES MULTIVISCERAL 
RESECTIONS IN 
HEPATOPANCREATOBILIARY SURGERY
A. Khithani, K. Lowe, D. Christian, A. Mejia and 
D. Jeyarajah
Methodist Dallas Medical Center, Dallas, Texas
Background: Multivisceral resections (MVR) in major 
hepatopancreatobiliary surgery (HS) are not common. HS 
may involve additional organs resections to achieve com-
plete resection. We report our experience of MVR with HS, 
specifi cally comparing MVR with a PD and MVR without a 
PD.
Methods: Records of patients with simultaneous MVR and 
HS were analyzed. We defi ned a MVR as one in which 
additional viscera were resected, not a part of the routine 
resection. The outcomes of MVR with PD were compared to 
those without PD.
Results: Nine patients underwent MVR with HR (6 had 
MVR with PD, 3 had MVR without PD). The median blood 
loss was 650 ml in the PD group and 450 ml in the non PD 
group. All patients with MVR in PD group required ICU stay 
whereas 1 ICU admission was seen in the non PD group. The 
median operating time was 270 min in the PD group and 
237 min in the non PD group. The median length of stay was 
15 days in both groups. One patient with PD had a 30 day 
mortality. All patients (100%) with MVR in the PD group 
developed morbidity whereas 1 patient (30%) developed 
morbidity in the non PD group. Three patients (50%) in the 
PD group had positive margins whereas 1 patient (30%) in 
the non PD group had a positive margin.
Conclusions: MVR involving PD is associated with 
increased morbidity compared with MVR without a PD. 
These cases must be taken on with extreme caution.
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PANCREATICOJEJUNAL ANASTOMOTIC 
STRICTURES: WHY REVISE WHEN 
THERES A 
PANCREATICOGASTROSTOMY
A. Khithani, K. Lowe, D. J. Christian and D. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Background: As long-survival following pancreatico-
duodenectomy (PD) improves, complications due to PD 
including pancreatojejunal anastomotic strictures (PJS) are 
increasingly seen. Some centers propose revision of the PJ 
anastomosis. This approach is technically challenging in a 
scarred abdomen and was associated with high morbidity. 
We propose a safe technique of managing a post PD duct 
obstruction.
Methods: All patients with PJS were treated by with a pan-
creaticogastrostomy (PG). Intraoperative and postoperative 
data were collected.
Technique: Using a midline laparotomy, the stomach is 
mobilized off the pancreatic remnant carefully staying away 
from the prior PJ. Pancreatic duct is identifi ed using ultra-
sound and then confi rmed using a 21 g needle. The duct is 
incised from the PJ towards the tail. A posterior gastrotomy 
is created and a single layer, running anastomosis is created 
between the stomach and the pancreatic duct.
Results: Four patients underwent PG for PJS. Three patients 
presented with acute abdominal pain and hyperamylasaemia. 
The median operating time was 154 mins. The median esti-
mated blood loss was 250 ml. There was no mortality within 
the 30 days. Morbidity (DVT) was seen in one patient. None 
of the patients needed a reoperation. The mean length of stay 
was 9 days. All patients remain asymptomatic over a median 
follow up of 6 months. Two patients were lost to follow up 
one patient died due to terminal lung cancer and one patient 
is asymptomatic at 18 months.
Conclusions: Side – side Pancreaticogastrostomy is a 
durable technique for treating PJS and appears to result in 
excellent postoperative outcome.
Table showing Indications of MVR in major hepatopancreatobiliary surgery
Primary procedure Indication Additional resection
Colectomy Ca Colon PD, Liver resection
Colectomy Ca Colon PD,Nephrectomy
Colectomy Ca Colon PD
Partial gastrectomy Ca Stomach PD
Radical cholecystectomy Ca Gall Bladder PD, Colectomy,
Radical cholecystectomy Ca Gall Bladder Gastrectomy, Colectomy
Liver resection Cholangio Ca PD
Liver resection HCC Adrenalectomy, Diaphragmatic excision
Liver resection Hepatoid Carcinoma Distal pancreatectomy with splenectomy,Colectomy
RIGHT HEPATECTOMY WITH 
PORTAL VEIN TUMOR 
THROMBECTOMY FOR HCC
K. Kim, G. Park, P. Park, J. Namgung, S. Jung, S. Yun, 
S. Lee, H. Park, C. Park and K. Kim
Asan Medical Center, Ulsan University, Seoul
Recent progress in imaging techniques has allowed the diag-
nosis of HCC at an early stage. However, portal venous 
invasion is still found in 12.5–39.7% of patients with HCC. 
A median survival is only 9.7 weeks for untreated patients 
with HCC and main portal vein tumor thrombus. According 
to our data, a hepatectomy with portal vein tumor thrombec-
tomy gave help to increase the survival rate in selected 
patients with acceptable hepatic functional reserve. In here I 
report my case by a video clip. 51-year-old male patient with 
HBV and HCC was admitted for surgery. The patient’s 3D 
CT scan showed about 10 sized mass involving right poste-
rior section and right portal vein tumor thrombus reached the 
bifurcation area. The important thing of this surgery was to 
remove the portal vein tumor thrombus safely and prevent 
going into the left portal vein of tumor thrombus during 
hepatectomy. The left glissonean pedicle and hepatoduode-
nal ligament were identifi ed and taped and the right portal 
vein was dissected and taped selectively. The exposed right 
portal vein was incised in order to remove tumor thrombus 
around the bifurcation area after tightening of the left glis-
sonean pedicle and hepatoduodenal ligament. The opened 
right portal vein was closed on both sides using Prolene 6–0 
and the hepatic parenchyma were transected using a Pringle’s 
maneuver, exposing middle hepatic vein. The operative time 
was 225 mins and estimated blood loss was less than 800 ml. 
There was no complication and the patient was discharged 
on postoperative day 12.
SUB-CENTIMETER COLORECTAL 
CANCER LIVER METASTASES ARE 
EFFECTIVELY TREATED BY ABLATION
T. Kingham1, M. Tanoue2, A. A. Eaton1, F. G. Rocha1, 
M. D’Angelica1, P. Allen1, R. P. DeMatteo1, Y. Fong1 and 
W. R. Jarnagin1
1Memorial Sloan-Kettering Cancer Center, New York, NY; 
2Creighton University School of Medicine, Omaha, 
Nebraska
Liver metastases are common in patients with colorectal 
cancer (CRC). Ablative therapies are frequently utilized, but 
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recurrence rates vary. We hypothesized that ablation is a 
reasonable treatment for small (sub-centimeter) tumors. A 
retrospective review of all patients with CRC liver metasta-
ses that were treated with ablation from 4/96 to 3/10 was 
performed. Kaplan-Meier analysis and Cox models were 
used to analyze ablation site recurrence rates and signifi cance 
on a per-lesion basis.
Results: 158 patients had 315 tumors ablated. 36 tumors 
(11%) recurred at the site of ablation. Median follow-up was 
1.6 years (range 11 days to 9 years). Mean tumor size was 
1.6 cm (±1.3). Treatments consisted of RFA (70%), cryo-
therapy (16%), and microwave (13%). 77% of ablations 
(n = 243) were performed in conjunction with a resection. 
On univariate analysis there were no signifi cant differences 
in ablation recurrence rates with age, method of ablation, or 
tumor location. Postoperative chemotherapy was associated 
with a higher 2-year ablation site recurrence free survival 
(RFS; 88% vs. 67%, p < 0.001). There was a signifi cant dif-
ference in 2-year ablation site RFS between small (≤1 cm) 
and large (>1 cm) tumors (92% vs. 78%; HR 2.4(1.249–
4.664; p = 0.01). Tumor size remained signifi cant (HR 2.3; 
p = .01) after adjusting for the use of pre- and post-op che-
motherapy in multivariate analysis. The estimated 2-year 
ablation site RFS for tumors >3 cm was 41%.
Conclusion: Patients are at high risk for additional metas-
tases after ablation of CRC liver metastases. The majority of 
ablated tumors >3 cm recur locally. Ablation of tumors 
≤1 cm, however, results in a low local recurrence rate.
Tumor size 
(cm) N
Median ablation 
zone size (range)
Recurrence 
rate
1 year ablation zone 
recurrence free survival
2 year ablation zone 
recurrence free survival
<=1 168 3 cm (1–5)  8% 0.95 0.92*
>1 147 3.5 cm (1.5–9) 17% 0.89 0.78
* = HR 2.4(1.249–4.664; p = .009)
IS THE EVER-EXPANDING SCOPE OF 
ROBOTICS SAFE FOR HEPATOBILIARY 
SURGERY TOO?
K. Kitisin1, V. Packiam1, S. Celinski1, S. Chalikonda2, 
J. Pingpank1, H. Zeh1, D. Bartlett1 and A. Tsung1
1University of Pittsburgh Medical Center, Pittsburgh, PA; 
2Cleveland Clinic, Cleveland, OH
Background: Robotic-assisted surgery is a valuable mini-
mally invasive treatment due to the inherent limitations of 
laparoscopic surgery. The purpose of this study was to assess 
the outcomes of robotic-assisted technology in hepatobiliary 
surgery.
Methods: A retrospective analysis assessed 46 robotic-
assisted hepatobiliary surgeries performed at the University 
of Pittsburgh Medical Center from November 2007 to 
September 2010.
Results: 45 patients, 61.3% male, underwent robotic-
assisted hepatobiliary surgery with a median age of 61 
(39–86) years. Indications for surgery included malignant 
disease in 30 patients (6 hepatocellular carcinoma, 5 cholan-
giocarcinoma, 19 metastatic liver cancers), and benign 
disease in 8 patients (1 hepatic hamartoma, 1 hepatic hem-
angioma, 2 benign biliary strictures, 1 choledochal cyst, 1 
choledocholithiasis, 2 gallstone pancreatitis). 23 patients 
received cholecystectomy as part of complex hepatopancre-
aticobiliary, gastric, and adrenal surgeries. 25 liver resections 
were performed; 24% major hepatectomies involving more 
than 3 segments, 16% anatomical left lateral segmentecto-
mies, and 60% non-anatomical liver resections. 96% of 
tumor resections had negative margins, with a mean tumor 
size of 3.8 ± 2.3 cm. 6 patients (13.3%) received robotic-
assisted placement of hepatic arterial infusion pumps. 4 cases 
(8.7%) were converted to open operations. Mean operative 
time was 251 ± 154 min, median blood loss was 248 (30–
3600) ml, and mean length-of-stay (LOS) was 6.1 ± 3.2 days. 
Major morbidity occurred in 1 patient with no 30-days 
mortality.
Conclusion: Robotic-assistance for hepatobiliary surgery is 
feasible based on reasonable operative time, blood loss, 
LOS, and morbidity/mortality. Future prospective studies 
should compare outcomes of robotic surgeries with other 
treatments.
PRESENTATION AND OUTCOMES OF 
HEPATOCELLULAR CARCINOMA (HCC) 
PATIENTS AT A WESTERN CENTER
K. Kitisin1, V. Packiam1, J. Steel1, A. Humar1, 
T. C. Gamblin2, D. A. Geller1, J. W. Marsh1 and A. Tsung1
1University of Pittsburgh Medical Center, Pittsburgh, 
Pennsylvania; 2Medical College of Wisconsin, Milwaukee, 
Wisconsin
Introduction: Hepatocellular cancer (HCC) incidence is 
rising in the United States. This study examines the presenta-
tion and outcomes of HCC at a Western center over the last 
decade.
Methods: 1,025 cases of HCC were managed at a single 
institution between 01/2000 and 09/2009. We performed a 
retrospective review and defi ned four main groups: no treat-
ment (NT), Sorafenib therapy (ST), hepatic artery-based 
therapy (HAT), and surgical intervention (SI) including 
radiofrequency ablation, hepatic resection and transplanta-
tion. Kaplan-Meier and Cox regression analysis analyzed 
survival and its predictors.
Results: HCC patients managed were 76% male, 87% 
Caucasian, and 84% cirrhotic. 52% had viral hepatitis, pre-
dominantly hepatitis C. AFP was diagnostic in 34% of cases 
(>400 ng/ml). 169 patients (16.5%) received NT, 25 (2.4%) 
received ST alone, 529 (51.6%) received HAT alone, and 302 
(29.5%) received SI. Overall median survival in NT, ST, 
HAT, and SI was 3.6, 5.6, 8.8, and 83.5 months, respectively 
(p = 0.001). Performing transplantation to patients with 
TACE-bridging therapy increased median survival from 8.3 
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to 54.7 months (p = 0.001). As MELD criteria changed (pre-
MELD, 02/2002–02/2003, 02/2003–09/2009), more HCC 
patients received transplants (6.6, 9.5, 14.2%), correlating 
with greater overall median survival (9.2, 13.2, 13.7 months). 
Multivariate analyses found treatment modality was a sig-
nifi cant predictor of survival (p = 0.001) after controlling for 
other important predictors; age (p = 0.001), gender (p = 
0.003), Child-Pugh class (p = 0.001), and AFP (p = 0.001).
Conclusions: This study illustrates the presentation and out-
comes of HCC at a Western center. Surgical intervention, 
especially transplantation, yields the greatest survival benefi t, 
though most patients are managed with HAT alone.
LAPAROSCOPIC HEMIHEPATECTOMY: 
EVOLUTION OF APPROACH AND 
TECHNIQUES OVER AN EXPERIENCE 
OF 252 CASES
A. Koffron, D. Niemeyer, N. Ali, V. Raofi , S. Cohn and 
J. Stein
Beaumont Hospitals, Royal Oak, MI
Background: Minimally-invasive liver resection (MILR) 
has become an integral part of the management of hepatic 
neoplasms both benign and malignant. While segmentec-
tomy and sectionectomy have been utilized by many groups, 
hemihepatectomy remains rare because of the technical chal-
lenges and limited experience associated with laparoscopic 
resections of this magnitude.
Objective(s): Review and describe the evolution of 
approaches and techniques of laparoscopic hemihepatectomy 
encountered during a large clinical series, in order to 1) 
advance the understanding of minimally-invasive major liver 
resection and 2) highlight the pivotal technical and clinical 
nuances to shorten the surgical learning curve in centers 
embarking on major resection.
Methods: We retrospectively reviewed our clinical experi-
ence over time with regard to: 1) nature of neoplasm (malig-
nant, benign), 2) operative approach [pure laparoscopic 
(PLR), hand-assisted laparoscopic (HALR), or hybrid lapa-
roscopic resections (HyLR)], 3) vascular infl ow/outfl ow 
management and 4) parenchymal transection techniques.
Results: Included in this analysis are 99 left and 159 right 
hemihepatectomies. The Figure shows trends depicted in 
percentages.
Conclusions: Over this series, greater percentage of malig-
nant lesions, lesion size, and increased intrahepatic vascular 
management has led to conversion away from PLR. Pedicle 
management has evolved from exclusively extrahepatic to 
equal utilization of Glissonian approaches, based on lesion 
location and anatomy. Parenchymal transection has evolved 
towards coaptive devices as experience intrahepatic dissec-
tion has increased. This evolution has resulted in 80% of 
patients are now able to have MILR hemihepatectomy at our 
center.
FEASIBILITY AND PROGNOSTIC 
FACTORS OF SALVAGE LIVING DONOR 
LIVER TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA
Y. Konishi1, M. Taniguchi2, T. Shimamura3, T. Suzuki2, 
K. Yamashita4, K. Nakanishi2, H. Kamachi1, H. Yokoo1, 
M. Tahara1, T. Kamiyama1, M. Matsushita1, H. Furukawa5 
and S. Todo1
1Department of General Surgery, Graduate School of 
Medicine, Hokkaido University, Sapporo, Hokkaido; 
2Department of Organ Transplantation and Regeneration, 
Graduate School of Medicine, Hokkaido University, 
Sapporo, Hokkaido; 3Division of Organ Transplantation, 
Graduate School of Medicine, Hokkaido University, 
Sapporo, Hokkaido; 4Department of Molecular Surgery, 
Graduate School of Medicine, Hokkaido University, 
Sapporo, Hokkaido; 5Department of Gastroenterologic and 
General Surgery, Asahikawa Medical College, 
Asahikawa, Hokkaido
It is reported that the outcome of Salvage liver transplanta-
tion (SLT) is comparable with that of primary liver transplan-
tation in hepatocellular carcinoma (HCC) patients. However, 
the prognostic factors of SLT are still unclear. This study 
retrospectively investigated the feasibility and prognostic 
factors of salvage living donor liver transplantation (LDLT). 
From October 1997 to January 2010, 206 patients underwent 
LDLT at our institution, including 51 patients with HCC. Of 
51 cases, Salvage LDLT was performed in 11 cases. Recipient 
demographics, tumor characteristics at Primary liver resec-
tion (PLR) and Salvage LDLT, the duration from PLR to both 
HCC recurrence and Salvage LDLT, and the prognosis were 
analyzed. All patients but one were received LDLT for HCC 
recurrence. The median interval from PLR to HCC recur-
rence, and Salvage LDLT were 11 months (range 4–78), and 
34 months (range 8–128), respectively. The median follow 
up time after Salvage LDLT was 69 months (range 3–120). 
Of 11 patients, 2 patients (18.2%) had HCC recurrence after 
Salvage LDLT, and 3 patients (27.3%) were died of trans-
plant-related complication. The over all survival and the 
recurrence rate at 5 years were 72.7% and 18.2%. In patients 
with HCC recurrence, the interval from PLR to HCC recur-
rence was less than 2 years, and the tumors exhibited portal 
invasion microscopically at PLR. The combination of prior 
liver resection and LDLT is feasible for the patients with 
HCC. Salvage LDLT for the patients whose HCC reveals 
portal invasion at PLR and recurs within 2 years after PLR 
appears to show poor prognosis.
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RADIOEMBOLIZATION FOR 
TREATMENT OF METASTATIC OCULAR 
MELANOMA TO THE LIVER: AN 
INITIAL EXPERIENCE
K. Kosari, E. Ehrenwald, S. Inampudi, S. MacKenzie, 
P. H. Sullivan, L. Wilson and T. D. Sielaff
Virginia Piper Cancer Institute; Abbott Northwestern 
Hospital, Minneapolis, MN
Introduction: Purpose of this study was to evaluate the 
clinical outcomes of liver-directed radioembolization (LR) 
in treatment of metastatic ocular melanoma (OM) to liver 
(MOML).
Methods: Patients treated with LR with Yttrium-90 micro-
spheres for MOML were identifi ed from a prospectively 
maintained database. Primary outcome was survival from 
time of initial LR. Secondary outcomes were effi cacy of LR 
as measured by follow-up liver axial imaging and treatment 
toxicity as measured by NCI Common Toxicity Criteria v2.0. 
Pearson Chi-Square was used to compare correlations.
Results: Among 144 patients (153 LRs), 4 women under-
went 15 LRs for MOML (Table). Median interval from diag-
nosis of OM to MOML was 5.4 yrs and from MOML to fi rst 
LR was 5.5 months (33 days from fi rst LR consult to fi rst 
LR). Median of 61% of recommended dose was deliverable. 
In 4 treatments, LR was done to both lobes of the liver in 
one session. Median follow up was 18.4 months. There were 
no major complications. Grade-1 toxicity occurred after 53% 
of treatments and resolved within the fi rst 48 hrs. Intrahepatic 
disease burden improved after 73% of LRs while extrahe-
patic disease worsened after 45% of LRs. Median survival 
from diagnosis of MOML was 18.4 months, and from time 
of fi rst LR was 12.5 months. There was no correlation 
between survival and how early LR was done with respect 
to time of diagnosis of MOML (p = 0.21).
Conclusion: LR treatment is safe in management of patients 
with MOML and can result in intrahepatic improvement of 
disease burden.
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REPEAT CURATIVE INTENT SURGERY 
FOR COLORECTAL LIVER METASTASIS 
– AGGRESSIVE MULTI-DISCIPLINARY 
MANAGEMENT ALLOWS EXCELLENT 
OUTCOMES
A. N. Kulaylat, P. Hagan, I. Deshaies, E. T. Kimchi, 
J. T. Kaifi , K. F. Staveley-O’Carroll and N. J. Gusani
Section of Surgical Oncology, Department of Surgery, Penn 
State College of Medicine, Hershey, PA
Background: Following liver resection/ablation for 
colorectal liver metastasis (CRLM), the outcome after sub-
sequent curative-intent treatment for recurrence is not widely 
reported.
Methods: A retrospective chart review of 125 consecutive 
patients with CRLM treated in a single institution was 
performed.
Results: Median follow-up for all patients was 17 months. 
8 patients had persistent disease and 63 patients developed a 
recurrence after initial liver surgery. The disease was con-
fi ned to the liver in 24 patients, to the lungs in 5 patients, 
and to the peritoneum in 3. The remaining patients had recur-
rent disease in more than one location. Median progression-
free survival (PFS) after the initial liver surgery was 16 
months [1–64]. Repeat curative-intent surgery was possible 
in 26 patients, who underwent 35 subsequent procedures. 13 
out of 26 patients then recurred after repeat curative intent 
treatment. Seven patients underwent a 3rd or 4th procedure. 
The complication rate and the length of stay after a repeat 
curative intent surgery were similar to the initial liver surgery. 
At the end of the study, 15 patients among the 26 treated with 
curative intent for recurrence after liver surgery were alive 
without evidence of disease (median f/u 33 months [8–59]). 
Repeat curative intent surgery results in a median progres-
sion free survival of 11 months after the repeat operation.
Conclusions: An aggressive approach to recurrence after 
liver surgery for CRLM, including iterative curative intent 
surgery is safe and effective.
EFFECTS OF SORAFENIB ON THE 
EARLY LIVER REPAIR RESPONSE 
FOLLOWING PARTIAL HEPATECTOMY 
IN MICE
P. C. Kurniali1,2, P. Somasundar1,2, N. J. Espat1,2, 
V. Falanga1,2 and S. C. Katz1,2
1Roger Williams Medical Center , Providence, RI; 2Boston 
University School of Medicine, Boston, MA
Background: Sorafenib is approved for the treatment of 
hepatocellular carcinoma, but its effects on liver repair and 
regeneration are not clear. We studied the effects of sorafenib 
on the early repair process in a murine partial hepatectomy 
(PH) model.
Materials and methods: We performed PH in C57Bl/6 
mice and liver repair response was assessed at 48 hours. 
Mice were treated with sorafenib (30 mg/kg or 60 mg/kg) or 
vehicle (CTRL). 5-bromo-2-deoxyuridine (BrDU) and Ki67 
staining among hepatocytes and liver sinusoidal endothelial 
cells (LSEC) was determined, with values expressed as per-
centage of cells positive relative to the CTRL group.
Result: Treatment with sorafenib did not result in any 
deaths following PH. Mean explanted liver: total body mass 
ratios were similar in the CTRL (5.1 ± 0.2%), 30 mg/kg (4.7 
± 0.2%), and 60 mg/kg (4.9 ± 0.2%) groups (p = 0.38). When 
we measured BrDU uptake to assess DNA synthesis, we 
found that hepatocytes were unaffected by the 30 mg/kg 
(0.82 ± 0.12, p = 0.29) or 60 mg/kg doses (0.99 ± 0.23, p = 
0.96). BrDU uptake by LSEC was also similar to the CTRL 
group for mice treated with 30 mg/kg (0.91 ± 0.19, p = 0.71) 
and 60 mg/kg (1.0 ± 0.21, p = 0.99) of sorafenib. Ki67 stain-
ing to quantify cell proliferation revealed that hepatocytes 
were not impaired by 30 mg/kg (0.86 ± 0.32, p = 0.71) or 
60 mg/kg (1.0 ± 0.13, p = 0.84) of the drug. LSEC Ki67 
expression was also not hindered by the 30 mg/kg (1.0 ± 
0.33, p = 0.89) or 60 mg/kg (0.84 ± 0.12, p = 0.33) doses.
Conclusion: Sorafenib did not alter the early repair response 
of the liver to PH as measured by changes in liver weight, 
DNA synthesis, and cellular proliferation. These initial 
fi ndings should be extended by analyzing the further time 
points and additional measures of repair and eventual 
regeneration.
 Abstracts 37
© 2011 The Authors
Journal Compilation © 2011 Americas Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 1), 1–77
THE SCIENCE OF PAINLESS JAUNDICE: 
ELUCIDATING THE MECHANISM OF 
BILE ACID INDUCED ANALGESIA
E. Kwon1, F. Alemi1, C. Godfrey1, J. Chiu1 and C. U. Corvera1,2
1University of California, San Francisco, San Francisco, 
CA; 2San Francisco VA Medical Center, San Francisco, CA
Introduction: Ludwig Courvoiseier’s 1890 treatise fi rst 
described the observation of “painless jaundice.” TGR5 is a 
membrane-bound G protein-coupled receptor responsive to 
bile acids (BAs) that is ubiquitously expressed in human 
tissue. We hypothesize that elevated levels of BAs during 
cholestasis activate TGR5, which mediates its analgesic 
effect through an endogenous opioid pathway.
Methods: TGR5 immunoreactivity in mouse spinal cord 
and dorsal root ganglia (DRG) was detected by immunofl uo-
rescence. The common bile duct was ligated/divided to 
induce cholestasis in C57BL/6 mice. Pain scores were mea-
sures using VonFrey (VF) fi laments every two days for ten 
days. C57BL/6 wild-type (WT) mice were injected subcuta-
neously in the plantar hindpaw with 10 uL normal saline 
(NS), deoxycholic acid (DCA) 2.48 mg/ml, ursodeoxycholic 
acid (UDCA) 2.48 mg/mL, or capsaicin 0.6 mg/mL. TGR5 
overexpressing-transgenic mice (TG) were also injected with 
DCA. Pain scores were measured following injection.
Results: TGR5 immunoreactivity was detected in DRG 
neurons and spinal cord, with localization mainly in lamina 
I, II, IV, and X. VF scores were signifi cantly increased for 
ligated animal compared to sham-operated mice, indicating 
a marked anti-nociceptive effect in the cholestatic group. WT 
and TG mice injected with DCA had signifi cantly higher VF 
scores compared to mice injected with NS, UDCA (weak 
TGR5 agonist), and capsaicin.
Conclusion: The distribution of TGR5 in the nervous system 
correlates with established pain pathways. Cholestatic mice have 
a decreased mechanical pain response. Local paw injections with 
DCA in WT and TG mice induce an analgesic effect mediated 
by TGR5. Therefore, bile acid-activation of TGR5 in cholestasis 
may be the underlying mechanism of “painless jaundice.”
1.5
1.0
0.5
0.0
H
ep
at
oc
yt
es
BrDU
VEHICLE 30 mg/kg 60 mg/kg
1.5
1.0
0.5
0.0
Ki67
VEHICLE 30 mg/kg 60 mg/kg
1.5
1.0
0.5
0.0
LS
E
C
VEHICLE 30 mg/kg 60 mg/kg
1.5
1.0
0.5
0.0
VEHICLE 30 mg/kg 60 mg/kg
BRUNNER’S GLAND HAMARTOMA: A 
CASE REPORT AND META-ANALYSIS
D. J. Laird1, M. N. Kennedy1, R. Selby2 and S. Kulkarni2
1Keck School of Medicine, University of Southern 
California, Los Angeles, CA; 2Division of Hepatobiliary 
and Pancreatic Surgery, LAC-USC and USC University 
Hospital, Los Angeles, CA
Purpose: Brunner’s gland hamartomas (BGH) are rare, 
benign lesions. First described by Cruveilhier in 1835, there 
are fewer than 200 cases reported in the English literature 
and no characterizing studies larger than 27 cases.
Methods: We describe a patient who presented with abdom-
inal pain, nausea, vomiting, melena, and jaundice found to 
have a 6 cm hamartoma just distal to the pylorus. We also 
include a meta-analysis of 93 cases of BGH dating from 1952 
to 2010.
Results: In 93 patients with BGH, 64.5% were male and the 
mean age was 52.6 years. The average lesion size was 4.2 cm 
and ranged from 0.5 to 12 cm. 52.7% were pedunculated. 
63.4% of hamartomas were in the fi rst part of the duodenum, 
23.7% were in the second, and the rest were distributed 
between the remaining duodenal segments, pyloric ring, 
stomach, and jejunum. The most common presenting 
symptom was abdominal pain/discomfort, which 56.6% of 
patients experienced. 53% of patients reported melena, while 
22.9% of patients reported fatigue, dizziness, weakness, or 
syncope and 21.7% were found to be anemic. Nausea and 
vomiting were found in 14.5 and 26.6 percent of patients, 
respectively. 25.8% of lesions were removed endoscopically, 
while 65% were removed at laparotomy. There were no 
adverse outcomes reported.
Conclusions: Brunner’s gland hamartomas are most often 
found in men and between the ages of 36 and 69. They often 
come to physician attention through physical complaints of 
abdominal discomfort and/or GI bleeding and can be removed 
endoscopically or surgically with excellent outcomes.
Figure 1. Mice undergoing partial hepatectomy were treated with vehicle (CTRL) or sorafenib. Livers were harvested after 
48 hours and stained for BrDU and Ki67. Percentage of cells positive for both markers were determined with fl ow cytometry 
and expressed as relative to CTRL
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WHICH IS MORE COST-EFFECTIVE 
UNDER THE MELD SYSTEM-LIVER 
TRANSPLANTATION, PRIMARY LIVER 
RESECTION, OR LOCO-REGIONAL 
THERAPY AND SALVAGE 
TRANSPLANTATION FOR HCC WITHIN 
MILAN CRITERIA?
M. P. Landman and D. E. Moore
Vanderbilt University Medical Center, Nashville, TN
Introduction: Hepatocellular Carcinoma (HCC) is one of 
the most common tumors worldwide and its incidence is 
increasing in the western world. The best strategy for dealing 
with HCC in patients with compensated cirrhosis has long 
been debated. Prior to implementation of the MELD system, 
wait times were prohibitively long and many patients died 
on the wait list secondary to tumor progression. Therefore, 
despite a high recurrence rate primary hepatic resection was 
often the preferred treatment. Under the MELD system, can-
didates with tumors within Milan Criteria are preferentially 
transplanted and drop outs from the wait list for tumor pro-
gression are fewer. The aim of this study is to evaluate the 
cost effectiveness of primary hepatic resection or loco-
regional therapy versus liver transplantation for HCC within 
Milan Criteria.
Methods: A Markov-based decision analytic model was 
created to simulate outcomes for patients undergoing primary 
hepatic resection or loco-regional therapy versus liver trans-
plantation for HCC with Milan Criteria. Baseline values and 
ranges were determined from literature review. Sensitivity 
analyses tested model strength and parameter variability.
Results: Patients undergoing primary hepatic resection had 
earlier recurrence and increased costs and decreased quality 
of life. Patients undergoing primary liver transplantation had 
decreased recurrence and increased quality of live. Primary 
hepatic resection and loco-regional therapy yielded 6.0 
QALYs at a cost of $80,000/QALY, whereas primary liver 
transplantation yielded 7.5 QALYs at a cost of $60,000/
QALY.
Conclusion: Primary liver transplantation is more cost-
effective than primary hepatic resection or loco-regional 
therapy for HCC within Milan Criteria.
IMPACT OF MULTIVISCERAL 
RESECTION IN PATIENTS WITH 
PANCREATIC CANCER: 
PERIOPERATIVE MORBIDITY 
AND SURVIVAL
M. K. Lee, J. DiNorcia, M. D. Winner, J. A. Lee, 
B. A. Schrope, J. A. Chabot and J. D. Allendorf
Columbia University College of Physicians and Surgeons, 
Department of Surgery, New York, NY
Purpose: To evaluate outcomes after multivisceral resection 
for primary pancreatic malignancies.
Methods: We identifi ed patients who required multivisceral 
resection for primary pancreatic malignancies and compared 
outcomes to patients who underwent standard pancreatico-
duodenectomy (PD) or distal pancreatectomy (DP) for 
similar pathology.
Results: Of 1139 patients who underwent PD or DP, a total 
of 23 (2%) patients required multivisceral resection. Stomach, 
colon, adrenal gland, small intestine, kidney, and liver were 
resected in 43%, 39%, 26%, 13%, 4%, and 4% of patients, 
respectively. Patients who required multivisceral resection 
during PD had similar morbidity (43% vs. 51%, p = 0.72) 
and decreased mortality (0% vs. 4%, p < 0.01) compared to 
patients who underwent standard PD. Those who had multi-
visceral resection during DP had similar morbidity (44% vs. 
44%, p = 0.99) and mortality (0% vs. 1%, p = 0.99) compared 
to standard DP. Median survival was similar between patients 
with pancreatic ductal adenocarcinoma who underwent mul-
tivisceral resection and those who underwent standard PD or 
DP (17.8 vs. 17.4 months, p = 0.30) and increased compared 
to patients whose PD or DP was aborted due to advanced 
disease (17.8 vs. 8.0 months, p < 0.01).
Conclusion: Multivisceral pancreatic resection can be per-
formed with similar morbidity and mortality rates compared 
to standard PD or DP. Survival after multivisceral pancreatic 
resection is comparable to that after standard PD or DP and 
improved when compared to resections that were aborted due 
to advanced disease. In select patients, an aggressive surgical 
approach to cure advanced tumors is safe and feasible.
Table 1. Patient demographics and tumor location
Percent
Male 64.5
Female 35.5
Tumor Location
D1 63.4
D2 23.7
D3 4.3
D4 1.1
Jejunum 2.2
Pyloric Ring 3.2
Stomach 1.1
Range Mean sd
Patient Age (years) 14–82 52.6 16.2
Tumor Size (cm) 0.5–12  4.2  2.8
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LEFT-SIDED GALLBLADDER WITH 
INTRAHEPATIC PORTAL VEIN 
ANOMALIES: A SINGLE CENTER 
EXPERIENCES (4 CASES)
K. Lee, E. Kim, J. Lee and H. Park
Hanyang University College of Medicine, Seoul
Purpose: The goal of this article was to characterize and 
explain the etiology of left-sided gallbladder with intrahe-
patic portal vein anomalies encountered at a single center.
Methods: We reviewed surgical recording movies, database 
information, and preoperative radiologic examinations of 
1141 patients who underwent cholecystectomies in our 
institution from between August 2007 and July 2010 to 
assess the presence of left-sided gallbladder and combined 
anomalies.
Results: Four of 1141 patients (0.35%) were diagnosed with 
left-sided gallbladder. In all cases, the gallbladder was 
located on the left side of the falciform ligament, under the 
left lobe of the liver, typical abnormal intrahepatic portal 
venous branching. The right posterior portal vein came 
directly from the main portal vein, and the right anterior 
portal vein originated from the left portal vein, but the liga-
mentum teres joined to the left branch of the portal vein in 
the liver.
Conclusion: Left-sided gallbladder with intrahepatic portal 
venous branching anomaly resulted from the defective devel-
opment of the central portion of the liver rather than abnor-
mal regression of the left umbilical vein with persistence of 
the right umbilical vein.
ORGAN SPACE INFECTION AFTER 
PANCREATIC SURGERY: ARE WE 
IMPROVING?
M. J. Leonardi, H. A. Pitt, M. E. Kilbane, T. J. Howard, 
C. M. Schmidt, A. Nakeeb, N. J. Zyromski, M. G. House 
and K. D. Lillemoe
Indiana University Department of Surgery, 
Indianapolis, IN
Background: In pancreatic surgery mortality has improved, 
but morbidity remains high. Organ space infection (OSI) is 
a major complication which is likely a surrogate for clini-
cally signifi cant pancreatic fi stula. Participation in the 
American College of Surgeons-National Surgical Quality 
Improvement Program (ACS-NSQIP) has been shown to 
improve many outcomes. The aim of this analysis is to deter-
mine whether OSI has improved after pancreatic surgery.
Methods: The ASC-NSQIP database was analyzed from 
2006 to 2009 for pancreatic operations at risk for pancreatic 
fi stula.
Results: Over the 4-year period, 10359 pancreatic opera-
tions were performed in ACS-NSQIP hospitals, and the 
number of operations increased each year from 1496 in 2006 
to 3449 in 2009. Pancreatoduodenectomy (60%) and distal 
pancreatectomy (32%) were the most common operations, 
followed by pancreatic-enteric anastomosis (PEA) (6%), and 
enucleation (2%). OSI rates for each operation are listed by 
year in the Table. OSI rates were higher for pancreatoduode-
nectomy (10.8%, p < 0.001) and lower for PEA (6.5%, p = 
0.002) when compared to all other operations. No changes 
in OSI rates were observed over the 4-year period for all 
pancreatic surgery or for any of the individual operations.
Table. Organ Space Infection Rates (%)
2006 2007 2008 2009 2006–09
Pancreaticoduodenectomy n = 6210 9.7 12.0 11.4 10.4 11.0*
Distal Pancreatectomy n = 3272 10.4 10.8 9.3 8.8 9.6
Pancreatic Enteric Anastomosis n = 629 9.0 4.3 8.7 6.5 6.8*
Enucleation n = 248 7.9 7.8 7.5 10.1 8.5
All Operations n = 10359 9.9 11.0 10.4 9.7 10.2
*p < 0.01 when compared to all other operations
Conclusions: While ACS-NSQIP is capturing a large pro-
portion of the pancreatic surgery being performed in the 
United States, organ space infection (OSI) rates are not 
decreasing in participating hospitals. Since pancreatic fi stula 
is likely a large contributor to OSI after pancreatic surgery, 
pancreatic surgeons should devise new strategies, such as 
early drain removal, to improve this ongoing problem.
NOVEL 3-D IMAGING TECHNIQUE 
IMPROVES ACCURACY OF HEPATIC 
VOLUMETRIC ASSESSMENT
R. V. Levy, B. J. DuBray, K. D. Conzen, G. Upadhya, 
C. D. Anderson and W. C. Chapman
Washington University School of Medicine, St. Louis, MO
Purpose: With preoperative prediction of liver volume 
becoming increasingly important to safely carry out complex 
hepatic resections, we aimed to validate the accuracy of a 
3-D liver resection planning software (Planisight TM) in 
assessing hepatic volumetrics.
Methods: Between 1999 and 2006, we performed 32 live 
donor liver resections for transplantation. Analysis of eleven 
patients who had preoperative volumetrics by the Radiology 
department and documented operative weights was per-
formed. Retrospectively, images were uploaded to generate 
3-D hepatic models from interactive software. Volumetrics 
were assessed based on the corresponding resections. 
Predictions by radiologists and the 3-D system were com-
pared to the actual volumes, which were calculated using a 
standardized liver density (1.05 g/ml). Accuracy of each 
group was measured followed by a means test to establish 
signifi cant differences.
Results: Overall accuracy was signifi cantly improved by 
3-D planning software (84.4% ± 10.7 vs. 76.4% ± 11.1, p = 
0.0057). The 3-D system signifi cantly improved CT-based 
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assessments (82.3% ± 11.2 vs. 74.3% ± 11.3, p = 0.031), 
whereas MR-based assessments were not different (90.0% ± 
8.2 vs. 81.6% ± 10.3, p ≥ 0.05). Assessment of the left lateral 
section was signifi cantly improved by the 3-D system (89.9% 
± 7.2 vs. 79.1 ± 9.5, p = 0.0127), whereas right hepatectomies 
were not (83.2% ± 8.9 vs. 76.3% ± 12.7, p ≥ 0.05).
Conclusions: The overall accuracy of hepatic volumetric 
assessment is signifi cantly improved using 3-D planning 
software. The signifi cance of the software is greatest for 
CT-based assessments of the left lateral section. This 
approach gives surgeons the ability to actively plan resec-
tions and assess volumetrics with relative ease.
Technique
Overall 
accuracy
CT-based 
accuracy
MR-based 
accuracy
Left lateral section 
accuracy
Right hepatectomy 
accuracy
3-D planning (Planisight TM) 84.4% 82.3% 90.0% 89.9% 83.2%
Standard radiologic reconstruction 76.4% 74.3% 81.6% 79.1% 76.3%
GENERATION OF A RECOMBINANT 
HEME OXYGENASE TO PROTECT 
TRANSPLANTED STEATOTIC LIVERS 
FROM REPERFUSION INJURY
S. M. Livingstone1 and I. P. Alwayn1,2,3
1Department of Surgery, Dalhousie University, Halifax, NS; 
2Department of Pathology, Dalhousie University, Halifax, 
NS; 3Department of Immunology, Dalhousie University, 
Halifax, NS
Objective: The development of a cell penetrating heme 
oxygenase-1 (HO1) protein for the treatment of steatotic 
livers ex vivo to improve resistance to reperfusion 
injury.
Methods: Cell penetrating enhanced green fl uorescent 
protein (CPP-EGFP) and HO1 (CPP-HO1) clones were gen-
erated by PCR amplifi cation of cDNA using primers with an 
incorporated cell penetrating peptide (CPP) sequence. 
Products were cloned into an expression vector, transformed 
into E. coli; and protein synthesis induced with Isopropyl-
Β-D-1-thiogalactopyransodie (IPTG). Proteins were nickel 
column purifi ed and identifi ed by western blot analysis. 
CPP-HO1 function was confi rmed by quantifying bilirubin 
production from treated HEK293T cells supplemented 
with the necessary cofactors. Cell penetrating ability was 
confi rmed by examining treated cells for the presence of 
intracellular CPP-HO1 and CPP-EGFP using immunohisto-
chemistry and fl uorescence microscopy.
Results: Generated CPP-EGFP and CPP-HO1 clones were 
confi rmed by sequencing. Protein expression resulted in a 
color change of the media and bacterial pellet of CPP-HO1 
expressing E. coli due to the production of biliverdin. 
Western blot analysis confi rmed successful protein purifi ca-
tion. Bilirubin was generated by CPP-HO1 treated, but not 
untreated HEK293T cells. Both CPP-HO1 and CPP-EGFP 
were found to penetrate hepatoma cells in vitro.
Conclusions: The successful generation of a functional HO1 
protein that is able to penetrate hepatoma cells in vitro. Further 
work will determine if 1) CPP-HO1 can protect cells in an in 
vitro model of reperfusion injury 2) if CPP-HO1 can penetrate 
hepatocytes of ex vivo treated livers and 3) if CPP-HO1 treat-
ment is able to protect steatotic livers from reperfusion injury.
DOES THE PRESENCE OF METASTATIC 
LYMPH NODES PREDICT MARGIN 
POSITIVE RESECTION IN PANCREATIC 
CANCER?
K. Lowe, A. Khithani, D. Christian and R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: The presence of lymph node metastases 
(LNM) in pancreatic cancer is a marker of advanced disease 
and is associated with decreased survival. As imaging tech-
niques become more sensitive, patients discovered to have 
LNM pre-operatively will likely undergo neoadjuvant 
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chemoradiotherapy to reduce disease burden pre-operatively 
and increase rates of R0 resection. Herein, we test the 
hypothesis that LNM predict margin status of the pancreato-
duodenectomy specimen.
Methods: Charts of 120 patients who underwent pancreato-
duodenectomy for head of pancreas, periampullary, or bile 
duct cancers were reviewed. LNM and margin status were 
recorded. Sensitivity, specifi city, negative predictive value 
and positive predictive value were calculated to assess the 
potential of LNM for predicting margin status.
Results: Of lymph node positive specimens, 29 had positive 
margins while 53 had negative margins. Of lymph node nega-
tive specimens, 8 had positive margins, while 30 had negative 
margins. Sensitivity (Sn) of lymph node metastasis for detect-
ing positive margins was 78% and negative predictive value 
(NPV) was 79%, while specifi city (Sp) and positive predictive 
value (PPV) were 36% and 35% respectively.
Conclusion: Patients with pancreatic cancer who have met-
astatic lymph nodes are more likely to have positive margins 
on fi nal pathology than those without lymph node involve-
ment. The sensitivity and negative predictive value of LNM 
are suffi cient to allow preoperative stratifi cation of patients 
with pancreatic cancer. Preoperative chemoradiation should 
be considered in patients with known lymph node metastasis 
to potentially increase R0 resection rate.
CG, 65% (13 pts) had R0 resections. R0 resections occurred 
in patients with jaundice and with multivisceral resection. 
Historically, both have suggested advanced disease which 
has gone unresected.
Conclusion: Patients with gall bladder cancer diagnosed by 
imaging have advanced disease. They are less likely to 
undergo resection for curative intent and less likely to 
undergo R0 resection. Decisions concerning resectablity of 
gall bladder cancer found by imaging are best undertaken by 
surgeons who frequently encounter this disease.
MARGIN STATUS AFTER 
PANCREATODUODENECTOMY FOR 
PERIAMPULLARY AND HEAD OF 
PANCREAS TUMORS: ANATOMY OR 
TUMOR BIOLOGY?
K. Lowe, A. Khithani, D. Christian and R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Cancers of the periampullary (AMP) region 
have better outcomes than those of the head of pancreas 
(HOP). Previous reports suggest that this refl ects either a 
difference in tumor biology or earlier diagnosis due to biliary 
obstruction in AMP cancers. Herein, we test the hypothesis 
that AMP tumors are more amenable to margin negative 
resection than HOP cancers.
Methods: Charts of 109 patients diagnosed from 2005 to 
2010 with either AMP or HOP were reviewed. These included 
27 AMP and 82 HOP cancers. Results were analyzed by 
Fisher’s exact test.
Results: Of the 27 AMP cancers 3 (11%) were margin posi-
tive, while in 82 HOP cancers 32 (39%) were margin positive 
(P = 0.004). In addition to this difference in margin status 
between the groups, the percent of PD specimens with lymph 
node metastasis was fewer in AMP cancers than in HOP 
cancers (50% versus 77%). However, the lymph node ratio 
was not different between the two groups (0.22 in both 
groups). There was no signifi cant difference in average total 
number of lymph nodes recovered in AMP and HOP cancers 
(20 and 19).
Conclusion: AMP cancers are more likely to be resected 
with negative margins than HOP lesions. AMP cancers have 
fewer lymph node metastases at surgery than HOP cancers, 
but when lymph node metastases are present, ratios are 
equal. These fi ndings suggest that earlier detection of disease 
rather than differences in tumor biology are responsible for 
better outcomes of AMP versus HOP cancers.
CORRECT UTILIZATION OF HEPATITIS 
B CORE ANTIBODY POSITIVE DONOR 
LIVER GRAFTS
M. P. MacConmara, N. Vachharajani, J. Wellen, 
C. D. Anderson, J. Lowell, S. Shenoy, W. Chapman and 
M. Doyle
Department of Surgery, Section of Transplant Surgery, 
St. Louis, Missouri
Background: Inclusion of hepatitis B core antibody posi-
tive liver donors (HBcAb) is a strategy utilized to increase 
organ availability. This study examined HBcAb transplanta-
tion practices to identify specifi c factors infl uencing outcome.
Margin+ Margin−
LN + (%) 29 (24%) 53 (43%) PPV 35 %
LN – (%)  8 (6 %) 30 (25 %) NPV 79 %
Sn 78 % Sp 36 %
GALL BLADDER CANCER DIAGNOSED 
WITHOUT CHOLECYSTECTOMY: 
AUTOMATIC REFERRAL TO A 
HEPATOBILIARY SURGEON?
K. M. Lowe, A. Khithani, D. Curtis, D. Christian, 
A. Majia, S. Cheng and R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Pessimism concerning outcomes in gall 
bladder cancer (GBC) and lack of understanding of its opera-
tive treatment have led to under treatment of GBC. Increasing 
use and sensitivity of pre-operative imaging may lead to 
increased referral of GBC patients to hepatobiliary centers. 
Herein, we evaluate the hypothesis that patients referred to 
tertiary centers based on pre-operative imaging without cho-
lecystectomy have more advanced disease than those who 
have incidental diagnosis after cholecystectomy.
Methods: Charts of all GBC patients from 2005 to 2010 
were reviewed. Reason for referral, curative resections, R0 
and R1 resection were recorded.
Results: Of 35 patients with GBC, two groups were identi-
fi ed: The imaging group (IG) included 15 patients referred 
after imaging suggested malignancy, but did not undergo 
cholecystectomy. The cholecystectomy group (CG) included 
20 patients referred on fi nding malignancy after cholecystec-
tomy. In IG, 53% (8 pts) were not candidates for resection 
while in the CG only 27% (5 pts) were not candidates for 
surgery. In IG, only 37% (6 pts) had R0 resections while in 
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Methods: Twenty fi ve recipients of HBcAb livers were 
identifi ed retrospectively from 868 adult transplants between 
1/1/1997 and 12/31/2009. Twelve (48%) recipients had hepa-
titis C and 5 (20%) had hepatitis B. Patient and donor demo-
graphics, preoperative morbidity, transplant data and 
outcomes were examined. Statistical analysis used Student-T, 
Chi-Square test as appropriate and Log-Rank test for Kaplan-
Meier curves with p < 0.05 considered signifi cant.
Results: There was no difference in age, BMI or co-mor-
bidities between HBcAb and control groups. Interestingly, 
MELD scores >30 were signifi cantly more frequent in 
HpBcAb recipients (32% v 15%, p = 0.04). All patients 
received immunoglobulin and antiviral therapy long-term as 
prophylaxis against graft hepatitis B resurgence. No patients 
receiving HBcAb livers developed Hep B infection on fol-
low-up. Overall survival at 30 days, 1 year and 5 years in 
HBcAb recipients was 92%, 74% and 74% compared to 
96%, 89% and 76% in the control group (p = NS, Log-Rank 
Test). All deaths in the HBcAb group, except one recipient, 
occurred within 90 days post-operative, and in patients with 
MELD > 30.
Conclusion: The practice of transplanting HBcAb grafts 
incurs low risk for infection using current prophylaxis treat-
ments. The highest mortality risk was in the early postopera-
tive period, specifi cally in patients with very high MELD 
scores and likely refl ects the practice of using HBcAb grafts 
in emergent situations.
ments 5 to 8). Two small incisions are performed around hilar 
plate according specifi c anatomic landmarks. A laparoscopic 
vascular clamp was introduced in those incisions resulting in 
ischemic delineation of right liver. Clamp was replaced by a 
vascular stapler and stapler is fi red. Liver parenchyma is 
divided with harmonic scalpel combined with vascular 
stapler. The specimen was extracted through suprapubic inci-
sion. Intraoperative cholangiography confi rmed a 2 cm 
common bile duct stone which was immediately removed by 
endoscopy (ERCP). Falciform ligament was sutured to main-
tain the liver in its original anatomical position avoiding 
hepatic vein kinking, and abdominal cavity was drained.
Results: Operative time was 180 minutes, with blood loss 
estimated at 50 ml, without need for transfusion. Postoperative 
recovery was uneventfully and patient was discharged on the 
4th postoperative day.
Conclusion: Laparoscopic intrahepatic Glissonian approach 
is feasible and it is a useful technique for a rapid and safe 
control of the right liver pedicle, facilitating laparoscopic 
right hemihepatectomy.
RIGHT TRISECTIONECTOMY WITH EN 
BLOC PORTAL VEIN AND BILE DUCT 
RESECTION FOR RIGHT-SIDED 
KLATSKIN TUMOR: NO-TOUCH 
TECHNIQUE
M. A. Machado, F. F. Makdissi and R. C. Surjan
Department of Gastroenterology, Surgical Division, 
University of Sao Paulo, Sao Paulo, SP
Background: Right trisectionectomy with en bloc portal 
vein and bile duct resection, no touch technique, was reported 
as an independent survival prognostic for right-sided Klatskin 
tumor. The authors present a video of this technique.
Patient: 75-year-old male with hilar cholangiocarcinoma 
and jaundice underwent preoperative biliary drainage and 
right portal vein embolization. CT scan performed after 4 
weeks showed adequate compensatory hypertrophy of the 
future liver remnant (segments 2 and 3).
Results: Operation began with hilar lymphadenectomy. 
Common bile duct is sectioned. Right hepatic artery is 
ligated. Left hepatic artery is encircled. Portal vein is dis-
sected and encircled. Right liver is mobilized and detached 
from retrohepatic vena cava. Right and middle hepatic veins 
are divided. A right trisectionectomy along with segment 1 
is performed, leaving specimen attached only by the portal 
vein. Portal vein is severed above and below the tumor and 
specimen is removed. Portal vein anastomosis is done with 
6-0 prolene. Doppler confi rms normal portal fl ow. Procedure 
ends with Roux-Y hepaticojejunal anastomosis. Patient 
recovered uneventfully, without transfusion and was dis-
charged on 10th postoperative day. Final pathology con-
fi rmed hilar cholangiocarcinoma and R0 resection. Patient is 
well with no evidence of the disease 4 months after the 
procedure.
Conclusion: Right trisectionectomy with en bloc portal vein 
and bile duct resection is feasible and may enhance chance 
for R0 resection and a better late outcome. Although 
described in 1999, there are few detailed descriptions of this 
procedure. This video may help HPB surgeons to perform 
and standardize this challenging procedure.
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PURE LAPAROSCOPIC RIGHT 
HEPATECTOMY USING INTRAHEPATIC 
GLISSONIAN APPROACH
M. A. Machado, R. C. Surjan and F. F. Makdissi
University of Sao Paulo, Sao Paulo, SP, Brazil
Aim: To present a video of a pure laparoscopic right hepa-
tectomy using intrahepatic Glissonian technique.
Patient and method: A 41-year-old woman with right-
sided hepatolithiasis and choledocholithiasis was referred for 
surgical treatment. Patient is positioned in the left lateral 
position with the surgeon standing between patient legs. Four 
trocars were used. Operation begins with division of liver 
ligaments, right liver mobilization and exposure of the ret-
rohepatic vena cava. Cholecystectomy is performed, fol-
lowed by intrahepatic access to the right glissonian pedicle 
(containing arterial, portal and bile duct branches of seg-
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CYSTIC PANCREATIC NEOPLASM 
REMOVED BY CENTRAL 
PANCREATECTOMY THROUGH LESSER 
SAC APPROACH
D. A. Machado-Aranda1 and M. J. Jacobs2
1Department of Surgery, University of Michigan, Ann 
Arbor, MI; 2Department of Surgery, Providence Hospital 
and Medical Centers, Southfi eld, MI
Introduction: Central Pancreatectomy is an operation 
described for lesions located at the neck of the pancreas and 
serve as an alternative to a Near Total Distal Pancreatectomy. 
The purpose of this video is to demonstrate the surgical 
techniques involved in a segmental resection at the neck of 
the pancreas for a cystic neoplasm followed by a pancreatico-
jejunostomy of the distal stump.
Methods: Midline supraumbilical laparotomy was per-
formed. The lesser sac was entered through the gastrohepatic 
ligament. The neck of the pancreas was segmentally mobi-
lized superiorly and inferiorly exposing the Superior 
Mesenteric Vein and Portal Vein. The segment of pancreas 
containing the cystic tumor was resected with an adequate 
margin. Proximal stump was suture re-enforced and the distal 
stump was drained with a duct to mucosa end to side pan-
creaticojejunostomy. All anastomotic lines were buttressed 
with a falciform fl ap.
Results: Operative time was close to two hours with reason-
able blood loss (150 ml). Postoperative course was uncompli-
cated and upon return to the offi ce there was no evidence of 
pancreatic fi stula or pancreatic exo/endocrine insuffi ciency.
Conclusion(s): Tumors lying at the neck of the pancreas can 
be resected safely with a Central Pancreatectomy, thus avoid-
ing the sequelae of a more radical resection.
ISOLATED RESECTION OF CAUDATE 
LIVER LOBE BY HANGING TECHNIQUE
D. A. Machado-Aranda1, L. Bolo-Schreuder2 and 
M. J. Jacobs2
1Department of Surgery, University of Michigan, Ann 
Arbor, Michigan; 2Department of Surgery, Providence 
Hospital and Medical Centers, Southfi eld, Michigan
Purpose: Single lesions to the caudate lobe of the liver 
necessitate the resection of this lone segment but represent a 
challenge. We describe a technique that achieves easy vas-
cular identifi cation and control of the caudate lobe of the 
liver, without requiring a major hepatectomy.
Methods: Our series involved two patients with single 
lesions confi ned to segment 1 of the liver. After initial mobi-
lization of the organ as a whole by dividing major ligaments 
a retrohepatic avascular plane was developed just bellow that 
drainage of the hepatic veins into the Inferior Vena Cava 
(IVC). In the front and underneath the ligamentum venosum 
following Arantius canal this same avascular plane can be 
found and connected to the superior part. Using an umbilical 
tape the caudate lobe can be suspended and branches of the 
Portal vein, bile ducts will be found laterally and of the 
caudate caval drainage medially, all of which were easily 
controlled and divided.
Results: R0 resections were achieved successfully. Our 
average blood loss was less than 150 cc, with a mean opera-
tive time of 220 minutes. Patients’ postoperative course was 
uneventful with a mean length of stay of 4 days. No compli-
cations were reported within 30 days of follow-up.
Conclusion: An easy and safe resection of the caudate lobe 
can be achieved without requiring of a major hepatectomy. 
The suspension technique allows adequate tissue handling 
and exposure of the vascular infl ow and outfl ow of the 
caudate lobe facilitating its resection within acceptable oper-
ative times.
AN AGGRESSIVE MULTI-DISCIPLINARY 
APPROACH TO ADVANCED 
NEUROENDOCRINE TUMORS
S. MacKenzie, K. Kosari and T. Sielaff
Virginia Piper Cancer Institute, Minneapolis, Minnesota
Background: Advanced Neuroendocrine tumors continue to 
be diffi cult to treat, with a <70% 5-year survival. A 53-year-old 
female with jaundice, presents with a 13 cm pancreatic head 
tumor. The unresectable tumor occluded the portal vein and 
incased the hepatic artery. Neoadjuvant therapy included 
external beam radiation and chemotherapy. Subsequent, radio-
active octreotide (In111) was used to decrease the tumor size. 
The well-differentiated neuroendocrine tumor was resected 
with a pancreaticoduodenectomy, requiring a portal vein and 
a hepatic artery reconstruction (no peri-operative complica-
tions; blood loss = 400 cc; operative time = 636 min; LOS = 
9 days). The pathology revealed islet cell tumor with micro-
scopic islands of tumor in the peri-aortic tissue. The patient is 
well without clinical recurrence at 18 months, with a planned 
3rd cycle of radioactive octreotide. A 41-year-old female with 
abdominal pain, presents with a 24 cm neuroendocrine liver 
tumor. Imaging reveals tumor replacement of the right lobe 
and additional left liver lesions. The patient underwent radio-
active octreotide (In111) treatment to control the systemic 
disease. Surgery included resection of the primary jejunal 
lesion and a right hepatectomy (no peri-operative complica-
tions; blood loss = 250 cc; LOS = 6 days). During a staged 
liver resection the left lobe of liver was cleared. A 3rd round 
of radioactive octreotide was utilized. The patient is well with 
stable disease at 18 month follow up. Additional treatment 
options include Selective Internal Radiation Therapy (SIRT) 
and/or liver transplantation.
Conclusions: An aggressive multi-disciplinary approach to 
neuroendocrine tumors can be performed safely and may 
provide a survival benefi t.
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INFERIOR VENA CAVA RESECTION 
WITH HEPATECTOMY: CHALLENGING 
BUT JUSTIFIED
D. J. Malde, V. Upasani, K. R. Prasad, G. J. Toogood 
and J. P. Lodge
The Hepatobiliary and Transplant Unit, St. James 
University Hospital, Leeds, West Yorkshire
Introduction: The objective of this study was to evaluate 
the clinical signifi cance of hepatectomy combined with IVC 
resection and reconstruction for treatment of invasive liver 
tumours.
Methods: From 1995 to 2010, 35 patients underwent 
hepatic resection with IVC resection. They had a mean age 
of 58 years (range 32–84). Resections were carried out for 
colorectal liver metastasis (n = 21), hepatocellular carcinoma 
(n = 6), cholangiocarcinoma (n = 3) and other (n = 5). 
Resections were carried out with total vascular occlusion in 
34 cases and without in one. Intraoperative hypothermic 
perfusion was performed in 4, ante situm in 2 and Ex-vivo 
in 6 cases.
Results: There were 3 (8.6%) early deaths from multiple 
organ failure. Post operative complications occurred in 14 
(40%) cases with 3 (8.8%) requiring reoperation. Median 
operative time was 255 minutes (range 90–660) and median 
post operative hospital stay was 12 days (range 6–45). 
Transfusion was necessary in 19 (55.8%) patients (median 5 
units). All vascular reconstructions were patent at last follow 
up. The overall median survival was 20 months and median 
disease free survival was 16 months (5-year survival 14.7%). 
The 1-, 2- and 5-year survival was 76.2%, 38.1% and 9.5% 
for colorectal liver metastasis. The 1-year survival for HCC 
and Cholangiocarcinoma was 80% and 33% respectively.
Conclusion: Aggressive surgical management of liver 
tumours with IVC involvement offers the only hope for cure 
or palliation in selected cases. Resection by specialist teams 
affords acceptable peri-operative morbidity and mortality.
PANCREATICOCYSTOSTOMY FOR 
LIVING-RELATED DONOR PANCREAS 
TRANSPLANTATION
M. Maruyama, T. Kenmochi, N. Akutsu and T. Asano
Chiba-east National Hospital, Department of Surgery, 
Chiba City, Chiba Pref
Purpose: In living-related donor pancreas transplantation, 
distal part of the pancreas is transplanted. Drainage of 
the pancreatic juice into the urinary bladder is usually 
performed. One of the critical complications after living-
related donor pancreas transplantation is anastomotic 
failure. To prevent this failure we have developed a reliable 
pancreaticocystostomy.
Method: Since 2004 we performed 15 living-related donor 
pancreas transplantation and pancreaticocystostomy were 
performed. 15 cases were divided into 3 groups. In the fi rst 
group (n = 6) pancreatic dust was fi xed with cystic mucosa 
followed by suture of pancreatic parenchyma and cystic wall. 
In the second group (n = 4) in addition to the method of the 
fi rst group anastomosis was covered with felt-like bioabsorb-
able prostheses (polyglycolic acid sheet). In the third group 
(n = 5) approximation of the pancreas and the cystic wall 
with penetrating suture was added. In all 15 cases insertion 
of pancreatic tube was performed.
Results: The endocrine functions of the graft were well in 
all cases. Pancreatic fi stula was observed in 3 cases (50%) 
of the fi rst group, 1 case (25%) in the second group and 1 
case (20%) in the third group. These pancreatic fi stulae were 
cured without surgical procedure.
Conclusions: At present anastomosis covered by felt-like 
bioabsorbable prostheses with approximation of the pancreas 
and the cystic wall with penetrating suture is the best proce-
dure of the pancreticocystostomy for living-related donor 
pancreas transplantation.
OVER-EXPRESSION OF AQUAPORIN 8 
(AQP8) INHIBITS TUMOR FORMATION 
IN A RAT MODEL OF 
HEPATOCELLULAR CARCINOMA (HCC)
M. A. Mattocks, D. Sindram, J. B. Martinie, D. A. Iannitti 
and I. H. McKillop
Carolinas Medical Center, Charlotte, NC
Cells undergoing apoptosis exhibit apoptotic volume 
decrease necessitating rapid, AQP-dependent water loss from 
the cell. Human and animal models of HCC are characterized 
by decreased AQP expression and diminished apoptotic 
responsiveness. This study sought to determine whether 
AQP8 over-expression in HCC cells alters tumor growth in 
vivo. Rat H4IIE cells were stably transfected with a dual 
plasmid Tet-On system expressing rat AQP8 and hemagluti-
nin (HA) cDNA. Trasfected cells were isolated, expanded, 
and (≈107 cells) inoculated into the parenchyma of ACI rats. 
16-days later HCC cells from these tumors were isolated, 
cultured, and reinoculated into animals fed diets containing 
doxycycline. Successful cell transfection was determined 
using selective medium and detection of HA mRNA. In the 
absence of dietary doxycycline, transfected and non-trans-
fected cells reproducibly formed intrahepatic tumors after 15 
days. Non-transfected cells from these masses subsequently 
formed hepatic tumors in animals on doxycyclin-containing 
diets. Conversely, cells transfected to express AQP8 failed 
to form tumors in 50% of animals maintained on doxycyclin-
containing diet. Furthermore, in those animals in which HCC 
formed, tumors were signifi cantly smaller compared to non-
transfected cells (24 ± 9 vs 408 ± 82 mm3, transfected vs 
non-transfected, p < 0.05, n = 4). Over-expressing AQP8 in 
vitro signifi cantly inhibits rate and size of intrahepatic tumor 
formation in vivo. These data may have signifi cant future 
application when used in conjunction with irreversible elec-
troporation as a means to selectively increase AQP expres-
sion within targeted regions.
REFINING THE DEFINITION OF PERI-
OPERATIVE MORTALITY FOLLOWING 
HEPATECTOMY
S. C. Mayo1, A. D. Shore2, H. Nathan1, B. Edil1, 
K. Hirose1, R. D. Schulick1, M. A. Choti1, C. L. Wolfgang1 
and T. M. Pawlik1
1The Johns Hopkins Hospital, Baltimore, MD; 2The Johns 
Hopkins Bloomberg School of Public Health, Baltimore, 
MD
Background: Peri-operative mortality is commonly defi ned 
as death within 30-days of surgery. However this defi nition 
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may underestimate “true” peri-operative mortality among 
patients undergoing hepatic resection HR). To better defi ne 
peri-operative mortality, we assessed trends in risk of death 
during the fi rst 90-days after HR.
Methods: Using Surveillance, Epidemiology and End Results 
(SEER)-Medicare linked data, we identifi ed 2597 patients 
(colorectal liver metastasis [CRLM] = 1903; hepatocellular 
carcinoma [HCC] = 694) who underwent HR between 1991 
and 2007. Data on clinicopathologic characteristics, surgical 
management, and peri-operative mortality were collected and 
survival was assessed at 30-, 60-, and 90-days.
Results: HR included wedge resection (60%), hemi-hepa-
tectomy (35%), or extended hepatectomy (5%). Median 
length of hospitalization was 7 days for both CRLM and 
HCC patients (P = 0.35). Overall, 6% patients died within 
the fi rst 30 days, 78% of whom died during the same hospi-
talization. Post-operative mortality at 60- and 90-days was 
8% and 10%. In-hospital mortality after HR was greater 
among patients with HCC compared with CRLM (9% vs 
4%) (P < 0.001). For CRLM patients, mortality increased 
from 4% to 8% from 30- to 90-days, whereas mortality for 
HCC patients increased from 10% to 15% (both P < 0.05) 
(Figure). After controlling for other factors, patients with 
HCC were twice as likely to die within 30-days (OR = 2.4), 
60-days (OR = 2.0), and 90-days (OR = 1.9) vs CRLM 
patients (all P < 0.001). Differences in 30- and 90-day mor-
tality were greatest among HCC patients undergoing major 
hepatic resection (P < 0.05).
Conclusions: Only reporting deaths within 30-days of 
surgery underestimates the mortality associated with HR. 
Traditional 30-day defi nitions of mortality are inaccurate and 
surgeons need to report all peri-operative outcomes within 
90-days of HR.
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BILE DUCT INJURY REPAIR: 
TRANSITION TO A HIGH VOLUME 
CENTER IMPACTS IN OUTCOME
M. Mercado, B. Franssen, J. Arriola and M. Mercado
Instituto Nacional de Ciencias Medicas Y Nutricion, 
Mexico City, Distrito Federal
Bile duct injury associated to laparoscopic cholecystectomy 
remains constant (0.1–03%) and their impact in survival and 
quality of life has been studied. It has been shown that opera-
tive and long term results are better in interested HPB hos-
pitals. Here in we analyze the distribution and growth of the 
number of cases referred to our hospital as well as the techni-
cal variants of repair and long term results.
Methods: In a 20 years period, 510 complex circumferential 
injuries have been referred to our team for repaired at the 
INN Hospital Mexico City and 198 elsewhere (private and 
other cities). The record at the third level Academic University 
Hospital were analyzed and divided in three periods of time: 
1990–1999 (33 cases), GI, 2000–2004 (139 cases), 2004–
2008 (140 cases) GIII.
Results: All patients were treated with a Roux en Y hepa-
toyeyunostomy. A decrease for using transanostomotic stents 
was observed. Partial segment IV and V resection was done 
more frequently (to obtain a high bilioenteric anastomosis). 
Operative mortality, postoperative cholangitis, anastomosis 
strictures, short and long term complications and need of 
reoperation were signifi cantly better in the last period.
Conclusions: Transition to a high volume center with inter-
ested HPB surgeons has improve dramatically operative and 
long term results of bile duct injury repair. Even interested 
and tertiary care centers have a learning curve.
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COMMON BILE DUCT EXPLORATION: 
A LOST ART
J. E. Meyer, H. A. Pitt, A. Nakeeb, E. M. Kilbane and 
K. D. Lillemoe
Department of Surgery, Indiana University, Indianapolis, 
IN
Purpose: In 1970 common bile duct exploration (CBDE) 
was performed in 15% of patients undergoing cholecystec-
tomy. With the introduction of endoscopic sphincterotomy 
and laparoscopic cholecystectomy, CBDE has become a rare 
operation. The aims of this analysis are to a) document the 
current utilization as well as the outcomes and b) compare 
laparoscopic to open bile duct exploration.
Methods: The ACS-NSQIP database from 2005 to 2009 
was queried for cholecystectomy and CBDE. Patient demo-
graphics, mortality, serious morbidity and overall morbidity 
were compared for 649 (40%) laparoscopic and 953 (60%) 
open CBDE using standard statistical methods.
Results: Of 98,341 patients undergoing cholecystectomy, 
1464 (1.5%) had a CBDE. An additional 158 patients under-
going CBDE had previously had their gallbladder removed. 
Patients undergoing open CBDE were more likely (p < 0.05) 
to be older, male, diabetic, and to have multiple comorbidi-
ties, jaundice and/or cholangitis. Outcomes are reported in 
the Table.
Conclusions: In the modern era, common bile duct explora-
tion is an uncommon operation. Forty percent of the CBDEs 
are being performed laparoscopically in healthier patients 
with better outcomes. Efforts should be undertaken to train 
more surgeons to perform laparoscopic bile duct 
exploration.
CBDE 30-Day Mortality Serious Morbidity Overall Morbidity Length of Stay (d)
Laparoscopic 0.5%  2.0%  4.2%  3.5
Open 4.4%* 15.7%* 20.5%* 10.5*
Overall 2.9% 10.0% 14.8%  7.6
*p < 0.01 vs Laparoscopic
00–99 2000–2004 2004–2008
# % # % # %
Total 33 100 139 100 140 100
Male 6 18 39 28 31 22
Female 27 82 100 72 109 78
Age 38+/−11 43+/−15 40+/−13
Type of Cholecystectomy - - - - - -
open 27 82 104 75 89 63
lap 6 18 35 25 51 36
Previous repair
 0 17 51 72 52 71 51
 1 13 39 58 41 60 42
 2 2 6 8 6 10 7
 3 1 3 3 2 1 0.7
 >6 1 3 1 0.7
SEG IV – V resection 15 45 57 41 99 71
Transanastomotic stent 26 78 46 33 3 2
Hepatectomy at Repair 1 3 3 2 1 0.7
Post op Complications
 Cholangitis 18 54 35 25 19 13
 Stenosis 10 30 13 9 7 5
 Abscesses 5 15 7 5 8 6
 Fístula 3 9 6 4 4 3
 Biloma 4 12 10 7 18 13
Reoperation 15 45 25 18 16 11
Hepatectomy post Repair 1 3 2 1.5
Operative mortality 3 9 6 4 1 0.7
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OUTCOME OF PANCREATIC REMNANT 
FOLLOWING SEGMENTAL 
PANCREATECTOMY FOR NON-
INVASIVE INTRADUCTAL PAPILLARY 
MUCINOUS NEOPLASM (IPMN)
J. R. Miller1, J. E. Meyer2, J. A. Waters2, M. Al-Haddad3, 
J. DeWitt3, S. Sherman3, K. D. Lillemoe2 and 
C. M. Schmidt2
1Indiana University School of Medicine, Indianapolis, IN; 
2Department of Surgery, Indiana University, Indianapolis, 
IN; 3Department of Gastroenterology and Hepatology, 
Indiana University, Indianapolis, IN
Purpose: IPMN are often multifocal involving the entire 
pancreas. Due to morbidity of total pancreatectomy, surgeons 
will perform segmental pancreatectomy, resecting only the 
most “threatening” IPMN lesion(s). We sought to determine 
if the presence of residual IPMN following segmental pan-
createctomy for non-invasive IPMN increases the risk for 
subsequent development of invasive cancer and decreases 
survival.
Methods: From 1991 to 2010, data on patients undergoing 
segmental resection of non-invasive IPMN were prospec-
tively accrued at a high volume academic institution.
Results: Of 243 patients undergoing segmental resection for 
IPMN, 193 (79%) demonstrated non-invasive pathology. Of 
these, 152 (79%) had absence and 41 (21%) had presence of 
residual IPMN at initial operation. Of 41 with residual 
IPMN, 11 had positive IPMN margins, 23 had IPMN in 
remnant, and 7 both. During follow-up, 31 (20%) of 152 
patients without residual IPMN developed a new radio-
graphic lesion consistent with IPMN, and of these, 3(10%) 
were invasive cancer. One (2%) of 41 patients with residual 
IPMN developed invasive cancer. In summary, of 193 ini-
tially non-invasive IPMN, 4 invasive cancers (2%) devel-
oped during follow-up. The mean progression free interval 
of these 4 patients was 54 (20–99) months.
Conclusions: Compared to patients undergoing complete 
operative IPMN clearance, patients with residual IPMN after 
segmental pancreatectomy do not demonstrate an increased 
risk of developing invasive disease or reduced survival. In 
patients without residual IPMN, who later develop new 
IPMN, the risk of invasive IPMN is increased, but survival 
is not reduced when compared to patients who do not develop 
new IPMN.
DUCT-TO-DUCT BILIARY 
RECONSTRUCTION IN PATIENTS WITH 
PRIMARY SCLEROSING CHOLANGITIS 
UNDERGOING LIVER 
TRANSPLANTATION
J. Modaresi, T. Diago, M. Fujiki, P. Hodgkinson, 
K. Hashimoto, C. Quintini, F. Aucejo, D. Kelly, C. Winans, 
D. Vogt, C. Miller, J. Fung and B. Eghtesad
Cleveland Clinic, Department of Hepato-Pancreato-
Biliary/Liver Transplant Surgery, Cleveland, Ohio
Background: Reconstruction of biliary drainage after liver 
transplantation (LTX) in patients with primary sclerosing 
cholangitis (PSC) has been matter of controversy. Some 
favor Roux-en Y hepaticojejunostomy (RY) with better 
patient and graft survival and less anastomotic biliary stric-
tures over the duct-to-duct (DD) and others found no real 
difference between the two.
Method: Retrospective review of biliary complications, 
graft and patient survival after LTX in PSC patients based 
on type of biliary reconstruction and comparison of DD 
reconstruction in this group of patients and non PSC patients.
Results: Between 8/05 and 7/10, 54 LTX were done in 53 
patients with diagnosis of PSC. Seven patients were excluded 
because of; unexpected cholangiocarcinoma in the explant 
(3); and recipients of partial livers (4). Biliary reconstruction 
was done as DD in 18 and RY in 28. There was no reported 
bile leak. Anastomotic stricture happened in 2 patients with 
DD (11%) and one in RY (4%). Two patients in RY had 
intrahepatic strictures (7%) (not a recurrence), and one had 
recurrence of PSC 4 years after transplant. 1- and 3-year 
patient and graft survival for RY and DD were (96.7%, 
96.7%), (100%, 94.5%) respectively. Anastomotic strictures 
in 34 randomly selected patients transplanted for non-PSC 
diagnosis with DD reconstruction in the same era was 9% 
with 1- and 3-year patient and graft survival of 99.1% and 
88.5%.
Conclusions: DD biliary reconstruction at the time of LTX 
in selected PSC patients is both effective and safe with com-
parable outcomes with RY in these patients and DD in 
non-PSC group.
PERCUTANEOUS TRANSHEPATIC ISLET 
CELL AUTOTRANSPLANTATION AFTER 
PANCREATECTOMY FOR CHRONIC 
PANCREATITIS: A NOVEL APPROACH
K. A. Morgan, D. B. Adams, R. Ufl acker and 
M. Nishimura
Medical University of South Carolina, Charleston, SC
Background: In selected patients with chronic pancreatitis, 
extensive pancreatectomy can be effective for the treatment 
of intractable pain. The resultant morbid diabetes can be 
ameliorated with islet autotransplantation. Conventionally, 
islet infusion occurs intraoperatively after islet processing. A 
percutaneous transhepatic route in the immediate postopera-
tive period is an alternate approach.
Methods: A prospectively collected database of patients 
undergoing pancreatectomy with percutaneous islet auto-
transplantation (P-IAT) between March 2009 and May 2010 
was reviewed. Hospital billing data were obtained with per-
tinent median charges determined and compared to estimated 
charges for an intraoperative infusion method (I-IAT).
Results: Thirty-six patients (28 women; median age 48) 
underwent pancreatectomy with P-IAT. Median operative 
time was 232 minutes, with median EBL 500 cc. Median 
time from pancreatic resection to islet transplantation was 
269 minutes. A median of 208,248 IEq (2298 IEq/kg) were 
harvested. Peak portal venous pressure during islet infusion 
was a median 13 mmHg. Postoperative complications 
occurred in 17 patients (47%), including hepatic artery pseu-
doaneurysm and portal vein thrombosis (PVT). PVT occurred 
in 2 patients with portal pressures during infusion > 
30 mmHg. With median follow-up of 8 months, 8 patients 
(23%) are insulin-free. Median pertinent charges for P-IAT 
were $36,318, while estimated median charges for I-IAT 
were $56,440. Surgeon opportunity cost allowed by 
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P-IAT versus I-IAT was demonstrated by 66 additional pro-
cedures and $463,375 billed.
Conclusions: Percutaneous transhepatic islet cell autotrans-
plantation is feasible and safe. Islet infusion in the immediate 
postoperative period is cost effective. Further follow-up is 
needed to assess long term results.
OUTCOMES OF ROBOTIC-ASSISSTED 
PANCREATIC RESECTION FOR 
PANCREATIC ADENOCARCINOMA: 
A SINGLE-INSTITUTION REVIEW
I. W. Nasr, A. H. Zureikat, M. Daoudi, D. L. Bartlett, 
H. Zeh and A. J. Moser
University of Pittsburgh Medical Center Dept of Surgery, 
Pittsburgh, PA
Introduction: Robotic surgery in advanced pancreatic 
resections is gaining momentum due to improved surgical 
dexterity and visualization. We analyzed oncologic outcomes 
for a consecutive series of robotic-assisted pancreatic resec-
tions (RAPR) for pancreatic adenocarcinoma (PAC).
Methods: Single-institution retrospective review of all 
patients (n = 21) undergoing RAPR for PAC between 2008 
and 2010 in a tertiary referral center.
Results: We identifi ed thirteen robotic-assisted pancreatico-
duodenectomies and eight distal pancreatectomies. Average 
age was 70 years with equal gender distribution (48% 
women). Median blood loss was 300 cc (range 30–1000), 
while median OR time was 489 mins (range 174–686). The 
major complication rate (Clavien) was 19% (4/21) with a 
single delayed postoperative death at day 87 (1/21). A pan-
creatic leak occurred in 10% (2/21) of the patients. Median 
length of stay was 9 days (range 4–15 days). The conversion 
rate to open was 29% (6/21): 2 conversions were caused by 
failure to progress, whereas the other 4 were due to vascular 
abutment. Mean tumor size was 3 cm and the margin nega-
tive resection rate was 86% (18/21). Median lymph nodes 
(LN) harvested was 18 and the median LN positive was 1. 
Median time to receiving adjuvant chemotherapy was 69 
days. Conversion to open correlated with a signifi cantly 
higher risk of R1 status following traditional resection, sig-
nifying unexpected locally-advanced disease (p < 0.004).
Conclusions: Robotic-assisted pancreatic resection is a safe 
and feasible option for adenocarcinoma. Early experience 
suggests that oncologic endpoints are comparable to the open 
approach, with conversions to open resection refl ecting 
tumor status rather than technical failure of the robotic 
approach.
DIAGNOSTIC ACCURACY OF 
MAGNETIC RESONANCE 
CHOLANGIOPANCREATOGRAPHY IN 
PATIENTS WITH SUSPECTED 
CHOLEDOCHOLITHIASIS
P. N. Nau, S. Cowgill, E. Ellison, W. Melvin and 
P. Muscarella
The Ohio State University Medical Center, Columbus, OH
Introduction: Choledocholithiasis is present in 8–20% of 
individuals undergoing a cholecystectomy for symptomatic 
cholelithiasis. Clinical signs and symptoms suggestive of 
choledocholithiasis require additional work-up prior to surgi-
cal intervention.
Methods: A retrospective chart review was performed for a 
fi ve-year period from 1998 until 2003. Patient demographics, 
perioperative data and outcomes were recorded. Statistical 
analysis was performed using SPSS 16.0. Statistical signifi -
cance was defi ned as p < 0.05.
Results: The records of 380 patients who underwent MRCP 
examinations over a fi ve-year period at The Ohio State 
University Medical Center were reviewed. Twenty-four 
patients met criteria for inclusion in the study. The sensitivi-
ties and specifi cities of MRCP for identifying choledocholi-
thiasis were 60% and 72% respectively. Six of 10 patients 
had true-positive results and 8 of the 13 patients had true-
negative results. Three of 24 patients (12%) were noted to 
have equivocal MRCP fi ndings wherein the presence or 
absence of the diagnosis could not be clearly identifi ed by 
the radiologist.
Conclusions: As today’s surgeon becomes more facile with 
laparoscopic common bile duct explorations and intra-oper-
ative cholangiography, and with the increased availability of 
endoscopic modalities, MRCP adds little to the perioperative 
work-up of a patient with suspected choledocholithiasis.
A NEW TECHNIQUE FOR 
PANCREATICOJEJUNOSTOMY USING 
FULL THICKNESS PANCREATIC STAY 
SUTURES AND VIDEO MICROSCOPY
N. N. Nissen and G. Berci
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: The leak rate after pancreaticojejunostomy 
continues to be signifi cant, ranging 5–20% despite numerous 
modifi cations and techniques. Some leaks may occur because 
the bowel separates from the pancreas due to bowel edema or 
distension. A technique is presented that utilizes full thickness 
pancreatic stay sutures followed by duct-to-mucosa anastomo-
sis performed with assistance of video microscopy.
Methods: Monofi lament full thickness pancreatic stay 
sutures are placed on each side of the pancreatic duct, 
anchoring the posterior jejunum to the pancreatic face. Duct-
to-mucosa anastomosis with internal stent is fashioned prior 
to tying the stay sutures. The anterior surface of the bowel 
is further anchored with two or three horizontal mattress 
sutures. This technique differs from most anastomotic tech-
niques in that it is not a true two-layer technique, as the outer 
layer is not meant to be watertight. Rather, the stay sutures 
are meant to anchor the jejunum, but do so in a durable way 
not susceptible to disruption if the bowel becomes distended. 
The technique also uses video microscopy, which is a new 
method of magnifi cation that replaces standard Loupe mag-
nifi cation. Video microscopy uses a high defi nition camera 
mounted on a mechanical arm that allows the surgeon to 
work off a video screen. This system provides varialble mag-
nifi cation of 4X–12X and is simpler and more convenient 
than an operating microscope.
Results: This technique has been used in 8 consecutive high 
risk pancreatic anastomosis without evidence of pancreatic 
fi stula. The anastomotic technique and the use of video 
microscopy are demonstrated.
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RECURRENT HEPATOCELLULAR 
CANCER AFTER LIVER TRANSPLANT: 
IDENTIFYING THE HIGH-RISK PATIENT
N. N. Nissen1, V. Menon1, C. Bresee2, F. Poordad1, 
B. Boland1, J. H. Fair1, T. T. Tran1, J. K. Ryan1, 
A. S. Klein1, A. Annamalai1 and S. D. Colquhoun1
1Comprehensive Transplant Center – Cedars-Sinai Medical 
Center, Los Angeles, CA; 2Samuel Oschin Cancer Center 
– Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Recurrence of hepatocellular cancer (HCC) 
after liver transplantation (LT) is rarely curable. However, 
with the advent of new therapies, identifi cation of patients at 
high risk for recurrence at time of explant is critical.
Methods: We analyzed our database of 122 patients under-
going LT for HCC between 2002 and 2010. Pathologic fea-
tures of the explant were used to predict risk of recurrent 
tumor. All necrotic and viable tumor nodules were included 
in explant staging. All patients met radiographic Milan cri-
teria prior to transplant.
Results: Overall survival for the entire group at 1 and 3 
years was 93% and 85% respectively. Thirteen patients 
developed HCC recurrence at a mean of 16 months post-
transplant. By Kaplan-Meier analysis recurrence free sur-
vival at 1 and 3 years was 95% and 89% respectively. There 
were no recurrences in patients with explant pathology 
meeting Milan criteria (n = 68). Modeling of pathologic 
criteria determined that signifi cant predictors of recurrence 
included: i) stage exceeding UCSF criteria (p < 0.001); ii) 
>3 tumors (p < 0.001); iii) presence of vascular invasion (p 
= 0.007); and iv) presence of bilobar lesions (p = 0.029). 
Step-wise modeling showed that the major risk factor for 
recurrence was pathology beyond UCSF criteria, and that 
when combined with vascular invasion the risk was particu-
larly high (Table).
Conclusion: Explant pathology can be used to predict the 
risk of recurrent HCC after LT, which may allow for improved 
adjuvant strategies. In addition, our results provide addi-
tional support for continued acceptance of UCSF downstag-
ing criteria for LT for HCC.
Table. Step-wise Modeling of Recurrence-Free Survival after LT using Explant Patholologic Staging
Milan Stage
UCSF 
Stage
Vascular 
Invasion
1-Year 3-Year
Rate (95% CI) Rate (95% CI)
Within n/a n/a 100% 100%
Exceeding Within Absent 97% (95%, 100%) 91% (82%, 100%)
Present 90% (77%, 100%) 72% (48%, 100%)
Exceeding Absent 86% (72%, 100%) 63% (40%, 98%)
Present 57% (32%, 100%) 18% (4%, 97%)
GOOD OUTCOMES OF ORTHOTOPIC 
LIVER TRANSPLANTATION AT SMALL 
VOLUME CENTER
B. Nonthasoot, P. Limpavitayaporn, B. Sirichindakul, 
J. Suphapol, W. Taesombat and S. Nivatvongs
Department of Surgery, Faculty of Medicine, 
Chulalongkorn University, Bangkok
Introduction: Liver transplantation (LT) has been accepted 
as the best treatment for patients with end-stage liver disease. 
There are some reports showed that liver transplant outcomes 
are better at high volume centers. However, in developing 
country, it is quite diffi cult to have LT more than 20 cases a 
year due to shortage of liver donor and fi nancial problem. 
The fi rst LT in Thailand was performed at our hospital in 
1987. 132 cases of LT have been performed until December 
2009. We reported herein the recent outcomes.
Material and methods: The medical records of LT patients 
between January 2003 and December 2009 were retrospec-
tively reviewed. The operative outcomes and patient survival 
rate were analyzed.
Results: There were 69 patients and 70 LT procedures. 62 
patients were adults and 7 patients were children. The mean 
age was 46.8 years (0.58–69). Most common indication was 
HBV cirrhosis (40%). The type of liver grafts were whole 
cadaveric graft 63 cases (90%), reduced size graft 4 cases 
(5.7%), and lateral segment graft from living donor 3 cases 
(4.3%). The mean MELD/PELD score was 20.6 (1–40). The 
major complications were acute renal failure (27.1%), acute 
cellular rejection (22.9%) and biliary complications (22.9%). 
The cumulative 1, 3 and 5 year patient survival rate were 
86.6%, 80.3%, and 76.1% respectively which were compa-
rable to UNOS data.
Conclusion: This study showed that LT can achieve a good 
outcome at small volume center in developing country. So 
the small volume center should not be discouraged and con-
tinues to improve outcome by teamwork approach.
CHOLEDOCHAL CYST DISEASE: LONG-
TERM FOLLOW-UP AT A SINGLE HIGH-
VOLUME INSTITUTION
K. Olino, S. Goldstein, J. L. Cameron, S. Reddy, H. Hall, 
T. Pawlik, M. Choti, R. Schulick, C. Wolfgang and B. Edil
The Department of Surgery, The Johns Hopkins Medical 
Institutions, Baltimore, MD
The natural history and long-term complications after surgi-
cal intervention for choledochal cyst disease in Western 
society is not well characterized. This study reports long-
term follow-up of the largest Western series of patients with 
choledochal cyst disease.
Methods: 92 patients with choledochal cyst disease who 
underwent surgical management between 1976 and 2006 
were identifi ed. Data on long-term outcomes were obtained 
via chart review, offi ce records, and telephone-based patient 
interviews.
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Results: Greater than 6 months of follow-up was obtained 
for a majority of patients (n = 64; 70%), with a mean post 
operative follow-up of 10.1 years. About one-half of patients 
(n = 48; 52%) experienced a complication at some time 
beyond the 30 day peri-operative period (Table 1). Cholangitis 
(22%) and the need for a PTC/drain (19%) were the most 
common late complications. All cyst types except Type 3 
were associated with late complications. Adult choledochal 
cyst disease tended to be associated with a higher incidence 
of late complications than pediatric disease. Malignant 
disease was found either at the time of resection or during 
long-term follow up in 9 patients (9.8%).
24.8% of TxC) and Low (LV; 21.5 DDLT/TxC/Yr; 58.6% of 
TxC). Endpoints were allograft and recipient survival.
Results: Compared to their lower volume counterparts, HV 
centers more frequently utilized donors with higher DRI 
(HV:1.95, MV:1.84, LV:1.81; p < 0.001), met renal-ECD 
criteria, increased age (>40 years), death secondary to stroke 
and cardiac demise prior to donation (p < 0.001). Recipient 
characteristics (MELD, age), donor characteristics (DRI, 
race, age, cause of death) and region of donation were found 
to be independent factors for allograft and recipient survival. 
Risk adjusted models showed HV centers had better overall 
allograft (HV : OR 0.88, 95% CI 0.83–0.93) and recipient 
(HV : OR 0.86, 95% CI 0.80–0.91) survival when compared 
to LV centers (p < 0.0001). These trends persisted when 
observations with DRI below the median (1.9) were excluded 
(p < 0.0001).
Conclusion: HV centers utilized higher DRI livers more 
frequently and achieved improved risk-adjusted allograft and 
recipient survival. Further understanding of center specifi c 
results may improve allocation practices and future 
outcomes.
Associated 
cancer (%)
Biliary 
Stricture/ 
Stenosis 
(%)
PTC 
with 
stent 
or 
drain 
(%)
Intrahepatic 
stones (%)
Pancreatitis 
(%)
Cholangitis 
(%)
All types 
(N = 64)
14 14 19 8 9 22
Type 1 
(n = 42)
14 10 12 2 10 12
Type 2 
(n = 3)
0 33 33 0 0 33
Type 3 
(n = 3)
0 0 0 0 0 0
Type 4 
(n = 14)
14 29 29 21 14 36
Type 5 
(n = 2)
50 0 100 0 0 100
Adult 
∝18 yr 
(n = 43)
18 24 27 11 12 24
Child 
< 18 yr 
(n = 21)
5 0 11 0 5 16
SPONTANEOUS RUPTURE OF HEPATIC 
HEMANGIOMAS
F. Papaiordanou2, M. A. Ribeiro Jr.1,2, J. M. Goncalves2, 
E. Chaib3, T. C. Menezes2 and J. H. da Fonseca2
1UNISA – Universidade Santo Amaro, Sao Paulo, SP; 
2UNICID – Universidade Cidade de Sao Paulo, Sao Paulo, 
SP; 3HC-FMUSP, Sao Paulo, SP
Aim: To evaluate the incidence of spontaneous rupture of 
hepatic hemangiomas in the current literature considering the 
high incidence of this type of benign liver tumor in the 
population.
Material and methods: Medline and pubMed search from 
1993 to 2010 about the spontaneous rupture of hepatic 
hemangiomas.
Results: Hepatic hemangiomas can be divided into two 
major groups: capillary hemangiomas and cavernous heman-
giomas. These tumors more frequently affect females (80%) 
and adults in their fourth and fi fth decades of life. The most 
cases are asymptomatic but a few patients may present a 
wide variety of clinical courses, where spontaneous or trau-
matic rupture is the worst severe complication. Imaging 
studies used in the diagnosis of hepatic hemangiomas in most 
cases include ultrasonography, dynamic contrast-enhanced 
computed tomography (CT) scanning, magnetic resonance 
imaging (MRI). In cases which the spontaneous rupture 
Conclusions: Patients with choledochal cysts are prone to 
long-term complications, particularly in the adult population. 
Choledochal cyst disease carries a risk of developing malig-
nancy in addition to a risk of signifi cant morbidity following 
surgical intervention. Therefore, life-long surveillance 
should be considered.
EFFECT OF DONOR RISK INDEX (DRI) 
AND CENTER VOLUME ON LIVER 
TRANSPLANTATION OUTCOMES
D. K. Ozhathil, Y. Li, J. K. Smith, R. F. Saidi, 
A. Bozorgzadeh, J. F. Tseng and S. A. Shah
University of Massachusetts Medical School – UMass 
Memorial Medical Center, Worcester, MA
Utilization of expanded criteria donors (ECD) organs across 
the United States has increased in recent years, refl ecting the 
national organ shortage. Despite this, nearly 30% of marginal 
livers are discarded annually. Using a risk-adjusted model, 
we determined whether transplant center (TxC) procedure 
volume impacted marginal allograft utilization and survival, 
as well as recipient survival.
Methods: We queried the UNOS database for all deceased 
donor liver transplants (DDLT; n = 34,909) from 2002 to 
2008, excluding split liver transplants. TxC (n = 141) were 
categorized by volume into tertiles: High (HV; 73.4 DDLT/
TxC/Yr; 16.7% of TxC), Medium (MV; 47.8 DDLT/TxC/Yr; 
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PANCREATODUODENECTOMY IN 
PATIENTS WITH HEPATIC CIRRHOSIS: 
IS IT WORTHWHILE?
J. B. Patel, A. Chauhan, T. J. Howard, J. R. Butler, 
A. Nakeeb, C. M. Schmidt, H. A. Pitt, M. G. House, 
K. D. Lillemoe and N. J. Zyromski
Indiana University, Indianapolis, IN
Background: Occasionally, unexpected hepatic cirrhosis is 
encountered during exploration for pancreatic resection. 
Surgical outcome data on pancreatectomy in cirrhotic 
patients are scant. This study examined the short- and long-
term outcomes of cirrhotic patients undergoing pancreatic 
head resection.
Methods: With IRB approval, records of 848 patients 
undergoing pancreatic head resection (1999–2009) were 
reviewed to identify concomitant liver disease. Demographics 
and outcomes were evaluated.
Results: Eleven patients with cirrhosis (4 female, median 
age 67.7 years) underwent pancreatic head resection (10 
pancreatoduodenectomy, 1 total pancreatectomy). Median 
preoperative MELD score was 9 (range 7–18); no patient had 
ascites. Pathology showed: pancreatic adenocarcinoma (8), 
ampullary adenocarcinoma (2), distal cholangiocarcinoma 
(1). Two patients (18%) died in the perioperative period; one 
on POD 6 from hepatic insuffi ciency, and one on POD 35 
related to myocardial infarction, gastrointestinal bleed, and 
delayed gastric emptying. Eight patients (73%) developed 
major perioperative complications: pulmonary (6), cardiac 
(3), gastrointestinal bleeding (2), and acute renal insuffi -
ciency (1). Five patients developed infections, 3 had delayed 
gastric emptying, 2 had pancreatic fi stula, and 2 developed 
ascites. Median length of hospital stay was 12 days (range 
7–51). Eight patients were discharged to home, and 2 to 
extended care facilities. Median survival was 32.5 months 
(range 12–60 months) with one patient alive at 5 years.
Conclusion: Patients with well-compensated liver disease 
tolerate pancreatic head resection, albeit with high peri-
operative morbidity and mortality. Long-term survival 
following cancer resections seemed surprisingly good. 
Pancreatoduodenectomy is acceptable for select patients with 
pancreatobiliary malignancy and concomitant liver disease.
occurs, clinical manifestations consist of sudden abdominal 
pain, and anemia secondary to a haemoperitoneum. 
Disseminated intravascular coagulopathy can also occur. 
Haemodynamic instability and signs of hypovolemic shock 
appears in about one third of the cases. As the size of the 
hemangioma increase, the greater is the chance of rupture. 
The rate of spontaneous rupture ranges 1–4%.
Conclusion: Surgical treatment should be restricted to spe-
cifi c situations. Absolute surgical indications are spontane-
ous or traumatic rupture with hemoperitoneum, intratumoral 
bleeding and consumptive coagulopathy (Kassabach-Merrit 
syndrome). In a patient presenting acute abdominal pain, 
with unknown abdominal disease, spontaneous rupture of a 
hepatic tumor like hemangioma should be considered as a 
rare differential diagnose.
THE ANATOMIC COURSE OF THE FIRST 
JEJUNAL BRANCH OF THE SUPERIOR 
MESENTERIC VEIN IN RELATION TO 
THE SUPERIOR MESENTERIC ARTERY
P. Papavasiliou, R. Arrangoiz, M. Lareef, F. Zhu, 
Y. S. Chun, K. Edwards and J. P. Hoffman
Fox Chase Cancer Center, Philadelphia, PA
Introduction: The purpose of this study is to determine the 
anatomic course of the fi rst jejunal branch of the superior 
mesenteric vein (SMV) in relation to the superior mesenteric 
artery (SMA).
Methods: Three hundred consecutive contrast-enhanced 
computed tomography (CT) scans were reviewed by a surgi-
cal oncologist with confi rmation of fi ndings by an attending 
radiologist. Data recorded included the relationship of the 
fi rst jejunal branch of the SMV to the SMA, branch diameter 
and inferior mesenteric vein (IMV) drainage.
Results: The overall incidence of a fi rst jejunal branch 
coursing anterior to the SMA was 41%.There was no correla-
tion between patient gender and position of the jejunal 
branch. In addition, there was no correlation between size of 
the fi rst jejunal branch and its location in relation to the 
SMA. The IMV drained into the SMV in 27% of the patients. 
The IMV drained into the SMV-portal vein confl uence in 
17% of patients and inserted into the splenic vein in 54%. 
An anterior coursing fi rst jejunal branch statistically corre-
lated with an IMV that drained into the SMV-portal vein 
confl uence (p = 0.009).
Conclusion: The fi rst jejunal branch of the SMV has a 
highly variable course in relation to the SMA and has a 
higher incidence of an anterior location in this population 
than previously reported. This knowledge is relevant to the 
abdominal surgeon.
Table. Results of SMV/IMV Anatomy
Number (Percentage)
Gender
Male 137 (46%)
Female 163 (54%)
1st Jejunal Branch Course 123 (41%)
Anterior to SMA 177 (59%)
Posterior to SMA 16 (5%)
No Common SMV Trunk
IMV Drainage
Splenic Vein 163 (54%)
SMV-Portal Vein Confl uence 52 (17%)
SMV 82 (27%)
Ileal Branch 1 (0.3%)
Jejunal Branch 2 (0.67%)
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THE PROGNOSTIC IMPORTANCE OF 
LYMPHOVASCULAR INVASION IN 
CHOLANGIOCARCINOMA ABOVE THE 
CYSTIC DUCT: A NEW SELECTION 
CRITERION FOR ADJUVANT THERAPY?
S. H. Patel1, D. A. Kooby1, J. Sarmiento2, C. Staley1 and 
S. K. Maithel1
1Emory University Department of Surgery, Division of 
Surgical Oncology, Winship Cancer Institute, Atlanta, GA; 
2Department of Surgery, Division of General Surgery, 
Emory University, Atlanta, GA
Background: No standard criteria exist for the administra-
tion of adjuvant chemotherapy for completely resected 
cholangiocarcinoma (CC); however, lymph node (LN) 
metastases are an indicator of aggressive biology often used 
to select patients for chemotherapy. A limitation of this 
approach is that LN recovery after hilar and intrahepatic CC 
resection is typically minimal to none; therefore, a surrogate 
is needed.
Methods: All patients between 1/00 and 9/09 who under-
went resection for hilar or intrahepatic CC at a single institu-
tion were identifi ed from a prospectively maintained 
database. Pathologic factors were recorded and primary 
outcome was overall survival (OS).
Results: 69 patients underwent resection for hilar (n = 34) 
and intrahepatic (n = 35) CC. Median age was 66 years; 42 
patients (39%) were male; median follow-up was 24.5 
months, and median OS was 17 months. The median tumor 
size was 5 cm, 23% had a positive resection margin, 44% 
had perineural invasion (PNI), 32% had lymphovascular 
invasion (LVI), and 25% had positive LNs. The median 
number of LNs removed was 2, and the median number of 
positive LN was 0. Presence of LVI was associated with a 
reduced OS (11.9 vs 23.1 months, p = 0.023) (Figure). After 
accounting for all other adverse tumor factors, presence of 
LVI persisted as the only negative prognostic factor on mul-
tivariate Cox regression for OS (Table).
Conclusion: After complete resection of hilar and intrahe-
patic cholangiocarcinoma, the presence of lymphovascular 
invasion is the strongest pathologic factor for predicting 
reduced overall survival. This may potentially be used as a 
selection criterion for administering adjuvant chemotherapy.
SARCOPENIA NEGATIVELY IMPACTS 
SHORT-TERM OUTCOMES IN PATIENTS 
UNDERGOING HEPATIC RESECTION 
FOR COLORECTAL LIVER METASTASIS
P. Peng, M. Van Vledder, S. Tsai, M. De Jong, J. Ng, 
I. Kamel, B. H. Edil, K. Hirose, C. L. Wolfgang, 
R. Schulick, M. Choti and T. M. Pawlik
Johns Hopkins Hospital, Baltimore, MD
Background: As indications for liver resection expand and 
more patients are offered surgery, objective measures to 
assess risk of peri-operative morbidity are needed. We sought 
to investigate the impact of sarcopenia (reduced muscle 
mass) on short- and long-term outcome of patients undergo-
ing liver resection for colorectal liver metastasis (CRLM).
Methods: Sarcopenia was assessed in 259 patients undergo-
ing liver resection for CRLM by measuring total psoas area 
(TPA) on CT-scans and normalizing for height. The impact 
of sarcopenia was assessed after controlling for background 
clinicopathological factors using multivariate modeling.
Results: Median patient age was 58 yrs and most patients 
(60%) were male. Forty-one (16%) patients had sarcopenia 
(TPA < 500 mm2/m2). There were no differences in baseline 
clinical, pathological, or operative characteristics between 
patients with or without sarcopenia (P > 0.05). Post-
operatively 60 patients had a complication for an overall 
morbidity of 23.2%; 26 patients (10.0%) had a serious com-
plication (Clavien grade 3–5). Presence of sarcopenia was 
strongly associated with increased risk of serious post-oper-
ative complication (OR 3.44; P = 0.007). Patients with sar-
copenia had a longer hospital stay (6.7 vs 5.4 days; P = 0.03). 
On multivariate analysis, sarcopenia remained independently 
associated with increased risk of post-operative complica-
tions (OR 2.98; P = 0.03). However, sarcopenia was not 
signifi cantly associated with long-term outcome as recur-
rence-free (HR = 1.07) and overall (HR = 1.05) survival were 
comparable in each group (both P > 0.05).
Conclusions: While patients with sarcopenia had increased 
risk of post-operative morbidity and longer hospital stay, 
long-term survival was not impacted by the presence of sar-
copenia. Sarcopenia may be helpful in identifying patients at 
highest risk of peri-operative morbidity following resection 
of CRLM.
Multivariate Cox Regression Analysis of Adverse 
Tumor Factors for Overall Survival (n = 69)
Variable HR 95% CI P-value
Tumor Size > 5 cm 0.64 0.33–1.28 0.21
Pos Margin 0.79 0.37–1.66 0.53
Pos LN 1.80 0.89–3.61 0.10
PNI 1.40 0.73–2.69 0.31
LVI 2.01 1.02–3.99 0.045
0.0 20.0 40.0 60.0 80.0 100.0
Time (months)
23.1 months
p = 0.023
LVI negative (n = 47)
LVI positive (n = 22)
11.9 months
Lymphovascular Invasion (LVI)
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RADIOLOGIC AND INTRAOPERATIVE 
DETECTION OF NEED FOR 
MESENTERIC VEIN RESECTION IN 
PATIENTS WITH ADENOCARCINOMA 
OF THE HEAD OF THE PANCREAS
M. R. Porembka, W. G. Hawkins, D. C. Linehan and 
S. M. Strasberg
Washington University In Saint Louis, Department of 
Surgery, Saint Louis, MO
Introduction: Effectiveness of radiologic/intraoperative 
prediction of need for SMV or portal vein resection during 
pancreatoduodenectomy for adenocarcinoma was 
evaluated.
Methods: 100/343 patients (29%) having pancreatoduode-
nectomy had vein resection based on radiologic and intraop-
erative assessments. Vein narrowing was the only preoperative 
radiologic sign considered to be absolute evidence of vascu-
lar involvement. Patients with abutment or loss of fat plane 
underwent trial dissection and had vein resection if the 
surgeon believed tumor adherence to vein was probable. 
Either actual invasion or microscopic tumor ≤1 mm from the 
resected vein (pathologic proximity) were criteria used to 
determine whether vein resection had actually been 
necessary.
Results: 77% of patients resected had one radiologic sign. 
23% were resected on the basis of operative fi ndings only. 
79/100 patients had suffi ciently detailed pathologic examina-
tion to assess tumor/vein relationship. In 41/79 patients there 
was microscopic invasion of the vein, while in 20/79 the 
tumor was ≤1 mm from the vein. In 18 patients (23%) the 
tumor was >1 mm from the vein. Consequently, in 61/79 
patients (77% of assessable specimens) a positive margin 
(R1 resection), would have been obtained without vascular 
resection. The SMV/portal vein resection margin was micro-
scopically negative (R0) in 98%, the same as the 243 patients 
without vein resection.
Conclusions: Combined radiologic/intraoperative assess-
ment resulted in moderately high sensitivity of the actual 
need for vascular resection. The requirement for resection is 
not apparent preoperatively in about one-quarter of patients 
needing it. Readiness to perform vascular resection under 
these conditions leads to a very high local R0 rate.
PANCREATIC CANCER FOLLOWING A 
DIAGNOSIS OF NEW-ONSET DIABETES: 
A POPULATION-BASED STUDY
E. Ragulin-Coyne, J. K. Smith, E. R. Witkowski, S. C. Ng, 
T. P. McDade, S. A. Shah and J. F. Tseng
Surgical Analysis & Outcomes Research (SOAR), University 
of Massachusetts Medical School, Worcester, MA
Background: There is an association between pancreatic 
cancer (PC) and preceding new-onset diabetes. We hypoth-
esized that patients with new-onset diabetes have important 
differences in tumor location, rate of resection, and 
survival.
Methods: SEER-Medicare 1991–2005 was used to identify 
diagnoses and dates for PC and diabetes. Kruskal-Wallis 
tests, stratifi ed univariate analysis, Chi square tests, and 
Kaplan-Meier survival analysis were performed.
Number 
of patients 
(%)
Linear Regression
Sarcopenia 
Index TPA 
mm2/m2 P-value
Complications
None or < grade 3 233 (89.9) 712 0.02
Grade 3–5 26 (10.1) 618
Length of stay
≤ 5 days 165 (63.7) 718 0.03
>5 days 94 (36.3) 675
Composite score*
0 161 (62.2) 717 0.02
1 76 (29.3) 705
2 22 (8.5) 589
*1 point for grade 3–5 complications, 1 point for LOS > 5 
days
MRNA GENE EXPRESSION 
CORRELATES WITH HISTOLOGICAL 
INJURY ASSOCIATED WITH 
CHEMOTHERAPY
C. H. Pilgrim1,2,3, W. Phillips1, B. Thomson1, S. Banting1, 
K. Brettingham-Moore1, A. Pham2, W. Murray1,3, 
L. Satgunaseelan2 and M. Michael1,3
1Peter MacCallum Cancer Centre, East Melbourne, 
Victoria; 2The Alfred Hospital, Melbourne, Victoria; 3The 
University of Melbourne, Melbourne, Victoria
Introduction: It may be possible to predict patients at risk 
of developing chemotherapy induced hepatic injury by anal-
ysis of genes that have been established to be associated with 
development of other forms of toxicity and which are 
involved in the metabolism of the chemotherapeutic agents.
Methods: Two hundred twenty samples kept in tissue bank 
following hepatic resection had RNA extracted and reverse 
transcribed into cDNA. Real time quantitative PCR using 
these samples was then employed to quantitate mRNA 
expression of nucleotide excision repair genes ERCC1 and 
ERCC2, of relevance in the neutralisation of damage induced 
by oxaliplatin, as well as genes encoding enzymes of rele-
vance to the metabolism of 5-fl urouracil, [thymidylate syn-
thase (TS), thymidine phosphorylase (TP) and 
dihydropyrimidine dehydrogenase (DPD)]. mRNA expres-
sion was correlated to histopathological injury patterns iden-
tifi ed by two independent pathologists, scored via previously 
validated methods in relation to steatosis, steatohepatitis and 
sinusoidal obstruction syndrome.
Results: High levels of TS mRNA were statistically signifi -
cantly associated with sinusoidal injury (p < 0.02). High 
levels of ERCC1 also displayed a trend towards this associa-
tion. Low levels of DPD mRNA was associated with the 
development of steatosis. Levels of ERCC1 and ERCC2 did 
not have any further association with injury patterns, and TP 
also had no relation to injury pattern.
Conclusions: Predisposition to the development of chemo-
therapy induced hepatic injury may be potentially predict-
able based upon individual patient expression level of genes 
encoding enzymes related to the metabolism of chemothera-
peutic agents.
54 Abstracts
© 2011 The Authors
Journal Compilation © 2011 Americas Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 1), 1–77
Results: 22493 PC patients were identifi ed, 44% with new 
onset diabetes preceding PC diagnosis. Females were less 
likely to present with diabetes (43.3% vs. 45.1% in males 
p = 0.006). Overall tumor locations were: head 51.8%, body 
9%, tail 10.3%, overlap/other 29%. Diabetic patients had 
fewer head tumors (50.9% vs. 52.4%) and more body tumors 
(10.1% vs. 8.3%). More diabetic patients were recommended 
for resection (33.9% vs. 32.7% p = 0.05), but with no sig-
nifi cant difference in a proportion actually resected (12.6% 
vs. 13.2% p = 0.21). Median duration of diabetes prior to PC 
was 37.7 (range 12.7–69.9) months. There was signifi cantly 
higher median survival in non-diabetics vs. diabetics for 
non-resected pancreatic head cancers (4.2 vs. 3.7 months 
p = 0.0008), and overall non-resected PC (3.4 vs. 3.1 months 
p = 0.0001)
Conclusions: There is a high proportion of new diabetics 
among PC patients, and diabetes may precede PC by a sub-
stantial period. While more patients with diabetes were 
recommended for resection, the proportion actually resected 
equaled non-diabetics. PC patients with diabetes without 
resection have diminished survival compared to their non-
diabetic peers. The relationship between diabetes and PC as 
a symptom, predictor, and consequence is complex and war-
rants further study.
AMBISPECTIVE COMPARATIVE STUDY 
OF TWO SURGICAL STRATEGIES FOR 
HYDATID DISEASE OF THE LIVER
J. M. Ramia, F. Ruiz, R. De La Plaza, J. E. Quinones, 
P. Veguillas and J. Garcia-Parreno
Hospital Universitario de Guadalajara, Guadalajara
Surgery is the preferred treatment for liver hidatidosis. Very 
few evidence clinical data exists about the technique of 
choice (radical vs conservative).
Purpose: To compare if results (feasibility, morbidity and 
mortality) of radical surgery are better that conservative 
techniques.
Material and methods: A total of 88 patients with 105 cysts 
made were operated on. The study had two periods. Data 
from fi rst period (January 2001–April 2007) (P1) were com-
piled retrospectively. The preferred surgical strategy was con-
servative surgery and T tube was placed. The second period 
May 2007–January 2010 (P2) was a prospective study con-
ducted according to protocol guided by the criterion the RS 
should be performed whenever it was technically feasible.
Results: The patients of the two periods showed no statisti-
cally signifi cant differences in age, gender, primary symptom, 
cyst location, previous surgery, mortality, or recurrence. 
Among the P2 patients, patients had more preoperative jaun-
dice, more preoperative ERCPs were performed, and cyst 
size was smaller (p < 0.05). In addition, the change in surgi-
cal strategy substantially increased the rate of radical surgery 
and diminished the number of T-tubes installed, morbidity, 
particularly biliary fi stula, and the mean stay (p < 0.001). 
A negative fi nding in P2 was the death of two very older 
patients (5.5%) who had been treated by means of CS. The 
rate of radical surgery in P2 was near 75%.
Conclusions: In our opinion, radical surgery should be tech-
nique of choice when it was feasible because it diminishes 
morbidity, hospital stay and relapse. Conservative surgery 
must be employed only in selected cases.
IS LIVER HYDATIDOSIS ALWAYS A 
SURGICAL DISEASE?
J. M. Ramia, R. De La Plaza, J. E. Quinones, P. Veguillas, 
C. Ramiro and J. Garcia-Parreno
Department of Surgery, Guadalajara
The most accepted treatment of liver hydatidosis (LH) is 
surgery. There are not any guidelines about which patients 
must be operated or not. Our Hospital is in an endemic area 
of LH and our criterion is that every LH should be operated 
on. We decided to perform a prospective study collecting 
every case not operated to observe their clinical characteris-
tics and reasons to not performing surgery.
Material and methods: Between May 07 and May 10 we 
have evaluated 62 patients suffering LH. We have operated 
on 40 patients, so 22 patients with 26 cysts have not been 
surgically treated. Demographic and clinical characteristics 
of both groups are in Table I. Reasons for non surgical treat-
ment were: synchronic diagnosis of advanced cancer 
(6 cases), patient choice (7 cases), combination of age + 
asymptomatic + location + comorbidities (7 cases), dissemi-
nated peritoneal disease with 6 previous laparotomies (1 
case), asymptomatic disseminated disease (1).
SURGERY GROUP
NON SURGICAL 
GROUP P
N 40 22
SEX 55.8 % MALE 55,4 % MALE NS
AGE 51.24 years (23–83) 71.3 (47–97) years p > 0.01
MAIN 
SYMPTOM
28 ABDOMINAL PAIN, 
8 JAUNDICE, 2 
SEPTIC SHOCK, 1 
CUTANEOUS 
FISTULA Y 
BILIOBRONCHIAL 
FISTULA 1
20 ASYMPTOMATIC p > 0.01
1 ABDOMINAL PAIN
2 JAUNDICE
RELAPSE 5 (14.7%) 2 (8.7%) NS
CYST 
LOCATION
BILATERAL 2, RIGHT 
15, LEFT 17
RIGHT 12 LEFT 3 p > 0.05
SPLEEN 2, 
ABDOMINAL WALL 
2
DISSEMINATED 2
SIZE (cm) 7.5 cm 5.7 cm p > 0.05
TREATMENT SURGERY (40 p) ERCP (2 p), PAIR 
(1 p)
Results: The commonest patient in non-surgical group 
(NSG) is an old (>75) patient with comorbidities that pres-
ents an asymptomatic cyst located centrally in right liver that 
requires a major surgery. Only in 6 patients (27%), the 
surgeon clearly disagree patient’s decision. In the rest of 
patients, hypothetical benefi t of surgery was doubtful. No 
patient in the follow up (15 months avg) has been 
operated.
Conclusions: Reasons for non-surgical treatment in LH 
are multiple: old asymptomatic patients with severe co-
morbidities, oncological patients and disseminated cases 
with previous laparotomies. Surgeon must evaluate carefully 
in these cases the real benefi t of surgical treatment.
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MULTICENTRE STUDY OF LIVER 
METASTASES FROM BREAST CANCER
J. M. Ramia1, R. Lopez-Andujar2, F. Pardo3, K. Muffak4, 
M. Caralt5, J. Gonzalez6, L. Sabater7 and J. Figueras8
1Department of Surgery, Guadalajara; 2Department of 
Surgery. Hospital La Fe, Valencia; 3Clinica Universitaria 
de Navarra, Pamplona, Navarra; 4Department of Surgery. 
Hospital Virgen de las Nieves, Granada; 5Department of 
Surgery, Hospital Vall D′Hebron, Barcelona; 6Department 
of Surgery. Hospital Santa Creu I San Pau, Barcelona; 
7Department of Surgery. Hospital Clinico Universitario, 
Valencia; 8Department of Surgery. Hospital Josep Trueta, 
Girona
Surgical resection of liver metastasis from breast cancer 
(LMBC) is increasingly last years. We have done a 
Multicentre study to know the data ol LMBC in Spain.
Material and methods: We have operated on 108 patients 
in 17 HPB Units. LMBC were 2.7% of total LM resection 
(108/3996). Mean age: 52 years (range: 30–79). Breast 
Cancer data: most frequent TNM was T2 (47%), N1 (51%) 
and M0 (84%). Most frequent stage was II (43%). Histology 
was ductal in 90%. Most frequent grade was G2 (65%). 
Estrogen receptors were positive in 72%. LMBC data: meta-
chronic (84%), interval between BC-LMBC was 55 months 
(range: 0–211), interval between LMBC diagnosis and liver 
surgery was 9.5 months (range: 0–72). LMBC were unique 
in 52%. Mean size: 3 cm (range: 0.5–8).
Results: Liver procedures: minor hepatectomy (55%), 
major (29%) and exploratory laparotomy (16%). 9% done by 
laparoscopy. RF in 5 cases. No blood transfusion (89%). R0: 
92%. Mortality: 0%. Morbidity: 14%. Relapse rate was 61%, 
70% in the liver. Survival was 30 months but DFS 19 months, 
with 28 months follow-up. Survival 1, 3 y 5 years were: 
87.7%, 66% y 33% and DFS: 57, 44 y 26.1%. Univariant 
analysis showed that sinchronic LMBC, number >3 and R1 
were negative prognostic factors, not confi rmed in multivari-
ant analysis.
Conclusions: Surgical results of LMBC are optimal. 
Interval between diagnosis and surgical resection is some-
times too long probably due to late referral to liver surgeons. 
A well defi ned guideline to treat LMBC will increase the 
patients resected that will imply a higher survival.
MULTICENTRE STUDY OF LIVER 
METASTASIS FROM COLORECTAL 
CANCER ON PATHOLOGIC LIVERS
J. M. Ramia1, R. Lopez-Andujar2, J. Torras3, L. Falgueras4, 
J. Gonzalez5, B. Sanchez6 and J. Figueras4
1Hospital Universitario de Guadalajara, Guadalajara; 
2Hospital La Fe, Valencia; 3Hospital Universitario 
Bellvitge, Barcelona; 4Hospital Josep Trueta, Girona; 
5Hospital Santa Creu I Sant Pau, Barcelona; 6Hospital 
Carlos Haya, Malaga
Resection of liver metastasis (LM) of colorectal cancer 
(CRC) in pathologic livers (cirrhosis or hepatopathy) is 
extremely rare. Several theories had been postulated for 
explaining this low rate but there is not a defi nitive 
explanation.
Material and methods: Retrospective muticentre study. 15 
HPB Units were asked but only 6 had CRC-LM in PL. These 
Units had resected 2364 LM. Only 20 patients with 38 
lesions were on PL (0.84%), 10 (cirrhosis) and 10 (chronic 
hepatopathy). Mean age was 65.4 years. 65% were male. 
Liver disfunction was known preoperatively in 18 cases 
(90%). Child status was always A. LM were sinchronic in 6 
patients (30%). Number of LM were 1.9 (range 1–4). Mean 
size was 3.4 cm (range 1.5–9). Preoperative CEA was: 32.3 
(range: 1–184).
Results: We performed: 12 subsegmentectomies, 6 left 
lateral sectionectomy, 4 segmentectomies, 3 RF ablation and 
4 exploratory laparotomy. Morbidity was 20% (Clavien I (1), 
II (2) y IVa (1)). Mortality: 0%. R0: 19 (95%). 12 patients 
(60%) did not receive postoperative chemotherapy. In the 16 
resected cases, 10 presented relapse (62%). Six relapses were 
located in liver. Four patients died at the 4, 15, 22, and 37 
months after surgery. Two of the deceased patients exhibited 
cirrhosis, another two chronic hepatopathy, while three of 
them had undergone resections.5-year Actuarial survival is 
39%. Disease free survival was 12.2 months and total sur-
vival 22.3 months.
Conclusions: Cirrhosis or cronic hepatopathy is not a con-
traindication for resection of CRC-LM and in selected cases 
liver resection is the best treatment.
A STANDARD DEFINITION OF MAJOR 
HEPATECTOMY: RESECTION OF FOUR 
OR MORE LIVER SEGMENTS
S. K. Reddy1, A. S. Barbas2, R. Turley2, J. L. Steel1, 
A. Tsung1, J. W. Marsh1, D. A. Geller1 and B. M. Clary2
1University of Pittsburgh Medical Center, Pittsburgh, PA; 
2Duke University Medical Center, Durham, NC
Introduction: While commonly used to describe liver 
resections particularly at risk for post-operative complica-
tions, no uniform defi nition of “major” hepatectomy exists. 
The objective of this study is to specify the extent of hepatic 
resection that should describe a major hepatectomy.
Methods: Demographics, diagnoses, treatments, and out-
comes of patients who underwent liver resection at two high-
volume centers were reviewed.
Results: From 2002 to 2009, 1,670 patients underwent 
hepatic resection (Table). There were no differences in post-
operative mortality (2.7% vs. 2.6%, p = 0.895), overall mor-
bidity (40.6% vs. 35.9%, p = 0.194), or readmission after 
initial discharge (18.3% vs. 14.0%, p = 0.116) after resection 
of three compared to less than three liver segments. In 
contrast, post-operative mortality (7.4% vs. 2.6%, p < 
0.0001), overall morbidity (49.3% vs. 36.9%, p < 0.0001), 
and readmission (20.7% vs. 14.9%, p = 0.002) were higher 
after resection of four or more segments compared to less 
than four segments. Hepatic, infectious, and septic complica-
tions were more common among patients who underwent 
resection of four or more segments compared to other 
patients (25.6% vs. 15.5%, p = 0.002) while there was no 
difference after resection of three and less than three seg-
ments (16.4% vs. 15.2%, p = 0.662). On multivariable analy-
sis, resection of four or more segments was independently 
associated with increased post-operative mortality (p = 
0.005), morbidity (p = 0.002), and hepatic, infectious, and 
septic complications (p = 0.0001).
Conclusions: Major hepatectomy should be defi ned as resec-
tion of four or more liver segments. This standard should be 
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considered when counseling patients about operative risks and 
evaluating studies that assess novel techniques and treatments 
to improve the safety profi le of liver resection.
Post-operative 
Outcome Hepatic resection
<3 segments 
(n = 814)
3 segments 
(n = 219)
≥4 segments 
(n = 537)
Mortality  21 (2.6%)  6 (2.7%)§  47 (7.4%)*
Morbidity 292 (35.9%) 89 (40.6%)§ 314 (49.3%)*
Hepatic/Infectious/
Septic 
Complications
124 (15.2%) 36 (16.4%)§ 163 (25.6%)*
Readmission 114 (14.0%) 40 (18.3%)§ 132 (20.7%)*
§p > 0.05 compared to patients who underwent resection of less than three 
segments.
*p < 0.01 compared to patients who underwent resection of less than four 
segments.
NOVEL QUANTIFICATION OF THE 
DECAY OF TEMPORAL ACCURACY OF 
HIGH QUALITY AXIAL IMAGING FOR 
PANCREATIC CANCER
S. Reddy, E. K. Fishman, J. L. Cameron, J. M. Herman, 
B. H. Edil, R. D. Schulick and C. L. Wolfgang
The Johns Hopkins University, Baltimore, MD
Purpose: Pancreatic adenocarcinoma is a dynamic disease 
that will progress through time in the majority of individuals. 
High quality pancreatic protocol CT (PPCT) scans are now 
considered the gold standard in evaluating pancreatic adeno-
carcinoma. To date, no study has quantifi ed the temporal 
accuracy of PPCT scans in pancreatic adenocarcinoma.
Methods: We retrospectively reviewed the results of 2589 
PPCT at a single institution over a 2-year time period and 
correlated radiographic to operative fi ndings for patients who 
later underwent exploration for curative intent for pancreatic 
adenocarcinoma.
Results: 292 PPCT were performed in 256 patients who 
underwent exploration for pancreatic adenocarcinoma. 
51.6% (132/256) were male, and the median age was 67 
years (range 30–95 years). Median time between PPCT and 
surgical exploration was 17 days (range 1–395 days). 20 
PPCT demonstrated metastatic disease. PPCT correctly pre-
dicted no evidence of metastatic disease in 226/272 (83.1%) 
scans. PPCT were more accurate at predicting the lack of 
metastatic disease if the study was performed within 28 days 
of surgery (88.1% vs. 68.1%, P = 0.003). The Figure depicts 
the depreciation of the negative predictive value of PPCT 
over time. The accuracy of PPCT in correctly predicting lack 
of vascular invasion was 82.9%, and this did not change over 
time (≤28 days 80.4%, >28 days 97.2%, P = 0.71).
Conclusions: PPCT is accurate in the preoperative staging 
of pancreatic adenocarcinoma. However, the accuracy of 
PPCT signifi cantly depreciates over time in regards to 
metastatic disease. Patients should undergo PPCT within 4 
weeks of planned operative intervention for pancreatic 
adenocarcinoma.
Neo-adjuvant 
chemotherapy 
(n = 89)
No neoadjuvant 
chemotherapy 
(n = 114) p
Age (median) 58 [32–79] 65 [33–80] 0.012
Male gender 54 (60.6%) 61 (53.5%) 0.379
Synchronous CRLM 66 (74.2%) 25 (21.9%) <0.001
Initial number of CRLM 
(median)
 2 [1–4] 1 [1–4] 0.017
Operatively explored 88 (98.9%) 114 (100%) 0.901
 Underwent resection/
 ablation£
87 (98.9%) 114 (100%) 0.897
 Intra-operative 
 EHMD not seen on 
 pre-operative 
 imaging£
 3 (3.4%) 4 (3.5%) 0.727
 More intra-operative 
 CRLM than seen 
 on pre-operative 
 imaging£
20 (22.7%) 19 (16.7%) 0.367
 Margin positive 
 resection*£
 3 (3.5%) 4 (3.5%) 0.935
Six month disease 
recurrence
19 (21.3%) 13 (15.3%) 0.082
£Includes patients who were operatively explored.
*Excludes patient with R2 resection.
DOES NEOADJUVANT CHEMOTHERAPY 
REVEAL DISEASE PRECLUDING 
SURGICAL TREATMENT OF INITIALLY 
RESECTABLE COLORECTAL LIVER 
METASTASES?
S. K. Reddy, A. Tsung, J. W. Marsh and D. A. Geller
University of Pittsburgh Medical Center, Pittsburgh, PA
Introduction: One rationale supporting neoadjuvant che-
motherapy for initially resectable colorectal cancer liver 
metastases (CRCLM) is to allow for growth of occult disease, 
thus preventing futile surgery. Yet evidence supporting this 
approach is lacking. This study aims to determine whether 
neoadjuvant chemotherapy reveals occult disease precluding 
surgical treatments of initially resectable CRCLM.
Methods: Demographics, radiologic imaging, treatments, 
and outcomes of patients aged 18–80 years, with one to four 
resectable CRCLM, without extra-hepatic metastatic disease 
(EHMD), and who had not undergone previous surgical 
treatment of CRCLM at a single center were reviewed.
Results: 203 patients evaluated from 2000 to 2010 met 
study criteria; 89 (43.8%) were treated with neoadjuvant 
chemotherapy. Patients treated with neoadjuvant chemother-
apy were younger (median 58 vs. 65 years, p = 0.012), more 
often presented synchronously with primary disease (74.2% 
vs. 21.9%, p < 0.0001) and had more lesions (median 2 vs. 
1, p = 0.017) compared to untreated patients (Table). There 
were no differences in frequency of hepatic resection and/or 
ablation (98.9% vs. 100%, p = 0.897), EHMD noted intra-
operatively and not on pre-operative imaging (3.4% vs. 
3.5%, p = 0.727), or frequency of more intra-operatively 
observed CRCLM compared to that noted on pre-operative 
imaging (22.7% vs. 16.7%, p = 0.367) between patients 
treated with and without neoadjuvant chemotherapy. Only 
one patient underwent an R2 resection. No differences in 
margin positive liver resections (3.5% vs. 3.5%, p = 0.935) 
or disease recurrence six months after resection (21.3% vs. 
15.3%, p = 0.082) between treated and untreated patients 
were observed.
Conclusion: Neoadjuvant chemotherapy for initially resect-
able CRCLM does not reveal occult disease precluding 
hepatic resection or affect early disease recurrence.
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CEACAM6 EXPRESSION IN 
GALLBLADDER CARCINOMA
F. G. Rocha, J. Torres, J. M. Butte, R. P. DeMatteo, 
Y. Fong, M. D’Angelica, P. J. Allen, D. S. Klimstra and 
W. R. Jarnagin
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: Gallbladder cancer is the most common 
biliary tract cancer with a dismal survival. CEACAM6 is a 
membrane protein involved in cell adhesion and signaling 
that is overexpressed in both pancreatic and biliary adeno-
carcinoma and associated with a poor prognosis. This study 
examines the signifi cance of CEACAM6 expression in gall-
bladder cancer and its relationship to outcome.
Methods: Tissue microarrays containing triplicate cores of 
paraffi n-embedded surgical specimens from patients with 
gallbladder cancer and control tissue were probed for 
CEACAM6 by immunohistochemistry. Clinical, pathologic 
and survival data were analyzed and correlated with 
CEACAM6 expression.
Results: 70 cases of gallbladder cancer from 1992 to 2007 
were assembled in the tissue microarrays. They included 1 
T1 (1%), 15 T2 (22%), 51 T3 (75%), 1 T4 (1%), tumors and 
4 Stage 1 (6%), 44 Stage 2 (64%), 1 Stage 3 (1%), 20 Stage 
4 (29%) patients. Positive CEACAM6 signal was present in 
37/70 (53%) tumors and none of the control tissues. Overall 
median survival was 17 months. CEACAM6 staining did not 
correlate with age, sex, grade of differentiation, positive 
lymph nodes, vascular invasion or metastases but was associ-
ated with margin positive resection (p < 0.008) and higher 
AJCC stage (p < 0.02). Survival analysis of patients who had 
a curative or R0 resection demonstrated that CEACAM6 
expression was not associated with disease-specifi c survival 
(19 months for positive vs 25 months for negative, p < 0.5).
Conclusions: CEACAM6 is a not prognostic factor in 
resected gallbladder carcinoma. However, it may serve as a 
marker of more aggressive disease.
CEACAM6
Parameter Yes No p-value
Age > 65 0.15
 Yes 59% 76%
 No 41% 24%
Male 0.11
 Yes 27% 45%
 No 73% 55%
Poor Diff 0.71
 Yes 48% 39%
 No 52% 61%
Vasc Inv 0.85
 Yes 44% 36%
 No 66% 64%
Lymph Node+ 0.42
 Yes 50% 40%
 No 50% 60%
Any Metastases 0.59
 Yes 59% 53%
 No 41% 47%
Curative Resection 0.008
 R1 23% 0%
 R0 77% 100%
AJCC Stage 0.02
 I/II 59% 81%
 III/IV 41% 19%
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SURVIVAL IMPACT OF MALIGNANT 
PANCREATIC NEUROENDOCRINE AND 
ISLET CELL NEOPLASM PHENOTYPES
C. L. Roland, A. Bian, J. C. Mansour, A. C. Yopp, 
G. C. Balch, R. Sharma, X. J. Xie and R. E. Schwarz
University of Texas Southwestern Medical Center, 
Dallas, TX
Introduction: Neoplasms of pancreatic neuroendocrine or 
islet cell origin encompass a wide variety of tumor types. 
The low incidence of malignant functional (F) or non-
functional (NF) neuroendocrine islet cell tumors (ICTs) 
represents a challenge to precise post-therapeutic survival 
prediction.
Methods: A pancreatic ICT data set was created from a 
US-based multi-institutional database from 1980 to 2004. 
Prognostic factors with survival impact, and relationships 
between surgical therapy and overall survival (OS) were 
analyzed.
Results: 2,350 individuals were identifi ed. Histologic des-
ignations included carcinoid tumors (n = 176), islet cell car-
cinomas (n = 959), neuroendocrine carcinomas (n = 1052), 
and malignant gastrinomas (n = 68), insulinomas (n = 47), 
glucagonomas (n = 30), or VIPomas (n = 18). Median tumor 
size was 4.8 cm. FICTs had a greater resection rate than 
NFICTs (43% vs. 30%, p = 0.003). Median OS was 30 
months, with group differences ranging from NE carcinomas 
(21) to VIPomas (96; p < 0.0001). Diagnosis group and 
resection status had an obvious OS association: median OS 
of resected vs. unresected FICTs was 172 vs. 37 months, 
while that of NFICTs was 113 vs. 18 months (p < 0.0001, 
see Figure). Multivariate OS variables were: age, grade, sur-
gical treatment (all at p < 0.0001), node involvement (p = 
0.0002), histopathologic group (p = 0.004), and primary 
tumor site (p = 0.03). Compared to VIPomas, hazard ratios 
were: gastrinomas 1.4, insulinomas 1.8, glucagonomas 1.9, 
carcinoid tumors 1.6, islet cell carcinomas 2.1 and NE car-
cinomas (NOS) 2.1.
Conclusions: When controlled for other established prog-
nostic parameters, histopathologic subtype assignment of 
pancreatic ICTs signifi cantly affects survival prediction. 
Resective local treatment is associated with superior survival 
for all tumor types and remains the standard of care.
IMPROVED PANCREATIC FISTULA 
RATE AFTER LAPAROSCOPIC DISTAL 
PANCREATECTOMY USING SALINE-
COUPLED RADIOFREQUENCY 
ABLATION FOR PARENCHYMAL 
DIVISION
J. W. Rostas1, W. O. Richards1 and L. W. Thompson2
1University of South Alabama Department of Surgery, 
Mobile, AL; 2Mobile Infi rmary Medical Center, Mobile, AL
Introduction: Post-operative pancreatic fi stula (POPF) is 
the most common signifi cant complication after distal 
pancreatectomy (DP) and results in substantial morbidity. 
Many methods are available to divide the pancreatic paren-
chyma and achieve stump closure, but demonstrating an 
improvement in the incidence of POPF has been diffi cult. We 
report improved clinically signifi cant fi stula rates after hand-
assisted laparoscopic DP with the use of saline-coupled 
radiofrequency ablation (RFA) as the only device for paren-
chymal division and stump closure.
Methods: A single institution retrospective review was 
conducted from October 2008 to August 2010 evaluating 
all hand-assisted laparoscopic DP utilizing saline-coupled 
RFA (Salient Surgical Technologies Endo SH2.0) as the 
exclusive method for division of the pancreatic parenchyma 
and closure of the proximal pancreatic remnant. POPF was 
defi ned in accordance with the International Study Group on 
Pancreatic Fistula. All signifi cant complications within the 
30 day peri-operative period were also included.
Results: Twenty-one patients met the above criteria. One 
patient was excluded because of loss to follow-up. One 
patient (5%) demonstrated a clinically signifi cant (grade B) 
POPF necessitating a prolonged duration of the operative 
drain. The only other signifi cant complication (5%) was a 
gastric perforation that required partial gastrectomy. Average 
length of stay was 5.85 days, and average blood loss was 
58 mL.
Conclusion: The use of saline-coupled RFA alone for 
pancreatic parenchymal division and closure after DP is 
safe and effective. Specifi cally, we report and overall signifi -
cant complication rate of 10%, consistent with previous 
reports, but with only a 5% rate of clinically signifi cant 
POPF.
OUTCOMES OF PARTIAL LIVER 
TRANSPLANTATION: DECEASED 
DONOR SPLIT VS LIVE DONOR LIVER 
TRANSPLANTATION
R. F. Saidi, Y. Li, S. A. Shah and A. Bozordzadeh
University of Massachusetts Medical School, 
Worcester, MA
Organ shortage makes partial liver transplantation (PLT) an 
alternative option to whole organ transplantation. The aim of 
the study was to assess the outcome of PLT comparing 
deceased donor split (DD-SL) and live donor liver transplan-
tation (LDLT) in adults as reported to the United Network 
for Organ Sharing (UNOS) in the MELD-era. Between 2002 
and 2009, 2272 PLT were performed: DD-SL (n = 557, 
24.5%) and LDLT (n = 1715, %75.5). DD-SL were per-
formed with a right/extend right (82.1%), left lobe allograft 
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(17.9%), while LDLT used the right/extend right lobe 
(95.9%) and left lobe (4.1%). Demographic differences in 
the groups were most noticeable for lower MELD scores in 
LDLT (14.5 vs 20.9) recipients (P < 0.001), younger recipient 
age in LDLT (50.7 vs 52.8), and younger donor age in 
DD-SL (23 vs 37.3) (P < 0.001). Recipients status was coded 
as sick/very sick in 39.8% and 25% of DD-SL and LDLT, 
respectively (p < 0.001). Allograft survival was comparable 
between groups (p = 0.438), However, there was a trend for 
better patient survival after LDLT (p = 0.052). In Cox regres-
sion analysis, LDLT was associated with better allograft (HR 
= 0.7, 0.63–0.79, 95% CI, p < 0.0001) and patient survival 
(HR = 0.6, 0.55–0.64, 95% CI, p < 0.0001) compared to 
DD-SL. Despite different in donor and recipient characteris-
tics, LDLT is associated with better allograft and patient 
survival compared to DD-SL. The benefi t of LDLT over 
DD-SL suggests that the risk to the donor may justify the 
benefi t when comparing it to the deceased donor 
alternative.
Table. Patients Characteristics
Variables DD-SL LDLT p
Age 52.8 ± 10 50.7 ± 11 <0.001
Sex (male) 44.5% 44.5% <0.001
Donor age 23 ± 9.4 37.3 ± 10 <0.001
Donor sex (male) 69.2% 50.7% <0.001
MELD 20.9 ± 9.2 14.5 ± 5.6 <0.001
CIT (h) 8.2 ± 3.7 3.1 ± 5.9 <0.001
Recipient status (Sick/very sick) 39.8% 25% <0.0001
5-year allograft survival 78.8% 79.8% 0.438
5-year patient survival 75.2% 78.2% 0.052
MARKED VARIANCE BETWEEN 
ESTIMATED AND CALCULATED BLOOD 
LOSS FOR PANCREATIC RESECTION 
SURGERY
N. J. Sanchez, S. Gondek, T. S. Kent, M. P. Callery and 
C. M. Vollmer
Beth Israel Deaconess Medical Center, Boston, MA
Introduction: Intraoperative blood loss estimated by sur-
geons/anesthesiologists (EBL) is a seminal outcome metric 
in high-acuity surgery, yet is notoriously inaccurate. 
However, more objective methods to gauge blood loss are 
available, but currently underemployed. We directly com-
pared these approaches in order to promote calculated blood 
loss (CBL) as a standardized quality indicator following pan-
creatic resection.
Methods: Pancreatic resections over 8 years with complete 
annotation were analyzed. EBL was quantitatively compared 
to CBL based on available objective parameters (hematocrit, 
height, weight, transfusions) using a validated equation.
Results: 569 resections included 369 Proximal, 170 Distal, 
6 Central, 9 Total, and 5 Other pancreatectomies. Generally, 
the median CBL is double the median EBL (Table). EBL 
underestimated CBL in 70% of the cases, while it overesti-
mated only 30%. There were great discrepancies for the 
extreme ranges of blood loss: For cases < 100 ml EBL = 
5.6% and CBL = 13.7%, while for cases > 1000 ml EBL = 
5.6% but CBL = 22.6%. For patients transfused intraopera-
tively (12.3% overall), CBL correlated much closer to EBL 
(Median: 689 vs 600 ml), and CBL > EBL in 49% of the 
cases (vs 74% non-transfused), suggesting better clinical 
estimates in these diffi cult cases. Circulatory adjustments 
from blood loss temporally continue up to a day after the 
operation as median CBL (24 hr) > CBL (Operation) by 
another 200 ml.
Conclusion: There is marked variation between estimated 
and calculated blood loss which also fl uctuates by the scope 
of operation. The effects of blood loss linger beyond the opera-
tion itself. These data argue for the more uniform adoption of 
CBL as a quality indicator for pancreatic resection surgery.
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Operation
Mean 
(ml)
Median 
(ml)
Range 
(ml) SD
Variance of Median 
(CBL vs EBL)
Overall EBL 407 300 50–6000 408 +282
(n = 569) CBL 646 582 0–5568 765 p < 0.001 (Wilcoxon)
Proximal EBL 406 300 25–2500 324 +266
(n = 369) CBL 624 566 0–5749 769 p < 0.001
Distal EBL 428 300 0–6000 566 +311
(n = 170) CBL 704 611 0–3759 809 p < 0.001
Central EBL 289 225 50–1000 258 +251
(n = 6) CBL 453 476 0–885 253 p < 0.001
Total EBL 394 400 100–600 159 +363
(n = 9) CBL 866 763 397–1450 386 p = 0.008
Other EBL 150 200 50–200  71 +145
(n = 5) CBL 509 345 294–809 270 p = 0.043
SAFETY OF HEPATIC RESECTIONS IN 
OBESE VETERANS
J. K. Saunders1,2, A. S. Rosman3, D. Neihaus2, 
T. H. Gouge1,2 and M. Melis1,2
1New York University School of Medicine, New York, NY; 
2NYHHS VAMC, New York, NY; 3Mount Sinai School of 
Medicine and Bronx VAMC, Bronx, NY
Introduction: We aimed to determine the effects of body 
mass index (BMI) on outcomes after liver resection per-
formed at the Veteran Administration.
Methods: We queried the VASQIP database for liver resec-
tions (2005–2008), and grouped the patients into fi ve catego-
ries: normal weight (NW, BMI 18.5–24.9), overweight (OW, 
BMI 25–29.9) Class 1 (OB1, BMI 30–34.9), Class 2 (OB2, 
BMI 35–39.9), and Class 3 obesity (OB3, BMI ≥ 40). 
Differences in risk factors and perioperative complications 
across groups were analyzed.
Results: Of 403 patients who underwent hepatectomy, 106 
(26.3%) were NW, 161 (40.0%) OW, 94 (23.3%) OB1, 31 
(7.7%) OB2, and 11 (2.7%) OB3. The BMI groups were 
similar in patient gender, age, diagnosis (90.3% malignancy), 
ASA class, rates of alcohol abuse, ascites, esophageal varices, 
and neoadjuvant treatment. Higher BMI was associated with 
increased rates of diabetes (18% vs. 27% vs. 36% vs. 39% 
vs. 45%, p 0.04) and lower incidence of smokers (53% vs. 
35% vs. 30% vs. 16% vs. 9%, p 0.0001). There were no 
differences in type of resection performed, operative time, 
work RVU. OB3 received more blood transfusions (OB3 4.3 
± 2.7 vs. NW 1.1 ± 0.2, p 0.02). There were no differences 
across BMI groups in overall and specifi c morbidity, as well 
in length of stay. Nevertheless, compared to the other groups 
OB3 had a higher 30-day mortality (27% vs. 6%, 0.05). 
Multivariate analyses confi rmed BMI > 40 as an independent 
predictor of post-operative mortality.
Conclusion: Obesity did not increase post-operative com-
plications in veterans after liver resection. Mortality was 
higher in patients with BMI > 40.
COMPLETE RESOLUTION OF A 
MALIGNANT BILIARY STRICTURE 
USING COMBINED NEOADJUVANT 
CHEMORADIATION AND 
BRACHYTHERAPY BOOST PRIOR TO 
ORTHOTOPIC LIVER 
TRANSPLANTATION
J. Schwartz, L. J. Hazard, J. Carlisle, A. Burdette, 
K. Jones, H. Thiesset, W. Hutson and J. Sorensen
University of Utah, Salt Lake City, Utah
This report demonstrates the complete resolution of a malig-
nant biliary stricture using chemo-radiation (rx) followed by 
brachytherapy (BT) boost prior to orthotopic liver trans-
plantation (OLT). The focus of this report is a 41 y.o. male 
with a 13 year history of primary sclerosing cholangitis. 
Cytological brushing of a known area of stricture (Figure 1) 
near the biliary confl uence was consistent with adenocarci-
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noma. Other clinical signs of primary liver disease were 
absent and he was selected to undergo percutaneous biliary 
access for intraluminal BT, external beam rx, neoadajuvant 
chemotherapy, staging laparotomy, and subsequent OLT. The 
patient was then transplanted using standard piggy back tech-
nique with Roux-en-Y biliary reconstruction at a calculated 
Model for End-Stage Liver Disease score of 17. Repeat chol-
angiography prior to OLT demonstrated complete resolution 
of the patient’s malignant stricture (Figure 1). An exhaustive 
search undertaken in the explanted liver demonstrated 
marked epithelial atypia, without defi nitive evidence of neo-
plasia. This report validates the use of chemorx and BT boost 
for early stage biliary neoplasia independent of, or as a com-
ponent of, a well-defi ned neoadjuvant protocol culminating 
in OLT or standard surgical resection. While it would be 
speculative to suggest that such methods could potentially 
facilitate an R0 resection in a previously unresectable patient, 
further study is clearly indicated. New techniques may facili-
tate radiation dose escalation without adding signifi cantly to 
normal tissue toxicity. Additional refi nement may allow for 
more effectual delivery of neoadjuvant therapy, stimulate the 
development of palliative treatments, and relegate therapeu-
tic nihilism to obsolescence.
DIAGNOSTIC UTILITY OF THE MODERN 
SILVERHAWK ATHERECTOMY 
CATHETER: A PILOT STUDY
J. Schwartz, H. Thiesset, J. Carlisle, A. Burdette, 
L. J. Hazard, F. Clayton, D. Adler, W. Hutson and 
J. Sorensen
University of Utah, Salt Lake City, UT
Objectives: As neoadjuvant protocols to facilitate ortho-
topic liver transplantation (OLT) in Stage I and II hilar 
cholangicocarcinoma (CCA) have resulted in signifi cant 
gains in long-term survival, the purpose of this study was to 
determine the initial diagnostic utility of the modern 
Silverhawk atherectomy (SA) catheter in the evaluation of 
malignant-appearing biliary strictures (MABS).
Methods: A total of 40 patients with cholangiocarcinoma 
were identifi ed during a retrospective review of medical 
records from 2006 to 2009. All were suspected of harboring 
MABS. The SA catheter was employed 9 times in 7 patients 
with MABS whose diagnoses were equivocal based on clini-
cal parameters (Table 1).
Results: A defi nitive exclusion of neoplasia was made in 5 
biopsy (bx) specimens. These three individuals were followed 
for 1–4 years to exclude the subsequent development of CCA. 
Four patients had samples positive for CCA; one of which 
became eligible for neoadjuvant therapy and OLT. All but one 
bx supplied suffi cient tissue for reliable examination
Conclusion: Endoluminal bile duct bx by SA catheter 
appears to be effective in excluding or diagnosing CCA in 
patients with MABS. The existence of this technique to 
provide defi nitive diagnoses based on tissue architecture may 
impact therapy by allowing earlier diagnosis as well as the 
more effi cient use of limited donor resources where protocols 
for OLT are available. Although initial results are promising, 
more experience with this approach is required to effectively 
determine clinical accuracy.
62 Abstracts
© 2011 The Authors
Journal Compilation © 2011 Americas Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 1), 1–77
PULMONARY AND VENOUS 
THROMBOEMBOLISM RATES 
AMONGST LIVER RESECTION 
PATIENTS: AN EXAMINATION OF 
NSQUIP DATA
J. Schwartz, G. M. Vargas, H. Thiesset, G. Stoddard, 
L. Neumayer and J. Sorensen
University of Utah, Salt Lake City, Utah
Objective: The aim of this study was to examine the national 
rate of fatal and near-fatal thromboembolic events in patients 
undergoing major liver surgery.
Methods: The National Surgical Quality Improvement 
Program (NSQUIP) database was queried to collect data on 
the incidence of Pulmonary Embolism (PE) and Deep Vein 
Thrombosis (DVT) in the population subset of liver resection 
patients performed nationally during the years 2004–2009. 
A matched sample McNemar test was used to examine dif-
ferences in annualized incidence rates.
Results: During the fi ve year study period, 6,084 liver 
resections were performed amongst 268 NSQUIP institutions 
nationally. During this time, DVT and PE occurred at a rate 
of 1.97 and 1.36%, respectively, with DVT occurring 1.45 
times more frequently than PE (RR = 1.45, 95% CI (1.09–
1.91), p = 0.009). Incidence rates remained constant over the 
study period (Figure 1).
Conclusion: Recent data suggests that the rate of pulmonary 
(PE) and deep venous thrombosis (DVT) in patients with 
recently diagnosed neoplasms is 7 times higher than the 
general population. As primary and metastatic hepatic malig-
nancies become increasingly more prevalent, surgical extirpa-
tion is being employed more frequently than in the past. 
However, thromboembolic prophylaxis (TEP) remains contro-
versial in this population due to the perceived risk of coagu-
lopathy in the setting of liver dysfunction. Examination of a 
national cohort indicates that the rate of VTE remains low after 
major liver resection. This fi nding may infl uence the decision 
to initiate TEP in a patient undergoing major liver surgery.
Table. Patient Disposition over time
Year
Patient Disposition
Home Other Facility Home Health Care
1993 74.5%  5.5% 20.0%
1994 69.8%  8.1% 22.0%
1995 63.6% 10.9% 25.5%
1996 61.7% 12.9% 25.5%
1997 63.9% 11.0% 25.1%
1998 61.3% 14.0% 24.7%
1999 63.1% 14.3% 22.6%
2000 58.5% 13.3% 28.2%
2001 57.6% 15.4% 27.0%
2002 62.1% 13.0% 24.9%
2003 58.05 13.6% 28.4%
2004 54.4% 11.1% 34.5%
2005 53.7% 13.3% 33.0%
NATIONAL TRENDS IN DISCHARGE 
DISPOSITION FOLLOWING 
PANCREATIC RESECTIONS FOR 
MALIGNANCY
B. C. Shah1, L. Smith2, F. Ullrich2, Q. P. Ly1, A. R. Sasson1 
and C. Are1
1University of Nebraska Medical Center, Division of 
Surgical Oncology, Department of Surgery, Omaha, NE; 
2University of Nebraska Medical Center, Department of 
Biostatistics, Omaha, NE
Aim: The aim of this study is to analyze the national trends 
in discharge disposition following pancreatic resection for 
malignancy.
Methods: The National Inpatient Sample database was 
queried (1993 to 2005) to identify patients that underwent 
pancreatic resection for malignancy. The status of patients at 
discharge (home, home health or other facility) was noted.
Results: A weighted total of 51,866 patients that underwent 
pancreatectomy for malignant neoplasm of the pancreas 
were identifi ed. After excluding patients that died in the post-
operative period and patients without a specifi ed discharge 
disposition, 46,602 patients were included in the study. The 
overall mortality improved over the period of the study from 
7.1% in 1993 to 5.2% in 2005. We noted a signifi cant increase 
in the number of patients being discharged to other facility 
(5.5% in 1993 to 13.6% in 2005). Similarly there was an 
increase in the number of patients discharged home with 
home health assistance (20% in 1993 to 28.4% in 2005). This 
corresponded with a statistically signifi cant decrease in the 
number of patients being discharged home without any assis-
tance. (74.5% in 1993 to 53.7% in 2005, p = 0.002).
 Abstracts 63
© 2011 The Authors
Journal Compilation © 2011 Americas Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 1), 1–77
Conclusion: The results of our study demonstrate that fol-
lowing pancreatic resection, nearly half of the patients will 
need some assistance upon discharge. This information needs 
to be included in the patient counseling during pre-operative 
risk and benefi t assessment.
REDUCTION IN TUMOR RECURRENCE 
FOLLOWING TREATMENT WITH AN 
NFKAPPAB INHIBITOR IN A MOUSE 
RESECTION MODEL OF PANCREATIC 
DUCTAL ADENOCARCINOMA
J. E. Shea1, S. K. Kuwada2 and C. L. Scaife1
1Department of Surgery; University of Utah, Salt Lake 
City, UT; 2Department of Gastroenterology, University of 
Hawaii, Honolulu, HI
Background: Long-term survival after resection of pancre-
atic ductal adenocarcinoma (PDA) is less than 20%. Patients 
frequently succumb due to tumor recurrence. NFkappaB is 
not only expressed to a greater degree at the time of cancer 
cell adhesion, but inhibition of this pathway prevents cell 
adhesion. The present study was designed to determine if an 
NFkappaB inhibitor could prevent the development of local 
or distant recurrence following resection of a primary ortho-
topic pancreatic tumor in a mouse model.
Materials and methods: Twenty-fi ve athymic mice were 
injected with MiaPaCa-2 cells into the tail of the pancreas. 
Four weeks after injection, mice with confi rmed tumors 
(23/25) underwent resection of the primary tumor. Mice were 
treated with either an NFkappaB inhibitor (Bay 11-7085 
(5 mg/kg)) or DMSO control 3 times a week. After 8 weeks, 
mice were assessed for tumor recurrence. Statistical differ-
ences were determined using chi-squared analysis.
Results: The recurrence rate in mice treated with the 
NFkappB inhibitor was 23% (3/13) compared with 50% 
(5/10) in mice given carrier (p < 0.05). Two of the treated 
mice developed local recurrence while one developed distant. 
In control mice, two developed local recurrences, one devel-
oped a distant recurrence, while two developed both local 
and distant recurrence.
Discussion: The NFkappaB inhibitor Bay 11-7085 reduced 
the number of mice that developed recurrence following 
resection of the primary PDA tumor. Any treatment that can 
potentially inhibit tumor recurrence, both local and distant, 
would be benefi cial for patient care.
GALLBLADDER PATCH REPAIR FOR 
LARGE-SIZED DUODENAL ULCER 
PERFORATIONS
A. Shimizu, H. Tanaka, T. Zuiki, Y. Sakuma, Y. Hosoya, 
N. Sata and Y. Yasuda
Department of Surgery, Jichi Medical University, 
Shimotsuke, Tochigi
Background: Omental patch is usually employed to repair 
a perforated duodenal ulcer. With a large defect of the duo-
denal wall, however, even if it is technically feasible, there 
remains a concern about postoperative stricture. Furthermore, 
the omentum is not readily available in some cases because 
of previous surgery or severe adhesions. Jejunal patch or 
Roux-en Y duodenojejunostomy is often used for those 
cases. Still such complicated procedures are not preferable 
because these patients are often elderly and seriously ill by 
the time of surgery. Gallbladder serosal patch has been 
applied for these cases with excellent outcome.
Method: The gallbladder was incised along the longitudinal 
axis up to the cystic duct, forming the pedicled serosal patch. 
The cystic artery was identifi ed and secured maintaining the 
blood supply to the patch. The cystic duct was ligated. After 
trimming of the friable margins around the duodenal wall 
defect, the outer peritoneal layer of the gallbladder was 
applied over the duodenal defect and sutured circumferen-
tially by using 4-0 PDS sutures. The macroscopic and micro-
scopic healing features were examined.
Results: An 82- and a 53-year-old male with giant duodenal 
ulcer perforations were managed with this technique. The 
duodenal defects ranged from 3.5 to 5 cm in size. No post-
operative perforation site leak, no signifi cant narrowing of 
the lumen was noted. Endoscopy also confi rmed that the 
patched duodenal defect was covered with neo-mucosa in 
weeks. Histological examination of the biopsy material 
revealed regenerated columnar epithelium.
Conclusion: Gallbladder patch repair is a safe and useful 
procedure for large-sized duodenal defects.
BEVACIZUMAB DECREASES PORTAL 
VEIN EMBOLIZATION INDUCED 
TUMOUR GROWTH
E. Simoneau1,2, A. Salman1, N. Abualhassan1, T. Cabrera3, 
D. Valenti3, R. Gadahadh3, M. Al Jiffry1, P. Chaudhury1 and 
M. Hassanain1,2
1McGill University Health Center, Department of Surgery, 
Section of Transplant and HPB Surgery, Montreal, Quebec; 
2King Saud University, College of Medicine, Department of 
Surgery, Riyadh, Riyadh; 3McGill University Health 
Center, Department of Radiology, Montreal, Quebec
Introduction: Portal vein embolization (PVE) can convert 
selected patients with colorectal cancer liver metastases from 
an unresectable to a resectable state. We previously reported 
that PVE stimulates hypertrophy in the future liver remnant 
with or without the use of bevacizumab (BEV). The effect 
of PVE on tumour growth has been of concern. In murine 
models, PVE has increased total tumour volumes (TTV). The 
objective of this study is to assess the impact of preoperative 
PVE on tumour volumes with and without BEV.
Methodology: CT scans prior to and 4 weeks after PVE were 
evaluated in patients who undergoing neoadjuvant chemo-
therapy between 2002 and 2009. TTV was measured (cm3) 
using dedicated volume measurement software on a 3D work-
station by two radiologists blinded to the type of chemother-
apy. BEV was discontinued at least 4 weeks prior to PVE.
Results: 71 patients were analyzed, 57.4% received BEV 
and 42.6% received non-BEV containing chemotherapy. 
There were no differences between the 2 groups. Mean age 
was 56. Male : female ratio was 1.6 : 1. Patients received an 
average of 7 cycles of chemotherapy prior to PVE. In both 
groups, TTV increased signifi cantly. The mean pre and post 
PVE TTV for the entire group were 58.5 cm3 and 81.0 cm3 
respectively, p = 0.001. Tumor growth was higher in the 
non-BEV group (ΔTTV 38.7 cm3) vs. the BEV group (ΔTTV 
14 cm3, p = 0.04).
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Conclusion: TTV increases after PVE. The increase in TTV 
appears to be less pronounced in patients receiving BEV as 
part of their chemotherapy regime.
THE AJCC STAGING SYSTEM FOR 
HEPATOCELLULAR CARCINOMA 
PREDICTS SURVIVAL IN MEDICALLY 
TREATED WESTERN PATIENTS
V. Siripurapu, M. T. Nguyen, C. S. Denlinger, 
J. P. Hoffman and Y. S. Chun
Fox Chase Cancer Center, Philadelphia, PA
Introduction: The American Joint Committee on Cancer 
(AJCC) staging system for hepatocellular carcinoma is based 
on pathologic features of surgically resected specimens. The 
aim of this study was to evaluate the prognostic signifi cance 
of the AJCC staging system in a medically treated Western 
patient population.
Methods: Medical records of 299 consecutive patients eval-
uated at a single institution for hepatocellular carcinoma 
between 1994 and 2009 were reviewed. Log-rank and Cox 
analysis of overall survival versus clinicopathologic factors 
was performed; P < 0.05 was considered statistically 
signifi cant.
Results: Surgical resection or orthotopic liver transplanta-
tion was performed in 44 of the 299 patients (15%), while 
255 patients (85%) received medical treatment, including 
ablation, chemoembolization, and/or sorafenib. Median 
overall survival of the cohort was 13.5 months, with 3- and 
5-year survival rates of 25% and 14%, respectively. On uni-
variate analysis, the following factors were signifi cantly 
associated with overall survival: race, gender, Child-Pugh 
class, multiple tumors, major vascular invasion, tumor grade, 
serum alpha-fetoprotein, Model for End-Stage Liver Disease 
(MELD) score, and AJCC stage (Figure). On multivariate 
analysis, AJCC stage was an independent predictor of overall 
survival (P = 0.002). Among the 255 medically treated 
patients, AJCC stage remained an independent predictor of 
survival (P = 0.006).
Conclusion: The AJCC staging system for hepatocellular 
carcinoma accurately stratifi es prognosis in a medically 
treated Western patient population.
MINIMALLY INVASIVE 
RETROPERITONEAL NECROSECTOMY 
IN SEVERE ACUTE PANCREATITIS: 
SINGLE CENTER EXPERIENCE
V. Sitaram1, P. Joseph1, F. L. Vyas1, R. S. Raju1, 
J. C. Singh2 and K. N. Chacko2
1Christian Medical College, Vellore, Tamilnadu; 2Christian 
Medical College, Vellore, Tamilnadu
Introduction: Severe acute pancreatitis (SAP) can be lethal. 
We reviewed our experience to see infl uence of minimally 
invasive techniques.
Methods: Data from hospital records of patients with SAP 
during the period March 2007 to May 2010 was entered into 
a standard proforma and analyzed.
Results: Nineteen patients had infected pancreatic and/or 
peripancreatic necrosis (IPPN). Four patients underwent 
open necrosectomy (2 died). One patient underwent sinus 
tract necrosectomy through postoperative wound drain track. 
Fourteen patients were treated by ‘step-up’ approach 
(anatomy of necrosis permitted placement of radiologically 
guided drain). Of these, 1 patient improved with only radio-
logically guided pigtail catheter drainage; remaining 13 
required minimally invasive retroperitoneal necrosectomy 
(MRPN). Mean age: 38.6 years; 86.6% males. Etiology: 
alcohol abuse (56%), biliary (25%). Forty-four percent had 
undergone abdominal procedures earlier. Eleven/15 patients 
had necrosis involving >50% of pancreas on CT. All had trial 
with antibiotics following drain insertion. All had culture 
positive necrosis at fi rst procedure (fungal elements 3, poly-
microbial 9). E. coli was the commonest organism. Post 
procedure ICU stay range: 0–26 days (median 3). 
Complications included bile leak (1), bleeding (1). Both 
resolved without intervention. Median (range) hospital stay 
was 44 days (25–101). Two patients in MRPN group died. 
Late complications included incisional hernia (1) and groin 
abscess (1).
Conclusions: MRPN is safe and effective in treating IPPN. 
Previous operation is not a contraindication. Anatomy of 
necrosis should provide access for placement of radiological 
guided drain. Drain tract is used as approach for MRPN.
THERAPY OF LIVER METASTASES OF 
CARCINOID – OUR EXPERIENCES
T. Skalicky
Charles University Prague, University Hospital Pilsen, 
Department of Surgery, Pilsen, West Bohemia
Introduction: Authors are presenting group of 15 patients 
with liver metastases of the carcinoid. Patients were cured 
between 2000 and 2009 in Dpt. of Surgery, University 
Hospital in Pilsen.
Methods: Diagnosis of liver metastases was in our group of 
patients made by liver ultrasound, dynamic computer tomog-
raphy and in some cases by magnetic resonance. In case of 
unknown primary tumor localization or absence of liver 
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Figure. Overall survival by AJCC stage in 299 patients with 
hepatocellular carcinoma
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metastases we have used Octreoscan. Therapy was radical 
resection or palliative surgery in non-resectable tumors with 
carcinoid syndrome to perform cytoreduction. Also open, 
laparoscopic or transcutaneous radiofrequence ablation 
(RFA) was performed as well as chemoembolisation.
Results: Our group contained 15 patients, we have per-
formed 25 radical and palliative operations, radical liver 
resection was made in 7 cases, the rest of interventions were 
repeated surgery in 8 patients (16 × RFA, 1 × chemoemboli-
sation of large secondary tumor with severe carcinoid 
syndrom. The primary tumors were in pancreas (3×), bile 
duct (1×) and in ileocecal region (11×). We did not fi nd extra 
abdominal localization of tumor. From our group 1 patient 
died 2 years after RFA due to generalization, 14 patients are 
alive. Mean time of follow-up is 8 years. All patients after 
radical resection are without recurrence of disease, the others 
are without presence of carcinoid syndrom. Palliative surgery 
was made after consultation with oncologist in cases of con-
servative treatment failure. Complications were in 33%, right 
side fl uidothorax after radical resection, severe postemboli-
sation syndrom after chemoembolisation. There was no 
death in postoperative period.
RECOMMENDATIONS AND 
PERFORMANCE OF RESECTION FOR 
LOCALIZED HEPATOCELLULAR 
CARCINOMA IN THE MEDICARE 
POPULATION
J. K. Smith, Y. Li, S. Ng, E. R. Witkowski, J. F. Tseng and 
S. A. Shah
Surgical Outcomes Analysis & Research, University of 
Massachusetts Medical School, Worcester, MA
Background: Along with liver transplantation, surgical 
resection remains an effective treatment strategy for early 
stage hepatocellular carcinoma (HCC) in the US. We sought 
to examine the factors associated with recommendation 
and receipt of resection among patients with resectable 
HCC.
Methods: Medicare-eligible patients ≥65 years of age at 
time of diagnosis of HCC who had localized, presumably 
resectable, disease were identifi ed from the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare linked 
database, 1991–2005. Univariate, multivariate, and survival 
analyses were performed to examine the outcomes of recom-
mendation for resection, receipt of resection, and median 
survival.
Results: Among 2445 patients with localized HCC, 698 
(34.1%) were recommended for surgery, and 90.8% of those 
recommended underwent resection. Resection primarily took 
place at urban teaching hospitals. After adjusting for patient 
and hospital characteristics, factors signifi cantly associated 
with being recommended for surgery included: younger age, 
higher socioeconomic status (defi ned by US Census 2000 
data on income, poverty level, and education), and lower 
comorbidity index (Figure). Patients with resectable HCC 
who underwent surgical resection had a higher median sur-
vival compared to those who did not undergo any therapy 
(36.9 vs. 3.6 months; p < 0.0001).
Conclusions: Patients with localized HCC undergoing 
resection exhibit a survival advantage over their nonresected 
peers. Despite this, only 34.1% of these patients with 
localized HCC are being recommended for surgery, with 
demonstrated socioeconomic and racial disparities. Further 
studies regarding the barriers to access and referral for 
surgery in this increasingly common malignancy are 
warranted.
Figure. Odds ratio estimates for probability of recommendation for surgical resection among all patients with resectable HCC
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HEPATIC ADENOMATOSIS: OUTCOMES 
AND HISTOLOGIC HETEROGENEITY
R. L. Smoot1, M. J. Truty1, T. Schnelldorfer1, T. C. Smyrk2, 
G. J. Gores3 and D. M. Nagorney1
1Mayo Clinic Division of GI and General Surgery, 
Rochester, MN; 2Mayo Clinic Department of Pathology 
and Laboratory Medicine, Rochester, MN; 3Mayo Clinic 
Division of Gastroenterology and Hepatology, Rochester, 
MN
Hepatic adenomatosis, defi ned as 4 or more adenomas, is a 
rare condition. The optimal management of these patients has 
yet to be defi ned. Previous work in single adenomas has 
demonstrated distinct molecular subtypes with adenomas 
demonstrating constitutively active β-catenin having a higher 
risk of malignant progression. Patients were retrospectively 
identifi ed from surgical and medical indexes for the years 
1990–2008. Charts were reviewed for demographic, clinical, 
and procedural data. Available tissue blocks were examined 
for histologic classifi cation and stained for β-catenin local-
ization. Adenomas were classifi ed histologically as steatotic, 
infl ammatory (telangiectatic), or unclassifi ed. Forty-six 
patients (87% female, median age 37 years), were identifi ed. 
Presenting symptoms were abdominal pain (24 patients, 
52%), bleeding (13 patients, 28%), abdominal fullness (4 
patients, 9%), and early satiety (1 patient, 2%). Thirty-three 
patients (72%) underwent operative treatment. One patient 
(2%) had hepatocellular carcinoma (HCC). A total of 92 
adenomas from 30 patients (median 3 per patient) were avail-
able for pathologic review. All adenomas demonstrated 
normal cytoplasmic staining for β-catenin. Nineteen patients 
(63%) had a single histologic subtype, while 11 patients 
(37%) had two subtypes. Twenty-six patients (87%) had an 
unclassifi ed adenoma, 8 (27%) had an infl ammatory 
adenoma, and 6 patients (20%) had a steatotic adenoma. 
Median follow-up was 25.9 months with no progression to 
carcinoma noted and no recurrence in the patient with HCC. 
In patients with hepatic adenomatosis there is heterogeneity 
in histologic subtype from adenoma to adenoma within an 
individual patient. This heterogeneity hinders classifi cation 
of patients with multiple adenomas.
LAPAROSCOPIC PANCREAS SPARING 
PARTIAL DUODENAL RESECTION
J. A. Stauffer, R. F. Goldberg, J. M. Parker, S. P. Bowers 
and H. J. Asbun
Mayo Clinic, Florida, Jacksonville, FL
Introduction: Partial excision of the duodenum to treat a 
variety of duodenal pathology have been described in litera-
ture. These partial duodenal resections often spare patients 
the morbidity of a whipple operation when performed for 
appropriate indications. Advantages of an organ sparing 
operation include restoration of a near normal gastrointes-
tional tract with improved absorptive capacity, weight gain, 
and quality of life. More recently, a minimal access approach 
has been applied to this operation, sparing the patient the 
morbidity of an open operation. Although technically chal-
lenging, this procedure has been successfully performed and 
Pt Age Sex Preoperative
Pancreas-preserving 
Duodenal resection Reconstruction Pathology
1 70 F Duodenal adenoma Proximal duodenal 
resection/distal 
gastrectomy
Stapled loop Billroth II 
gastrojejunostomy
5 cm tubular adenoma
2 56 M FAP with duodenal 
adenomas
Total duodenectomy 
and distal 
gastrectomy
Pancreaticojejunostomy; 
choledochojejunostomy; 
stapled loop Billroth II 
gastrojejunostomy
Multiple tubular 
adenomas; no dysplasia
3 77 F Duodenal adenoma 
with high grade 
dysplasia
Pylorus preserving 
resection of the 1st 
and 2nd portion of 
the duodenum
Handsewn loop 
duodenojejunostomy
3.5 cm tubulovillous 
adenoma with non-
invasive intra-mucosal 
carcinoma
4 19 F Large retroperitoneal 
mass behind 
pancreas and 
duodenum
Hand assisted 
resection of the 3rd 
and 4th portion of 
the duodenum and 
uncinate process
Stapled side to side 
duodenojejunostomy
8.5 cm non-invasive 
lymphangiolipoma
5 78 M Duodenal carcinoid Pylorus preserving 
resection of the 1st 
and 2nd portion of 
the duodenum
Handsewn loop 
duodenojejunostomy
2 cm carcinoid tumor
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we aim to describe our experience over the past 18 months 
with this procedure.
Methods and procedures: This is an IRB-approved retro-
spective cohort study from a single tertiary-care referral 
center. Between May 2009 and September 2010, fi ve patients 
underwent laparoscopic pancreas sparing partial duodenal 
resection. All 5 patients underwent an entirely laparoscopic 
procedure.
Results: Patient age, sex, preoperative diagnosis, portion of 
duodenum resected, reconstruction method, and fi nal pathol-
ogy is given in the Table below. The illustration below 
depicts the separation of the duodenum from the pancreas 
for patient 2. The only remaining attachment is the duct.
Conclusions: Laparoscopic separation of the duodenum 
from the pancreas appears to be feasible and may spare 
patients from undergoing a pancreaticoduodenectomy. The 
magnifi ed view afforded by laparoscopy may offer a techni-
cal advantage in this step of the procedure. Partial duodenal 
resection is an option in selected patients with duodenal 
pathology and signifi cant comorbidities who would not oth-
erwise be a candidate for major pancreaticoduodenal 
resection.
PANCREATICODUODENECTOMY IN 
THE ELDERLY PATIENTS: AN 
EVALUATION OF THE MODIFIED 
POSSUM SCORING SYSTEM
T. Tanaka
Shimane University, Izumo City, Shimane
Objective: In recent years, pancreatic resection has come to 
be indicated mainly in the elderly. The safety of pancreatico-
doudenectomy (PD) was investigated retrospectively in 
elderly patients.
Methods: From 1996 to 2007, 316 patients underwent PD. 
The subjects were divided into two groups by the aged 75 
and above (aged group, n = 62) and the aged 74 and below 
(control, n = 254). For risk assessment using the POSSUM 
system, data on 12 parameters related to physiological score 
(PS) and 6 parameters related to operative severity score 
were derived from the database. Two modifi ed versions of 
POSSUM, such as elderly POSSUM (E-POSSUM) and at 
Hiroshima (H-POSSUM), were estimated. The frequency of 
observed and expected complications (O/E ratio) was com-
pared in both groups.
Results: Postoperative complications were seen 33/62 
(53.2%) in the aged group, 94/254 (37.0%) in the control. 
The rate of hospital death occurred 10/62 (4.8%) in the aged, 
7/254 (2.8%) in the control. The PS of the aged group (18.9 
+ 3.4) was signifi cantly higher than the control (16.0 + 3.2). 
The morbidity and mortality rate among patients with PS 
scores of 21 were signifi cantly higher as compared with 
those with PS scores of ?20. The O/E ratio of postoperative 
complication was 0.87 in the aged group, and 0.72 in the 
control by original POSSUM, 1.14 and 0.94 by E-POSSUM, 
1.14 and 0.95 by H-POSSUM.
Conclusion: The modifi ed POSSUM scoring systems are 
useful as a means of risk assessment in elderly patients 
undergoing PD.
OUTCOMES AFTER TIPS: A BRIDGE TO 
NOWHERE
P. Toomey, F. C. Golkar, K. Luberice, J. Hernandez, 
N. Donn, A. Marcadis, C. Okpaleke, M. Vice, S. B. Ross, 
A. Alsina and A. S. Rosemurgy
University of South Florida and Tampa General Hospital 
Digestive Disorders Center, Tampa, FL
Background: While fi rst being promoted as a “bridge to trans-
plantation”, TIPS has become the modality of choice for portal 
decompression for patients with refractory variceal bleeding or 
ascites due to cirrhosis and portal hypertension. This study was 
undertaken to determine outcomes after TIPS and the utility of 
TIPS as an effective “bridge” to transplantation.
Methods: All patients who underwent TIPS from 2001 to 
2010 at a university affi liated hospital were studied. Median 
data are presented.
Results: TIPS was undertaken in 256 patients with a median 
MELD score of 12; 91% of patients had cirrhosis due to 
alcohol and/or hepatitis. TIPS decreased portal vein – IVC 
gradients from 17 mmHg to 5 mmHg, p < 0.001. 62 (24%) 
patients underwent reinterventions for stenosis/occlusion. 
153 (60%) patients have died; survival after TIPS was 7.5 
months (Figure). MELD score, Child-Pugh Score, Child 
Class, etiology of cirrhosis, and urgency for TIPS did not 
predict subsequent transplantation after TIPS. 35 (14%) 
patients underwent liver transplantation; 10 (27%) have died. 
Calculated survival after transplantation was 28 months 
(Figure).
Conclusion: TIPS effectively decompresses portal hyper-
tension. As a defi nitive therapy for complicated portal hyper-
tension, TIPS leads to frequent reinterventions and short 
survival. After TIPS, subsequent transplantation cannot be 
predicted and is uncommonly undertaken. TIPS is a “bridge” 
to transplantation that is seldom “crossed” and transplanta-
tion after TIPS is plagued by relatively poor survival when 
undertaken. Outcomes after TIPS and the infrequency of 
transplantation following TIPS make TIPS very diffi cult to 
recommend on merit.
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PREOPERATIVE TUMOUR MARKERS AS 
PROGNOSTIC FACTORS OF 
COLORECTAL LIVER METASTASES
V. Treska1, J. Vrzalova2, I. Treska1 and O. Topolcan2
1University Hospital, Pilsen; 2University Hospital, Pilsen
Background: Tumour recurrence develops in 45–80% of 
patients at various time intervals after liver resection or 
radiofrequency ablation (RFA) for colorectal liver metasta-
ses. The aim of study was to assess the prognostic signifi -
cance of preoperative tumour marker serum levels for disease 
free interval (DFI) and overall patient survival (OS) after 
liver surgery.
Methodology: In prospective non-randomized study preop-
erative serum levels of carcinoembryonic antigen -CEA, CA 
19-9, CA 72-4, thymidine kinase (TK), tissue polypeptide 
antigen (TPA) and tissue polypeptide specifi c antigen (TPS) 
were evaluated by multiplex analysis in 235 patients oper-
ated on for colorectal liver metastases (CLM). Liver resec-
tion was performed on 164 patients and radiofrequency 
ablation on 71 patients.
Results: Preoperative serum levels of TPA (cut off level = 
53 IU/L, HR = 4.5, p < 0.01) and TPS (cut off level = 81 
IU/L, HR = 5.1, p < 0.007) were important for OS and DFI 
after liver resection. Preoperative serum levels of TPA were 
also important for OS (p < 0.003) and DFI (p < 0.001) after 
RFA. Preoperative serum levels of TPS correlated with OS 
(p < 0.005) and DFI (p < 0.0001) after RFA.
Conclusions: TPA and TPS are important predictive markers 
for OS and DFI after liver resections and radiofrequency 
ablations for colorectal liver metastases. The study was sup-
ported by grant IGA MZ NS 9727-4 and NS 19240-3/09.
SURGICAL TREATMENT OF NON-
COLORECTAL LIVER METASTASES
V. Treska, T. Skalicky and A. Sutnar
University Hospital, Department of Surgery, Pilsen, NO
Background/aim: Non-colorectal liver metastases (NCLM) 
represent small group of liver metastases with different bio-
logical behavior. That is why the surgical treatment of NCLM 
is still matter of discussion. The aim of the study was to 
evaluate the university center experience with surgical treat-
ment of NCLM.
Methods: Seventy nine patients were evaluated in the pro-
spective study (2000–9/2010). The average length of time 
after the primary surgery was 3.8 years (0–8.5 years). 
Radiofrequency ablation (RFA) was performed in 53 patients 
(67.1%), liver resection in 26 (32.9%). Preoperative chemo-
therapeutical downstaging or portal vein embolization was 
performed in 12 patients (15.2%).
Results: One, three and fi ve years patient’s survival after the 
liver resection or RFA was 88.6, 72.5 and 36.9%. The best 
survival rate was in patients with radically treated carcinoid 
(5 years – 100%), breast cancer (5 years – 33.8%), renal 
carcinoma (3 years – 44.4%) and gynecological tumors 
metastases (2 years – 72.9%). There was no difference 
between liver surgery and RFA in the long-term results. 
Patients with extrahepatic metastases (most often nodules of 
hepatoduodenal ligament, lung metastases) had worse prog-
nosis (p < 0.01) in spite of their surgical or RFA removal. 
Non ablation was borderly stastically signifi cant (p < 0.08) 
from the point of long term patient’s survival.
Conclusions: The long-term results of patients after liver 
resection or RFA of NCLM are promising. Liver resection 
or RFA have a comparable results and takes the fi rm place 
in multi-modal treatment strategy. This work was supported 
by the grants NS 9727-4 /2008, NS 10240-3/2009 and NS 
9723-4.
HEPATIC RESECTION FOR METASTATIC 
GASTROINTESTINAL STROMAL 
TUMORS IN THE TYROSINE KINASE 
INHIBITOR ERA
R. S. Turley1, A. S. Barbas1, S. K. Reddy2 and B. M. Clary1
1Duke University Department of Surgery, Durham, NC; 
2University of Pittsburgh Department of Surgery, 
Pittsburgh, PA
Up to 40% of patients who undergo primary resection of their 
gastrointestinal stromal tumors (GISTs) will recur within 
18–24 months. Before the advent of tyrosine kinase inhibi-
tors (TKIs), surgical resection was the primary treatment for 
hepatic GIST metastases with 5-year survival rates reported 
as 27–34%. Whether the availability of tyrosine kinase inhib-
itors has prolonged survival after extirpation of hepatic GIST 
metastases remains unclear. Here, we assess long-term sur-
vival and outcomes for patients undergoing hepatic resection 
for metastatic GIST tumors in the era of TKIs.
Methods: Demographics, treatments, and outcomes of 
patients who underwent hepatic resection at a high-volume 
center were reviewed from 1998 to 2010. Recurrence and 
survival were measured from the date of metastectomy. 
Actuarial survival curves were generated using the Kaplan-
Meier method.
Results: Twenty-two patients underwent hepatic resection 
for metastatic GISTs, with 12 patients receiving adjuvant 
therapy with TKIs. With a mean follow-up of 38 months, 13 
(59%) of patients suffered recurrence (intrahepatic only, n = 
6; extrahepatic only, n = 4; both = 3) with a median time of 
8.6 months. The 1-, 3-, and 5-year overall survival rates were 
95.0, 62.7, and 54.9% respectively. Four patients (18.1%) 
suffered complications classifi ed as 3 or greater on the 
Clavien scale. There was one operative mortality (4.95%).
Age (Med, IQR) 62.5 (54.6–67.8)
Primary Size (cm) (Med, IQR) 9 (5.5–18)
Primary GIST Site, n(%)
Stomach 11 (50)
Small Intestine 9 (41)
Rectum 1 (5)
Unknown 1 (5)
Neoadjuvant TKI, n(%) 8 (38)
Adjuvant TKI, n(%) 12 (55)
Major Hepatectomy, n(%) 9 (41)
Other Major Procedure, n(%) 6 (27)
Hepatic Lesion Size (cm), (Med, IQR) 4.5 (2.2–9.7)
Number of Hepatic Lesions, 
(Med, IQR)
1 (1–2)
Clavien Class III or greater 
complication, n(%)
4 (18)
Death, n(%) 1 (5)
Readmission, n(%) 4 (18)
Reoperation, n(%) 1 (5)
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Conclusions: In the era of TKIs, patients undergoing hepatic 
resection for metastatic GIST exhibit survival rates exceed-
ing historical reports. This study supports a multidisciplinary 
approach for treating metastatic GISTs and provides ratio-
nale for a prospective clinical trial examining the optimal 
timing of liver resection and systemic therapy.
VASCULAR SURGERY 
COLLABORATION DURING 
PANCREATICODUODENECTOMY WITH 
VASCULAR RECONSTRUCTION
R. S. Turley1, A. S. Barbas1, E. P. Ceppa1, K. Peterson2, 
E. K. Paulson2, D. G. Blazer1, B. M. Clary1, T. N. Pappas1, 
D. S. Tyler1, R. L. McCann1 and R. R. White1
1Department of Surgery, Durham, NC; 2Department of 
Radiology, Durham, NC
Once considered unresectable, pancreatic cancer patients 
with venous involvement now have survival after pancreati-
coduodenectomy (PD) with en-bloc vascular resection (VR) 
comparable to patients without vascular involvement. We 
hypothesize that a multidisciplinary approach involving a 
dedicated vascular surgeon will minimize morbidity and 
improve patency of vascular reconstructions.
Methods: We identifi ed 204 patients who underwent PD for 
pancreatic adenocarcinoma from 1997 to 2008. Patients who 
underwent PD with VR (N = 42) were compared to patients 
who underwent standard PD (N = 162). Vascular reconstruc-
tions were performed by a vascular surgeon and utilized 
primary repair (N = 8), vein patch (N = 25), or interposition 
grafting (N = 9) with femoral or other venous conduit.
Results: Patients undergoing PD with VR had larger tumors 
(3.0 vs 2.5 cm, p < 0.01) but did not have different rates of 
positive margins (26% vs. 28%, p = 0.84) or lymph nodes 
(50% vs 38%, p = 0.14). The VR group had higher mean 
blood loss (875 mL vs 550 mL, p = 0 < 0.01), but no differ-
ences in mortality, complication rates, length of stay, or read-
mission rates. After a median follow-up of 29 months, overall 
survival rates were similar (Figure). Predictors of death on 
multivariate analysis included histological grade, number of 
positive lymph nodes, and tumor size, but not VR (Table). 
When evaluated by CT scans within 6 months, 97% of recon-
structions remained patent.
Conclusions: The need for VR is not a contraindication to 
potentially curative resection in patients with pancreatic 
adenocarcinoma. High patency rates and lack of increased 
perioperative morbidity may have been attributable to the 
routine collaboration of an interested vascular surgeon.
COMPLICATIONS OF ROBOT-ASSISTED 
LAPAROSCOPIC 
PANCREATICODUODENECTOMY: 
AN EARLY EXPERIENCE
R. Uppal, P. Newell, C. Hammill, M. A. Cassera and 
P. D. Hansen
Providence Portland Medical Center, Portland, OR
Introduction: Robot-assisted laparoscopic pancreaticoduo-
denectomy (RALPD) is a technically complex procedure 
which is being tested in certain specialty centers.
Methods: Data was collected retrospectively on all patients 
who underwent elective RALPD between 4/2009 and 9/2010. 
An attempt was made to determine whether the initial com-
plication was attributable to the robotic approach.
Results: Twenty-three patients were scheduled for RALPD, 
of which twenty were completed laparoscopically and three 
converted open due to bleeding (1), portal vein invasion (1), 
and adhesions (1). Mean operative time was 606 minutes 
(range 455–935) and estimated blood loss was 300 mL. 
Mean length of stay for all patients was 18 days (6.4 days in 
uncomplicated cases). Complications were reported in 14 
patients, including 6 patients with major complications 
(Clavien Dindo >3b), who had a mean length of stay of 42 
days. There were no perioperative deaths. Three patients 
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leaked at the duodenojejunostomy, compared to zero duode-
nojejunal leaks in the 34 patients who underwent open pan-
creaticoduodectomy in the same time period. 5 patients had 
intra-abdominal abscesses as their initial complication, of 
whom 2 had no prior ERCP. One patient had a pulmonary 
embolism post operative day 2. Other complications occurred 
with roughly the same frequency as in open cases.
Conclusion: Extended operative time and duodenojejunos-
tomy anastomotic technique are unique to the laparoscopic 
approach and may have contributed to several of the major 
complications described. The overall complication rate is 
similar to open pancreaticoduodenectomy. With critical revi-
sion of operative technique, we believe we can reduce the 
complication rate for LARPD.
DISTAL PANCREATECTOMY FOR 
PANCREATIC ADENOCARCINOMA: 
CLINICOPATHOLOGIC 
CHARACTERISTICS AND LONG 
TERM SURVIVAL
R. Venkat, K. Olino, S. Reddy, J. L. Cameron, M. Choti, 
H. Nathan, N. Ahuja, T. M. Pawlik, B. H. Edil, 
R. D. Schulick and C. L. Wolfgang
The Johns Hopkins Medical Institutions Department of 
Surgery, Baltimore, MD
Objective: The outcome of resected pancreatic adenocarci-
noma of the body/ tail of the pancreas requiring distal pan-
createctomy (DP) is less well studied than head/ uncinate 
tumors resected by pancreaticoduodenectomy (PD).
Methods: Between 1990 and 2010, patients who underwent 
DP (n = 215) or PD (n = 1703) for adenocarcinoma were 
identifi ed. Information on demographics, operative charac-
teristics, pathology and survival were compared between DP 
and PD.
Results: The DP and PD patients were comparable in age, 
sex and Charlson score at presentation (Table). PD patients 
had a longer hospital length of stay than DP patients (10 vs. 
7 days, p = 0.04. When comparing DP to PD, there was a 
higher proportion of T1 (p = 0.009), T2 (p < 0.0001) and T4 
lesions (p = 0.003) with less T3 lesions (p < 0.0001). The 
median total lymph nodes harvested were comparable across 
the groups; however, DP was associated with a lower rate of 
lymph node positivity (p < 0.0001). DP also had a lower risk 
of vascular invasion (p = 0.04) and margin positivity (p < 
0.0001). DP was associated with a signifi cantly better unad-
justed overall long-term survival than PD (P = 0.03, Figure). 
However, there were no signifi cant differences in the periop-
erative mortality and long-term survival between PD and DP 
after adjusting for multiple clinico-pathological factors.
Conclusion: Patients who are found to be resectable at the 
time of presentation and undergo DP have better pathological 
tumor characteristics in contrast to PD. Despite differences 
at the time of initial presentation, DP for adenocarcinoma has 
similar perioperative outcomes with no signifi cant differ-
ences in adjusted long-term survival compared to PD.
Number (Percent)
DP
N = 215
PD
N = 1703 p-value
Age (median, yrs) 67 68 0.97
Female 109 (50.7) 790 (46.4) 0.23
Caucasian 180 (83.7) 1502 (88.2) 0.06
Charlson Comorbidity score*
 0–2 22 (10.9) 166 (10.3) 0.75
 3–6 117 (58.3) 907 (56.2)
 >7 62 (30.8) 540 (33.5)
Length of stay 
(median, days)
7 10 0.04
Tumor size 
(median, cm)
3.5 3.0 <0.0001
T Stage
 T1 17 (7.9) 68 (4.0) 0.009
 T2 72 (33.5) 157 (9.2) <0.0001
 T3 87 (40.5) 1065 (62.5) <0.0001
 T4 13 (6.0) 42 (2.5) 0.003
Total lymph nodes 
harvested 
(median)
17 17 0.38
Lymph node 
metastases
128 (59.5) 1336 (78.4) <0.0001
Vascular invasion† 73 (48.3) 726 (56.9) 0.04
Perineural invasion‡ 155 (89.1) 1273 (90.9) 0.45
Positive margin 31 (15.0) 477 (28.1) <0.0001
30-day mortality 
[n (%)]
3 (1.4) 20 (1.2) 0.74
90-day mortality 
[n (%)]
10 (4.6) 74 (4.3) 0.84
Female 109 (50.7) 790 (46.4) 0.23
Caucasian 180 (83.7) 1502 (88.2) 0.06
Charlson Comorbidity score*
 0–2 22 (10.9) 166 (10.3) 0.75
 3–6 117 (58.3) 907 (56.2)
 >7 62 (30.8) 540 (33.5)
Length of stay 
(median, days)
7 10 0.04
Tumor size 
(median, cm)
3.5 3.0 <0.0001
T Stage
 T1 17 (7.9) 68 (4.0) 0.009
 T2 72 (33.5) 157 (9.2) <0.0001
 T3 87 (40.5) 1065 (62.5) <0.0001
 T4 13 (6.0) 42 (2.5) 0.003
Total lymph nodes 
harvested 
(median)
17 17 0.38
Lymph node 
metastases
128 (59.5) 1336 (78.4) <0.0001
*Charlson score was unavailable in patients operated 
before 1993.
†Vascular invasion status not known: DP (n = 64), PD 
(n = 428)
‡Perineural invasion status not known: DP (n = 41), PD 
(n = 302)
**Margin status not known DP (n = 8), PD (n = 6)
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INTRADUCTAL PAPILLARY MUCINOUS 
NEOPLASMS (IPMN) <3 CM ON 
IMAGING: CLINICOPATHOLOGICAL 
CHARACTERISTICS AND THE 
IMPORTANCE OF SOLID COMPONENTS
R. Venkat1, S. Reddy1, K. Olino1, M. Weiss2, 
J. L. Cameron1, M. A. Choti1, R. H. Hruban3, 
T. M. Pawlik1, N. Ahuja1, B. H. Edil1, R. D. Schulick1 and 
C. L. Wolfgang1
1Johns Hopkins Medical Institutions Department of 
Surgery, Baltimore, MD; 2Memorial Sloan-Kettering 
Cancer Center, New York, NY; 3Johns Hopkins Medical 
Institutions Department of Pathology, Baltimore, MD
Objective: To evaluate the validity of the Tanaka criterion 
and assess characteristics at presentation and long term sur-
vival of resected side-branch or mixed-type IPMN <3 cm 
with or without a solid component.
Methods: A retrospective review of clinico-pathological 
data in patients who underwent a pancreatectomy for side-
branch or mixed-type (MT) IPMN <3 cm (N = 98) from a 
single institution’s prospectively maintained database.
Results: The average age at presentation was 66.7 years and 
60.2% were females. Thirty-eight (38.8%) were mixed type 
and 60 (61.2%) were side-branch. Twenty-six (26.5%) were 
located in the body/tail and 72 (73.5%) in the head/uncinate. 
Thirty-four (34.7%) IPMNs had solid components on radiol-
ogy. Pathology revealed the following: 26.5% (n = 26) low-
grade dysplasia, 29.6% (n = 29) moderate-grade dysplasia 
and 22.4% (n = 22) high-grade dysplasia (carcinoma in situ; 
CIS), 3.1% (n = 3) IPMN (NOS) and 18.4% (n = 18) with 
associated invasive cancer. IPMN with solid components 
were signifi cantly associated with a higher proportion of 
invasive cancer (p < 0.0001) and with a poorer long term 
survival (p = 0.004, Figure).
Conclusion: Our fi ndings suggest that small BD or MT 
IPMN with radiological evidence of a solid component is 
strongly associated with invasive cancer. In the absence of a 
solid component, a large proportion harbor CIS but not inva-
sive cancer. These fi ndings support the international consen-
sus guidelines. However, given the high proportion of CIS 
in small lesions without a solid component, prospective clini-
cal trials are needed to determine whether smaller lesions 
should be resected before they progress to invasive carci-
noma or if other characteristics can be identifi ed to stratify 
this group further.
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Tumor size 
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Age (mean, yr) 68.1 64.1 0.12
Type of tumor
 Side-branch 43 (67.2) 17 (50) 0.10
 Mixed type 21 (32.8) 17 (50)
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 IPMN with  2 (3.1) 16 (47.1) <0.0001
Recurrence  5 (7.8)  6 (17.6) 0.14
CIN: Carcinoma in situ, NOS: Non-specifi c.
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FIRST DISSECTION OF THE SUPERIOR 
MESENTERIC ARTERY IN 
PANCREATICODUODENECTOMY FOR 
CANCERS OF THE PERIAMPULLARY 
REGION
E. Vicente, Y. Quijano, H. J. Duran, M. Marcello, 
P. Galindo, E. Diaz-Reques, A. Lopez, L. Cordoba, 
A. Muro, E. Garcia and E. Vicente
Madrid Norte Sanchinarro Hospital, Madrid
Pancreaticoduodenectomy (PD) is the only effective treat-
ment for cancers of the periampullary region. Many technical 
modifi cations of reconstruction after PD have been described. 
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One of the important predictive factors of prognosis is the 
presence of retroperitoneal lymph node metastases, which 
are present in 20–77% of resected specimens of patients with 
carcinoma of the head of the pancreas. Hence, lymph node 
dissection to the right of the superior mesenteric vessels is a 
minimum requirement. In order to achieve an oncologically 
acceptable lymph node clearance, we describe the technique 
of PD in which the SMA is dissected fi rst and the posterior 
pancreatic capsule is dissected early during the operation. 
The posterior part of the pancreatic head is dissected off the 
vessels fi rst without dividing the pancreatic neck. This 
method allowing early detection of inoperability accom-
plishes adequate lymphadenectomy and easier identifi cation 
and safeguarding of a replaced right hepatic artery, if one is 
present. The video illustrate the different surgical steps.
SURGICAL TECHNIQUE OF ARTERIAL 
RESECTION IN RADICAL PANCREATIC 
SURGERY
E. Vicente, Y. Quijano, M. E. Marcello, P. Galindo, 
H. J. Duran, E. Diaz-Reques, B. Alvarez, J. Villanueva, 
M. Torres, E. Garcia and E. Vicente
Madrid Norte Sanchinarro Hospital, Madrid
Arterial resection performed at the time of oncological pan-
createctomy for adenocarcinoma remains controversial. 
Neoplasms in the pancreatic head and/or body may be 
deemed locally unresectable at laparotomy because they 
appears to encase the celiac axis, common hepatic artery, 
right hepatic artery or superior mesenteric artery We present 
patients who underwent arterial resection with and without 
reconstruction at the time of pancreaticoduodenectomy. The 
video illustrate the surgical different steps.
VASCULAR GRAFTS OF CADAVERIC 
DONOR. AN EXCELLENT ALTERNATIVE 
FOR HEPATIC VENOUS OUTFLOW 
RECONSTRUCTION IN PATIENTS WITH 
RECURRENT LIVER METASTASES 
INVOLVING HEPATIC VENOUS 
OUTFLOW
E. Vicente, Y. Quijano, P. Galindo, M. E. Marcello, 
H. J. Duran, E. Diaz-Reques, C. Corbacho, B. Morato, 
P. Hidalgo, E. Garcia and E. Vicente
Madrid Norte Sanchinarro Hospital, Madrid
Introduction: Resection of recurrent liver tumors involving 
the hepatic venous outfl ow remains controversial. Resection 
provides the best chance of cure. Adequate surgical clearance 
can require resection and reconstruction of the hepatic veins.
Methods: A 32-year-old man was referred to our hospital 
with a history of an elective low anterior resection because 
of distal rectal cancer, right hepatic trisectionectomy and 
nonanatomic metastasectomy from the central part of seg-
ments 2 and 3 because liver metastases. Fourteen months 
postoperatively a recurrence developed within the liver 
remnant. A CT scan and venography reveals a 4 cm liver 
mass in the left liver remnant, which appeared to be closely 
apposed to the left hepatic vein. A positron emission tomog-
raphy with 18 FDG show the evidence of solitary liver meta-
static disease.
Results: The preoperative diagnosis was a recurrence of 
colorectal liver metastases involving the hepatic venous 
outfl ow and surgical treatment was indicated; Nonanatomic 
metastasectomy with resection and reconstruction of the 
intrahepatic venous outfl ow with vascular graft of cadaveric 
donor.
Conclusion(s): Hepatic vein involvement by hepatic malig-
nancies does not necessarily preclude resection. Liver resec-
tion with reconstruction of the hepatic veins can be performed 
in selected cases. The vascular grafts of cadaveric donor 
offer an excellent alternative for hepatic venous outfl ow 
reconstruction.
CHOLANGIOCARCINOMA IN SITU 
WITH EXTENSIVE INTRAEPITHELIAL 
SPREAD IN A NON-CIRRHOTIC PATIENT 
PRESENTING WITH BILIARY 
OBSTRUCTION
Z. Wang1, R. Z. Swan1, K. N. Lau1, W. A. Ahrens2, 
D. Sindram1, J. B. Martinie1 and D. A. Iannitti1
1Division of HPB Surgery, Department of Surgery, 
Carolinas Medical Center, Charlotte, NC; 2Department of 
Pathology, Carolinas Medical Center, Charlotte, NC
Purpose: Biliary intraepithelial neoplasia (BilIN) is a spec-
trum of cellular atypia and a precursor to cholangiocarci-
noma. BilIN-3 is equivalent to cholangiocarcinoma in situ 
(CIS). BilIN-3 is described in the setting of viral and alco-
holic cirrhosis, but not in non-cirrhotic patients. A character-
istic of cholangiocarcinoma is diffuse intraepithelial spread, 
the pathogenesis of which remains unclear. Dysplastic cells 
may spread extensively before invasion; conversely, invasive 
carcinoma may spread laterally during invasion. We describe 
a case of CIS with extensive intraepithelial spread presenting 
with biliary obstruction in a non-cirrhotic patient.
Methods: Review of patient charts, radiologic imaging, and 
pathologic specimens.
Results: A 59-year-old female with a history of colon cancer 
treated by colectomy without adjuvant therapy in 2005 is 
found on follow-up to have an elevated alkaline phosphatase 
(817 IU/L). She has no history of cirrhosis, hepatitis, autoim-
mune disease, or alcohol abuse. CEA level was normal and 
CA19.9 was elevated (65 U/mL). CT scan and MRI showed 
mildly dilated right intrahepatic bile ducts with mild central 
right ductal thickening. ERCP showed a 2 cm stenosis at the 
confl uence of the right anterior and posterior sectoral ducts. 
Brushing cytology was negative. The patient underwent a 
laparoscopic right hepatectomy. Pathologic analysis showed 
CIS with extensive spread of atypical cells to sectoral bile 
ducts in the setting of mild peri-portal infl ammation, fi brosis, 
and macrosteatosis.
Conclusion: We report a rare case of extensive CIS present-
ing with biliary obstruction in a non-cirrhotic patient. 
Pathologic analysis suggests that extensive intraepithelial 
spread of CIS may occur prior invasion.
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THE ROLE OF THE RENIN-
ANGIOTENSIN SYSTEM ON 
MACROPHAGE PLASTICITY IN 
COLORECTAL LIVER METASTASES
S. Wen, E. I. Ager and C. Christophi
The Department of Surgery, Austin Health, The University 
of Melbourne, Heidelberg, VIC
This study aimed to determine if the renin-angiotensin 
system (RAS), which has immunomodulatory effects and 
can be targeted to inhibit tumour growth, could affect mac-
rophage activation status and if liver macrophages are altered 
during growth of colorectal liver metastases. In vitro, mouse 
macrophage cells (P338D1) expressed key RAS receptors; 
angiotensin (ANG) II type 1 receptor (AT1R) and AT2R. The 
expression of CD14 (a marker of classical activation) by 
P338D1s increased when treated with the classical RAS 
peptide ANG II compared to the alternative RAS peptide 
ANG-(1-7). This effect was mitigated by AT1R blockade. 
In contrast, no change in the alternative activation marker 
CD206 was observed. The counter-regulatory effects of the 
classical and alternative RAS peptides were confi rmed by 
their divergent effect on iNOS expression by P338D1s. 
Using a murine model of colorectal liver metastases, macro-
phage depletion by gadolinium chloride (20 mg/kg) during 
the late stages of tumour growth decreased tumour load com-
pared to controls, an effect not observed when macrophages 
were depleted during the early stages of metastatic growth. 
Protein levels of key growth factors, VEGF and TNF-α also 
differed according to tumour growth stage. These results 
suggest that macrophages have divergent effects on tumour 
growth depending on the stage of tumour progression and 
that changes in macrophage function might be, at least in 
part, regulated by the RAS.
DENVER PERITONEOVENOUS SHUNTS: 
A SURGICAL OPTION FOR 
REFRACTORY ASCITES DUE TO 
MALIGNANCY OR CIRRHOSIS
M. A. White, W. J. Pories and E. E. Zervos
East Carolina University, Pitt County Memorial Hospital, 
Greenville, NC
Patients with chronic ascites due to either malignancy or 
cirrhosis may require frequent large volume paracentesis 
and/or high dose diuretics to control their ascites. 
Peritoneovenous shunting is another option to control medi-
cally refractory ascites but is perceived by many to carry 
unacceptable complication and device failure rates. However, 
these can be minimized with meticulous technique and 
careful patient selection. This video presentation is designed 
to review the indications for shunt placement and proper 
surgical placement technique to maximize a favorable result. 
Our patient, a 50-year-old female with end stage liver disease 
secondary to alcoholism and Hepatitis C, has a MELD score 
of 21 and is a Child’s class C cirrhotic. She presented with 
refractory ascites for a 2 month period that was unmanage-
able with high dose medical therapy, requiring biweekly 
large volume paracentesis. Percutaneous shunt placement 
technique is shown emphasizing: establishment of sterile 
ascites, percutaneous central venous access, large volume 
paracentesis, proper positioning of the venous catheter to 
reduce the incidence of thrombosis, secure placement of the 
pump chamber in a subcutaneous pocket, percutaneous 
access of the peritoneal cavity avoiding pneumothorax and 
liver laceration, and pursestring closure of the peritoneal 
entry site to prevent refl ux of ascites. The patient did well 
postoperatively and subsequently had complete resolution of 
her ascites without diuretics as verifi ed by CT scan. 
Peritoneovenous shunts can successfully provide palliation 
for patients with end stage liver disease. The procedure, 
while having well described complications, can be done 
safely with minimal morbidity in appropriately selected 
patients.
THE IMPACT OF SPINAL ANALGESIA 
ON PANCREATIC SURGERY OUTCOMES
M. D. Winner, J. DiNorcia, M. K. Lee, J. A. Lee, 
B. A. Schrope, J. A. Chabot and J. D. Allendorf
Columbia University Medical Center, Department of 
Surgery, New York, NY
Purpose: To evaluate outcomes after spinal and epidural 
analgesia in elective, open pancreatic surgery.
Methods: We reviewed the records of patients who had 
elective, open pancreatic surgery. We categorized patients as 
receiving epidural analgesia, spinal analgesia, or no spinal/
epidural (“PCA-only”), and compared fl uid intakes, pain 
scores, opiate use, operating room times, and complications 
between the three groups.
Results: Of the 129 patients who had elective, open pancre-
atic surgery in the last nine months of 2009, 107 had avail-
able data on epidural and spinal use. Post-operative pain 
scores were available for 79. Thirteen patients received epi-
dural catheters and 51 received intrathecal morphine injec-
tions (spinal). All 107 received a PCA. Patients receiving 
spinal analgesia had lower average post-operative pain 
scores (1.9 on a visual analog scale) when compared to the 
epidural and PCA-only groups (3.6 and 3.3 respectively, p < 
0.05), as well as lower consumption of additional intrave-
nous opiates in the fi rst 24 post-operative hours compared to 
PCA-only (5.2 mg vs. 10.1 mg dilaudid-equivalents, p < 
0.05.) Non-operative minutes in the operating room were 
signifi cantly higher in the Spinal (38 min) and in the Epidural 
groups (48 min) compared to the PCA-only group (25 min, 
p < 0.05). EBL, intra- and post-operative fl uid balances, 
morbidity, mortality, and length of stay were equivalent 
between the three groups.
Conclusion: In patients who had elective, open pancreatic 
surgery, spinal analgesia offered excellent post-operative 
pain control, though resulted in more non-operative minutes 
in the operating room. Spinal analgesia did not affect length 
of stay or post-operative morbidity or mortality.
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METHOD OF SPLENIC PRESERVATION 
DURING DISTAL PANCREATECTOMY 
IMPACTS FISTULA RATES
E. R. Winslow1, D. A. Kooby2, C. M. Schmidt3, 
A. Nakeeb3, D. Bentrem4, N. Mecrhcant5, A. A. Parikh5, 
R. C. Martin6, C. R. Scoggins6, S. A. Ahmad7, H. J. Kim7, 
W. G. Hawkins8, S. M. Weber1 and C. S. Cho1
1University of Wisconsin, Madison, WI; 2Emory University, 
Atlanta, GA; 3Indiana University, Bloomington, IN; 
4Northwestern University, Chicago, IL; 5Vanderbilt 
University, Nashville, TN; 6University of Louisville, 
Louisville, KY; 7University of Cincinnati, Cincinnati, OH; 
8Washington University, St. Louis, MO
Introduction: Distal pancreatectomy with splenectomy 
(DPS) has been the standard treatment for pancreatic body/
tail tumors, but spleen-preserving distal pancreatectomy 
(SPDP) is increasingly used. Two methods exist – splenic 
vessel preservation (SPDP-VP) and excision (SPDP-VE). It 
is unknown how the method of SPDP impacts postoperative 
pancreatic fi stula (POPF) rates.
Methods: Records from patients undergoing distal pancre-
atectomy at 9 academic medical centers were analyzed. Chi-
square tests and a multivariate model were used to assess the 
impact of surgical technique on POPF, accounting for center, 
operative approach, diagnosis, BMI, length of specimen, and 
blood loss.
Results: 675 patients were included. Pancreatic pathology 
included: cysts (34%), adenocarcinoma (19%), neuroendo-
crine tumors (16%), pancreatitis (15%), metastases (5%), 
and other (11%). When POPF rates between DPS and SPDP 
were compared, there was no signifi cant difference. When 
POPF rates were examined by method of splenic preserva-
tion, those undergoing SPDP-VP had signifi cantly higher 
POPF rates than those with SPDP-VE for both total (36% vs 
15%, p = 0.02) and clinically signifi cant (grade B/C) POPF 
(23% vs 7%, p = 0.02). When multivariate analysis was 
performed to control for other contributing factors, SPDP-VP 
remained an important risk factor for POPF (p = 0.006).
Discussion: In our multicenter data set, the approach to 
splenic vessels during SPDP had a signifi cant independent 
impact on POPF rates. These results suggest that preserva-
tion of the splenic vessels during SPDP may be associated 
with higher rates of POPF when compared to vessel excision. 
This observation should be confi rmed by prospective analy-
ses because it has the potential to alter the risk/benefi t ratio 
for splenic preservation.
Table 1. Comparison of operative approaches to distal pancreatectomy
Variable DPS SPDP-VP SPDP-VE
Patients (%) 563 (82%) 71 (10%) 41 (6%)
Laparoscopic (%) 168 (30%) 49 (69%) 34 (83%)
BMI (±SD) 27 ± 6.4 26.6 ± 6.4 28.8 ± 7.1
Pancreatic length (cm ± SD) 9.4 ± 3.8 7.4 ± 3.7 8.4 ± 3.2
EBL (mL ± SD) 561 ± 755 254 ± 354 537 ± 866
Cystic diagnosis 35% 56% 44%
Stapled technique 73% 53% 45%
Total leak rate 24% 36% 15%
Signifi cant leak rate 12% 23% 7%
NATIONWIDE PATTERNS IN RESECTION 
FOR METASTATIC PANCREATIC 
CANCER
E. R. Witkowski, J. K. Smith, E. Ragulin-Coyne, S. C. Ng, 
T. P. McDade, S. A. Shah and J. F. Tseng
Surgical Outcomes Analysis & Research, University of 
Massachusetts Medical School, Worcester, MA
Background: The role of resection in patients with meta-
static pancreatic cancer remains controversial. Limited data 
exists regarding operative management for metastases. We 
sought to determine whether patients are receiving resection 
for metastatic disease nationwide, and whether resected 
patients received any benefi t from surgery.
Methods: Patients ≥18 years with pancreatic adenocarci-
noma and distant disease were identifi ed in SEER 1998–
2007. Univariate and multivariate analyses were performed. 
Survival was analyzed by Kaplan-Meier methods and Cox 
proportional-hazard ratios.
Results: Among 22597 patients with metastatic disease, 
pancreatic resection was recommended to 3647 (16.1%), and 
performed on 753 (3.3%). 1901 (8.4%) received radiation. 
19895 (88.0%) received no radiation or surgery. There was 
a substantial decrease in patients recommended for surgery 
1998–2007 (33.94% to 8.19%, p < 0.0001), but no change 
in pancreatic resections performed (3.3% to 3.1%, p = 
0.7834). Female sex, younger age, and marital status were 
predictive of undergoing pancreatic resection (p < 0.05). 
Unadjusted median survival was higher in patients who 
received pancreatic resection (8 vs. 3 months, p < 0.0001). 
9.3% of resected patients also underwent resection of meta-
static site(s). In patients who received pancreatic resection, 
Cox modeling revealed that resection of metastatic site(s) 
was not associated with any additional benefi t.
Conclusions: For patients with metastatic pancreatic cancer, 
rates of pancreatic resection remain stable near 3%. Patients 
who underwent pancreatectomy had improved survival com-
pared to unresected peers, but additional resection of meta-
static site(s) did not improve survival. Given the 
highly-selected nature of the resected cohort, resection of 
primary disease should be approached with caution. Our 
analysis suggests that resection of metastatic site(s) is not 
indicated.
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PILOT STUDY OF 18F-FLUOROCHOLINE 
PET/CT OF THE LIVER IN PATIENTS 
WITH HEPATOCELLULAR CANCER
L. L. Wong1,2, G. Okimoto1 and S. Kwee1,3
1Cancer Research Center of Hawaii, Honolulu, Hawaii; 
2Hawaii Medical Center-East, Honolulu, Hawaii; 3Queens 
Medical Center, Honolulu, Hawaii
Background: Positron emission tomography (PET) with [18F]-
fl uorodeoxyglucose is valuable for cancer diagnosis/staging, but 
hepatocellular carcinoma (HCC) has metabolic characteristics 
that limit its usefulness. Upregulated phosphocholine synthesis 
is a hallmark of cancer and promising target for diagnosis/
therapy. The investigational tracer [18F]-fl uoromethylcholine 
(FCH) is a synthetic substrate for choline kinase and marker of 
phosphocholine synthesis. This pilot study addresses feasibility 
of detecting HCC using FCH PET/CT.
Methods: Fourteen patients with known HCC underwent 
FCH-PET/CT performed under IND. Data collected included 
patient characteristics, laboratory studies, MELD score. 
Maximum standardized uptake value (SUVmax) from tumor 
and adjacent liver were measured on PET.
Results: Mean Tumor SUVmax was signifi cantly increased 
compared to background (10.8 vs. 7.1, p < 0.01), supporting 
potential discrimination of HCC by FCH. The smallest tumor 
detected was 7 mm, indicating feasibility for classifying 
lesions <2 cm. Variations in global liver FCH uptake were 
observed in cirrhotic patients, with liver SUVmax signifi -
cantly inversely correlated with MELD score (r = −0.71, p < 
0.01). To further investigate FCH metabolism and liver func-
tion, normal liver FCH uptake in 20 healthy volunteers (from 
a previous IND biodistribution study) were compared to 
HCC patients, revealing signifi cant differences in FCH 
uptake between healthy livers and tumor-affected and unaf-
fected areas of HCC patients (SUVmax 11.7 vs. 7.1, p < 0.01, 
and 11.7 vs. 7.5, p < 0.01 respectively).
Conclusions: FCH is a novel molecular imaging agent that 
shows signifi cant promise in liver disease/cancer. Unlike 
other diagnostic imaging, FCH-PET/CT may have the ability 
to determine underlying liver function and therefore poten-
tially optimize selection of therapy.
ADOPTIVE T-CELL TRANSFER 
TARGETING PANCREATIC CANCER
A. C. Worth, A. M. Leen, U. L. Katari, W. E. Fisher and 
J. F. Vera
Baylor College of Medicine, Houston, TX
Background: Conventional chemotherapy and radiother-
apy produce a marginal survival benefi t in pancreatic cancer, 
underscoring the need for novel therapies. The aim of this 
study was to develop an adoptive T-cell transfer approach to 
target tumors expressing PSCA, a tumor-associated antigen 
which is frequently expressed by pancreatic cancer cells.
Methods: PSCA expression on primary tumor samples was 
confi rmed by immunohistochemistry. Patient-derived T cells 
were then activated in vitro using CD3/CD28 and transduced 
with a retroviral vector encoding a chimeric antigen receptor 
(CAR) targeting PSCA. The ability of these cells to kill 
tumor cells was analyzed in a chromium release assay.
Results: PSCA was expressed on 70% of primary tumor 
samples screened. Patient-derived activated T cells could be 
readily generated in clinically relevant numbers and trans-
duced with CAR/PSCA, with transduction effi ciencies 
>50%. These tumor-targeted T cells were able to specifi cally 
kill PSCA-expressing pancreatic cancer cell lines CFPAC, 
CAPAN1, and PL45 (60%, 99% and 71% killing at an effec-
tor : target (E : T) ratio of 20 : 1, respectively) in a 4-hour 
chromium release assay, with no non-specifi c killing of 
PSCA negative target cells (293T – 25% at 20 : 1 E : T), thus 
indicating the potential effi cacy and safety of this approach.
Conclusions: PSCA is frequently expressed on pancreatic 
cancer cells and can be targeted for immune mediated 
destruction using CAR-modifi ed adoptively transferred T 
cells. The safety and effi cacy of this approach deserves 
further study and may represent a promising novel treatment 
for patients with pancreatic cancer.
LAPAROSCOPIC LIVER RESECTION 
FOR HEPATOCELLULAR CARCINOMA; 
A SINGLE CENTER EXPERIENCE
S. Yoon and K. Kim
Asan Medical Center, Ulsan University, Seoul
Background: There are a few reports of the advantages of 
laparoscopic liver resection of hepatocellular carcinoma 
(HCC). The purpose of this study was to evaluate the short-
term result of laparoscopic liver resection.
Methods: From July 2007 to February 2010, there were 56 
patients with HCC who underwent laparoscopic liver resec-
tion in our hospital.
Results: The mean age was 55.3 ± 9.72 (range 35–70) years 
and mean tumor size was 2.82 ± 1.19 (range 1.0–5.5) cm. 
The median operative time was 212.93 ± 96.48 min (range: 
95–720 min), and median blood loss was 282.14 ± 120.88 ml 
(range: 150–800 ml) and two patients required intra-opera-
tive blood transfusion, but signifi cantly blood loss was none. 
The mean resection margin was 2.03 ± 1.68 cm (0.1–9.0 cm). 
There is no in hospital mortality, and two patients has post-
operative complication as wound seroma and ascites. Return 
to normal diet was achieved on average at 1.87 ± 0.8 days 
(range: 1–4 days). The mean hospital stay was 8.88 ± 2.34 
days (range: 6–17 days). The 34 months overall and disease-
free survival rates were 83.5% and 70.5%, respectively.
Conclusion: This procedure is developing and safe tech-
nique in a select group of patients including those with 
malignancies, resulting in short hospital stays, rapid return 
to normal diet, full mobility and minimal morbidity with 
acceptable oncological parameter.
EVOLUTION OF THE SURGICAL 
MANAGEMENT OF PERIHILAR 
CHOLANGIOCARCINOMA IN A 
WESTERN CENTER DEMONSTRATES 
IMPROVED SURVIVAL WITH 
ENDOSCOPIC BILIARY DRAINAGE AND 
REDUCED USE OF BLOOD 
TRANSFUSION
A. L. Young, T. Igami, Y. Senda, R. Adair, S. Farid, 
G. J. Toogood, K. R. Prasad and P. Lodge
St James’s University Hospital, Leeds, West Yorkshire
Introduction: Perihilar cholangiocarcinoma (PHCCA) 
remains a surgical challenge with few large reported series, 
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particularly in Western centers. We investigated which 
factors affected survival in our unit.
Methods: A prospectively maintained database was inter-
rogated to identify all resections. Clinico-pathological data 
was analyzed and assessed for impact on survival. 
Subsequently data for resections during the periods 1994–
1998, 1999–2003 and 2004–2008 were compared.
Results: 83 patients underwent resection. Almost 3/4 
required hepatic trisectionectomy. Overall survival was 70% 
at 1 year, 36% at 3 years and 20% at 5 years. Size of tumour, 
R0 status, distant metastasis, tumour grade, portal vein resec-
tion, microscopic direct vascular invasion, T-stage, and blood 
transfusion requirement signifi cantly affected outcome on 
univariate analysis. Distant metastases (p = 0.040), percuta-
neous biliary drainage (p = 0.015) and blood transfusion 
requirement (p = 0.026) were signifi cant on multivariate 
analysis. Survival outcomes improved signifi cantly in the 
most recent period and in addition blood transfusion require-
ment was signifi cantly reduced in the most recent time 
period.
Conclusion: This is the fi rst series to report blood transfu-
sion requirement and pre-operative percutaneous biliary 
drainage as independent poor prognostic indicators follow-
ing resection of PHCCA. Long term survival can be achieved 
following aggressive surgical resection of this tumour but a 
learning curve is apparent which supports the management 
of these patients in high volume centers to achieve improved 
outcomes.
REGIONAL TUMOUR DIFFERENCES IN 
PROSTAGLANDIN E2 LEVELS MAY 
PROMOTE DEVELOPMENT OF 
COLORECTAL LIVER METASTASES BY 
PROMOTING EPITHELIAL-
MESENCHYMAL TRANSITION
A. L. Young1, M. A. Hull2 and G. J. Toogood1
1St James’s University Hospital, Leeds, Yorkshire; 
2University of Leeds, Leeds, Yorkshire
Blocking Prostaglandin(PG)E2 production using COX inhib-
itors has proven benefi t in cancer therapy. NAD+dependent-
15-PG Dehydrogenase (15-PGDH) represents another level 
of control over tissue PGE2 levels (controls rate-limiting step 
in PGE2 breakdown). The hypoxic tumor microenvironment 
may affect PGE2 levels, promoting cancer cell invasion/
metastasis (epithelial-mesenchymal transition (EMT)). We 
investigated control of PGE2 levels in colorectal cancer liver 
metastases (CRCLM) relative to hypoxia and EMT. Paired 
central and peripheral tissue from 20 CRCLM were obtained 
to measure tissue PGE2, NAD+ levels, 15-PGDH enzyme 
activity and immunoreactive 15-PGDH and COX-2 protein 
levels. Parallel in-vitro studies used a LIM1863 CRC cell 
model of EMT. PGE2 levels were increased in the centre of 
CRCLM relative to peripheral tissue by a mean of 26% (95% 
CI: 1–52%; p = 0.045). Counter-intuitively, 15-PGDH 
protein levels were increased in the centre of tumors (immu-
noreactivity p = 0.036; [3H]PGE2 catabolism: p = 0.016). 
However, NAD+ levels were 59% (25–72%; p = 0.015) 
lower in the centre of CRCLM than the periphery suggesting 
ineffi cient 15-PGDH-dependent catabolism may explain 
raised PGE2 levels. In central areas of CRCLM, cancer cells 
exhibiting low E-cadherin expression (EMT marker) had 
higher expression of 15-PGDH than neighbouring E-cadherin-
positive cells. Our tissue observations were mirrored by in-
vitro experiments. 15-PGDH activity was signifi cantly 
decreased when NAD+ was present at a limiting concentra-
tion. Furthermore, PGE2 promoted EMT in LIM 1863 cells 
in a concentration-dependent manner. Regional differences 
in PGE2 levels and 15-PGDH expression/function are appar-
ent in CRCLM (possibly linked to hypoxia). PGE2 promotes 
EMT in human CRC cells. We present a new mechanism for 
how hypoxia promotes EMT through NAD+ depletion 
leading to decreased 15-PGDH function and increased PGE2 
levels.
CIRCULATING TUMOR CELLS IN 
PATIENTS UNDERGOING LIVER 
RESECTION FOR COLORECTAL 
CANCER LIVER METASTASES
G. Zogopoulos, S. Selvarajah, C. Ash, F. Schwenter, 
D. Chan, S. Gallinger and C. Moulton
Hepatobiliary and Pancreatic Surgical Oncology, 
University Health Network, University of Toronto, Toronto, 
Ontario
Hepatic resection improves the prognosis of patients with 
colorectal cancer (CRC) liver metastases, but recurrent 
disease occurs in >50% of patients. Dissemination of circu-
lating tumor cells (CTCs) likely occurs early in metastatic 
progression. The prognostic or predictive role of CTCs in 
CRC remains uncertain. However, some have suggested that 
patients can be stratifi ed into unfavorable and favorable 
prognostic groups based on CTC levels of ≥3 or <3 
CTCs/7.5 mls of blood. To understand the clinical relevance 
of CTCs in patients undergoing liver resection for CRC 
metastases, 7.5 mls of hepatic (HV) and peripheral (PV) vein 
blood were drawn intraoperatively from patients (n = 33, 
Male = 17, Female = 16, range 40–73 yr) prior to liver tran-
section. CTCs were enumerated using CellSearch® technol-
ogy, which distinguishes epithelial cells from leukocytes 
using specifi c antibodies. These early data reveal no differ-
ence in the number of CTCs in HV vs. PV samples (mean ± 
s.d = 8 ± 11 vs. 5 ± 6, p = 0.4). Univariant analyses did not 
show an association between unfavorable and favorable HV 
or PV CTC counts with age, sex, chemotherapy prior to liver 
resection (5-FU or FOLFOX or FOLFIRI ± Bevacizumab), 
number of liver metastases, or tumor volume. We have 
shown that there are detectable levels of circulating epithelial 
cells, likely representing CTCs, in patients with CRC liver 
metastases. These early data also suggest that there are no 
signifi cant differences in the number of CTCs in HV vs. PV 
circulations. Patients are being followed prospectively to 
determine if CTC counts will be predictive of recurrence.
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PLATINUM-BASED CHEMOTHERAPY IN 
PATIENTS WITH PANCREATIC CANCER 
AND GERMLINE BRCA2 MUTATIONS
G. Zogopoulos1, W. Al-Sukhni1, S. Moore1, B. Rosen2, 
C. Moulton1, M. Moore3 and S. Gallinger1
1Hepatobiliary and Pancreatic Surgical Oncology, 
University Health Network, University of Toronto, Toronto, 
Ontario; 2Gynaecologic Oncology, University Health 
Network, University of Toronto, Toronto, Ontario; 3Medical 
Oncology, University Health Network, University of 
Toronto, Toronto, Ontario
Patients with germline BRCA2 mutations have an increase-
drisk of developing breast, ovarian and pancreatic cancer. 
BRCA-defi cient malignant cells are particularly sensitive to 
cross-linking agents, providing a rationale for tailored che-
motherapy using platinum agents in germline BRCA2 muta-
tion carriers with pancreatic cancer. Therefore, we used 
platinum-based chemotherapy in two recent cases of pancre-
atic cancer with germline BRCA2 mutations. A 53-year-old 
woman with a history of previously treated breast cancer 
presented with locally advanced pancreatic cancer, abutting 
the portal vein and superior mesenteric artery. Tumor regres-
sion was observed with 2 cycles of cisplatinum/gemcitabine 
followed by external beam radiation with 5-FU. A standard 
pancreaticoduodenectomy was performed and pathology 
revealed a well-differentiated adenocarcinoma (T3) with 
negative resection margins and 26 negative lymph nodes. 
The patient received 4 adjuvant cycles of cisplatinum/
gemcitabine and remains disease-free at 30 months post-
resection. A 63-year-old woman presented with a resectable 
pancreatic cancer in the setting of recurrent ovarian cancer. 
She was previously treated with hysterectomy, bilateral 
salpingo-oophorectomy, omentectomy and intra-peritoneal 
carboplatin/paclitaxel. Following 6 cycles of systemic 
carboplatin/paclitaxel, there was complete regression of the 
ovarian cancer recurrence with stability in the pancreatic 
mass. At laparotomy, there was no evidence of carcinomato-
sis and a standard pancreaticoduodenectomy was performed. 
The pathology showed a well-differentiated adenocarcinoma 
(T3) with negative resection margins and 13 negative lymph 
nodes. She received 3 adjuvant cycles of carboplatin/pacli-
tataxel and is disease-free at 15 months post-resection. These 
results support the use of platinum agents in germline BRCA 
mutation carriers with pancreatic cancer.
